{"task_id": "parsing-relabel-r1-00001", "nct_id": "NCT00781638", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 229.0, "priority_reasons": ["missing_critical_rules=19", "rule_v1_missing=26", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 5, "history": 9, "lab": 2, "medication": 4, "other": 1, "procedure": 3, "sex": 1}, "extra_rules_by_field": {"condition": 5, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition", "medication", "procedure", "lab", "sex", "age", "other"], "eligibility_text": "Inclusion Criteria:\n\n1. Children and adolescents \\< 18 years\n2. Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)\n3. Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64\n4. Pancolitis or left-sided colitis\n5. Ulcerative colitis for at least 3 months\n6. Receiving or having received one or more of the following medicinal products before screening:\n\n   * Sulfasalazine, mesalamine and other 5-aminosalicylic acid (5-ASA) agents for 4 weeks or more with a stable dose for the last 2 weeks,\n   * 0.5mg/kg/body weight with a maximum of 20 mg per day of prednisone with a stable dose for the last 2 weeks, or\n   * 6-mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2).\n7. For female patients of child-bearing potential, a negative pregnancy test and agreement to use an effective contraceptive method or abstain from sexual activities during the course of the clinical investigation\n8. Agreement to participate in all visits\n9. Signed written informed consent document by patients and their legal guardian or representative\n10. Body weight must be more or equal 30kg\n11. Adequate peripheral venous access to allow for completion of the apheresis treatments\n\nExclusion Criteria:\n\n1. Febrile (\\>38ºC)\n2. Evidence of toxic megacolon\n3. Anticipated need for surgery within 12 weeks after Day 00\n4. Major surgery within the past 6 weeks\n5. Known obstructive diseases of the gastrointestinal system\n6. Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis\n7. A history of allergic reaction to heparin or heparin-induced thrombocytopenia\n8. A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures\n9. Known infection with enteric pathogens, pathogenic ova or parasites, or a positive assay for C. difficile toxin\n10. Symptomatic hypotension\n11. Pediatric heart conditions and problems at high susceptibility for thrombotic events (e.g. valve defects or similar)\n12. A history of physical findings compatible with a cerebrovascular accident\n13. Prosthetic heart valve, pacemaker or other permanent implant\n14. Severe cardiovascular or peripheral vascular disease\n15. Liver disease defined as levels of GOT \\[AST\\], GPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test\n16. History of cirrhosis\n17. Renal insufficiency, defined as serum creatinine \\>150% of the upper limit of the normal range for the laboratory performing the test\n18. Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment\n19. Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis\n20. Known infection with Hepatitis B or C, or HIV\n21. Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\<2,000/μl\n22. Fibrinogen level \\>700mg/dL\n23. Infection:\n\n    * Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening)\n    * Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)\n    * Less than 12 weeks from conclusion of therapy for systemic fungal infections to screening\n24. Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)\n25. History of dysplasia or carcinoma of the colon\n26. Current drug or alcohol abuse\n27. Pregnant, lactating or planning to become pregnant during the course of the clinical investigation\n28. Used within the last 30 days an investigational medicinal product, biologic or device\n29. Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics\n30. Steroid-resistance or -dependency, defined as inability to completely withdraw steroids without inducing a relapse or flare-up of the disease\n31. Topical therapy for ulcerative colitis within the last 2 weeks.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reaction to heparin or heparin induced thrombocytopenia", "unit": null, "evidence_text": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "unit": null, "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "physical findings compatible with a cerebrovascular accident", "unit": null, "evidence_text": "A history of physical findings compatible with a cerebrovascular accident"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cirrhosis", "unit": null, "evidence_text": "History of cirrhosis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "dysplasia or carcinoma of the colon", "unit": null, "evidence_text": "History of dysplasia or carcinoma of the colon"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known obstructive diseases of the gastrointestinal system", "unit": null, "evidence_text": "Known obstructive diseases of the gastrointestinal system"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Severe cardiovascular or peripheral vascular disease", "unit": null, "evidence_text": "Severe cardiovascular or peripheral vascular disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia", "unit": null, "evidence_text": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "unit": null, "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of physical findings compatible with a cerebrovascular accident", "unit": null, "evidence_text": "A history of physical findings compatible with a cerebrovascular accident"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation", "unit": null, "evidence_text": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)", "unit": null, "evidence_text": "Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of cirrhosis", "unit": null, "evidence_text": "History of cirrhosis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of dysplasia or carcinoma of the colon", "unit": null, "evidence_text": "History of dysplasia or carcinoma of the colon"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis", "unit": null, "evidence_text": "Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Used within the last 30 days an investigational medicinal product, biologic or device", "unit": null, "evidence_text": "Used within the last 30 days an investigational medicinal product, biologic or device"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "8.5", "unit": "g/dl", "evidence_text": "Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\<2,000/μl"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "150", "unit": "%", "evidence_text": "Renal insufficiency, defined as serum creatinine \\>150% of the upper limit of the normal range for the laboratory performing the test"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current drug or alcohol abuse", "unit": null, "evidence_text": "Current drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for p", "unit": null, "evidence_text": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics", "unit": null, "evidence_text": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Anticipated need for surgery within 12 weeks after Day 00", "unit": null, "evidence_text": "Anticipated need for surgery within 12 weeks after Day 00"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Major surgery within the past 6 weeks", "unit": null, "evidence_text": "Major surgery within the past 6 weeks"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)", "unit": null, "evidence_text": "Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Children and adolescents \\< 18 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a maximum of 20 mg per day", "unit": null, "evidence_text": "5mg/kg/body weight with a maximum of 20 mg per day of prednisone with a stable dose for the last 2 weeks, or"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64", "unit": null, "evidence_text": "Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a stable dose for the last 2", "unit": null, "evidence_text": "Sulfasalazine, mesalamine and other 5-aminosalicylic acid (5-ASA) agents for 4 weeks or more with a stable dose for the last 2 weeks,"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ulcerative colitis documented by clinical", "unit": null, "evidence_text": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)", "unit": null, "evidence_text": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Ulcerative colitis for at least 3 months", "unit": null, "evidence_text": "Ulcerative colitis for at least 3 months"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2).", "unit": null, "evidence_text": "mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2)."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Signed written informed consent document by patients and their legal guardian or representative", "unit": null, "evidence_text": "Signed written informed consent document by patients and their legal guardian or representative"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "For female patients of child-bearing potential, a negative pregnancy test and agreement to use an effective contraceptive method or abstain from sexual activities during the course of the clinical investigation"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known obstructive diseases of the gastrointestinal system", "unit": null, "evidence_text": "Known obstructive diseases of the gastrointestinal system"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Severe cardiovascular or peripheral vascular disease", "unit": null, "evidence_text": "Severe cardiovascular or peripheral vascular disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia", "unit": null, "evidence_text": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "unit": null, "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of physical findings compatible with a cerebrovascular accident", "unit": null, "evidence_text": "A history of physical findings compatible with a cerebrovascular accident"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation", "unit": null, "evidence_text": "Active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)", "unit": null, "evidence_text": "Febrile viral infection within 4 weeks of entry into the clinical investigation (screening)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of cirrhosis", "unit": null, "evidence_text": "History of cirrhosis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of dysplasia or carcinoma of the colon", "unit": null, "evidence_text": "History of dysplasia or carcinoma of the colon"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis", "unit": null, "evidence_text": "Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Used within the last 30 days an investigational medicinal product, biologic or device", "unit": null, "evidence_text": "Used within the last 30 days an investigational medicinal product, biologic or device"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "150", "unit": "%", "evidence_text": "Renal insufficiency, defined as serum creatinine \\>150% of the upper limit of the normal range for the laboratory performing the test"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "8.5", "unit": "g/dl", "evidence_text": "Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\<2,000/μl"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current drug or alcohol abuse", "unit": null, "evidence_text": "Current drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for p", "unit": null, "evidence_text": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics", "unit": null, "evidence_text": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g. immunosuppressants and biologics"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Anticipated need for surgery within 12 weeks after Day 00", "unit": null, "evidence_text": "Anticipated need for surgery within 12 weeks after Day 00"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Major surgery within the past 6 weeks", "unit": null, "evidence_text": "Major surgery within the past 6 weeks"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)", "unit": null, "evidence_text": "Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Children and adolescents \\< 18 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64", "unit": null, "evidence_text": "Moderate active ulcerative colitis at baseline evaluation, defined as follows:PUCAI between 35 and 64"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)", "unit": null, "evidence_text": "Ulcerative colitis documented by clinical symptoms, endoscopic findings and histology (in patient history)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Ulcerative colitis for at least 3 months", "unit": null, "evidence_text": "Ulcerative colitis for at least 3 months"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2).", "unit": null, "evidence_text": "mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the last 4 weeks Other UC medication is not allowed (see also Chapter 4.4.2)."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Signed written informed consent document by patients and their legal guardian or representative", "unit": null, "evidence_text": "Signed written informed consent document by patients and their legal guardian or representative"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "For female patients of child-bearing potential, a negative pregnancy test and agreement to use an effective contraceptive method or abstain from sexual activities during the course of the clinical investigation"}], "rule_v1_extra_rules": [{"id": "rule-764cedf0-7e53-4581-9cfd-dbe096136747", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a cerebrovascular accident", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "A history of physical findings compatible with a cerebrovascular accident", "source_span": {"start": 2149, "end": 2222}}, {"id": "rule-801fd1c9-9f28-4c52-8b0b-506297d5b2e7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an apheresis procedure or intolerance of apheresis", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "source_span": {"start": 1764, "end": 1880}}, {"id": "rule-e9525a2d-92a2-4730-830d-ca8f9d4b98ed", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "drugs other than 5 asa and derivatives", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Pre-treatment of UC with drugs other than 5-ASA and derivatives, azathioprine and or corticosteroids, e.g.", "source_span": {"start": 4038, "end": 4144}}, {"id": "rule-ea0b381e-68f0-4700-a7ed-fdc23badf4c2", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Known infection with enteric pathogens, pathogenic ova or parasites, or a positive assay for C.", "source_span": {"start": 1884, "end": 1979}}, {"id": "rule-a6cd075a-fb43-412b-b91a-96321c1ab1c9", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Known infection with Hepatitis B or C, or HIV", "source_span": {"start": 3016, "end": 3061}}, {"id": "rule-a3881e1a-6141-4649-b772-903eb8aab6b5", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "For female patients of child-bearing potential, a negative pregnancy test and agreement to use an effective contraceptive method or abstain from sexual activities during the course of the clinical investigation", "source_span": {"start": 873, "end": 1083}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00002", "nct_id": "NCT00995800", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 208.0, "priority_reasons": ["missing_critical_rules=19", "rule_v1_missing=22", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 9, "lab": 1, "medication": 7, "other": 2, "sex": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "medication", "condition", "other", "lab", "sex"], "eligibility_text": "Inclusion Criteria:\n\n1. Male or female subjects aged between 18 and 55 years inclusive.\n2. Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded at the screening visit prior to the first dose of study medication in each treatment period, be non-lactating, and be willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner.\n3. Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit.\n4. Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit.\n5. Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting β2-agonist or short-acting β2-agonist/anticholinergic use 12 hours and 6 hours prior to screening, respectively).\n6. Demonstrate AMP challenge PC20FEV1 \\< 60 mg/mL, following appropriate withholding of asthma medication (no short-acting bronchodilator use 6 hours prior to the AMP challenge test at Visit 2).\n7. Non-smoker for at least 12 months prior to study screening. Ex-smokers must have a smoking history equivalent to less than \"10 pack years\" (i.e. at least 1 pack of 20 cigarettes per day for 10 years or 10 packs per day for 1 year, etc.).\n8. Demonstrate satisfactory technique in the use of the pMDI.\n9. Willing and able to enter information in the diary and attend all study visits.\n10. Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study.\n11. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Near fatal or life-threatening (including intubation) asthma within the past year.\n2. Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit.\n3. History of omalizumab use within the past 6 months.\n4. Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia. 'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.\n5. In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.\n6. Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).\n7. Known Human Immunodeficiency Virus (HIV)-positive status.\n8. Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.\n9. Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within one week prior to the screening visit.\n10. History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit.\n11. Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function.\n12. Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodium within one week prior to the screening visit.\n13. Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components.\n14. Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid).\n15. Current participation in a clinical study.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which", "unit": null, "evidence_text": "'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "alcohol and/or substance abuse within 12 months prior to the screening visit", "unit": null, "evidence_text": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia", "unit": null, "evidence_text": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components", "unit": null, "evidence_text": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "leukotriene receptor antagonist use, e", "unit": null, "evidence_text": "History of leukotriene receptor antagonist use, e.g."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "omalizumab use within the past 6 months", "unit": null, "evidence_text": "History of omalizumab use within the past 6 months."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Known Human Immunodeficiency Virus (HIV)-positive status."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).", "unit": null, "evidence_text": "Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis)."}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.", "unit": null, "evidence_text": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myoca", "unit": null, "evidence_text": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit.", "unit": null, "evidence_text": "History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit.", "unit": null, "evidence_text": "Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.", "unit": null, "evidence_text": "In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Near fatal or life-threatening (including intubation) asthma within the past year.", "unit": null, "evidence_text": "Near fatal or life-threatening (including intubation) asthma within the past year."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or", "unit": null, "evidence_text": "Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within one week prior to the screening visit."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodi", "unit": null, "evidence_text": "Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodium within one week prior to the screening visit."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components.", "unit": null, "evidence_text": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function.", "unit": null, "evidence_text": "Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid).", "unit": null, "evidence_text": "Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit.", "unit": null, "evidence_text": "Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Non-smoker for at least 12 months prior to study screening.", "unit": null, "evidence_text": "Non-smoker for at least 12 months prior to study screening."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "60", "unit": "mg/ml", "evidence_text": "Demonstrate AMP challenge PC20FEV1 \\< 60 mg/mL, following appropriate withholding of asthma medication (no short-acting bronchodilator use 6 hours prior to the AMP challenge test at Visit 2)."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting", "unit": null, "evidence_text": "Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting β2-agonist or short-acting β2-agonist/anticholinergic use 12 hours and 6 hours prior to screening, respectively)."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit.", "unit": null, "evidence_text": "Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study.", "unit": null, "evidence_text": "Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Willing and able to enter information in the diary and attend all study visits.", "unit": null, "evidence_text": "Willing and able to enter information in the diary and attend all study visits."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Written informed consent obtained.", "unit": null, "evidence_text": "Written informed consent obtained."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded at the screening visit prior to the first dose of study medication in each treatment period, be non-lactating, and be willing to use adequate and highly effective methods of contraception throughout the study."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which", "unit": null, "evidence_text": "'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).", "unit": null, "evidence_text": "Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis)."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.", "unit": null, "evidence_text": "Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myoca", "unit": null, "evidence_text": "Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit.", "unit": null, "evidence_text": "History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit.", "unit": null, "evidence_text": "Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.", "unit": null, "evidence_text": "In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Near fatal or life-threatening (including intubation) asthma within the past year.", "unit": null, "evidence_text": "Near fatal or life-threatening (including intubation) asthma within the past year."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or", "unit": null, "evidence_text": "Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within one week prior to the screening visit."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodi", "unit": null, "evidence_text": "Anti-histamines within 2 weeks prior to the screening visit; non-steroidal anti-inflammatory drugs, oral decongestants, inhaled cromolyn sodium, nedocromil sodium within one week prior to the screening visit."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components.", "unit": null, "evidence_text": "Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function.", "unit": null, "evidence_text": "Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm and/or pulmonary function."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid).", "unit": null, "evidence_text": "Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit.", "unit": null, "evidence_text": "Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Non-smoker for at least 12 months prior to study screening.", "unit": null, "evidence_text": "Non-smoker for at least 12 months prior to study screening."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "60", "unit": "mg/ml", "evidence_text": "Demonstrate AMP challenge PC20FEV1 \\< 60 mg/mL, following appropriate withholding of asthma medication (no short-acting bronchodilator use 6 hours prior to the AMP challenge test at Visit 2)."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting", "unit": null, "evidence_text": "Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting β2-agonist or short-acting β2-agonist/anticholinergic use 12 hours and 6 hours prior to screening, respectively)."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study.", "unit": null, "evidence_text": "Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit.", "unit": null, "evidence_text": "Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Willing and able to enter information in the diary and attend all study visits.", "unit": null, "evidence_text": "Willing and able to enter information in the diary and attend all study visits."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Written informed consent obtained.", "unit": null, "evidence_text": "Written informed consent obtained."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded at the screening visit prior to the first dose of study medication in each treatment period, be non-lactating, and be willing to use adequate and highly effective methods of contraception throughout the study."}], "rule_v1_extra_rules": [{"id": "rule-fae6e6db-2942-4ec7-b558-f308b80ab07b", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00003", "nct_id": "NCT01045018", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 205.0, "priority_reasons": ["missing_critical_rules=19", "rule_v1_missing=21", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 13, "lab": 1, "medication": 2, "other": 1, "procedure": 2}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition", "medication", "procedure", "lab", "other"], "eligibility_text": "Inclusion Criteria:\n\nAdults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation in the study:\n\n1. IRB approved consent form signed and dated prior to any study-related activities\n2. Male or, if female, had undergone sterilization (hysterectomy or bilateral tubal ligation), was post-menopausal (defined as 1 year without menses) or has a negative pregnancy test at screening and, if heterosexually active, had used and agreed to continue to use: double-barrier method of contraception (condom and spermicide), oral or patch contraceptives, intrauterine device, or was in a monogamous relationship with a partner who had undergone a vasectomy.\n3. 18 years of age or older\n4. Newly diagnosed with ulcerative colitis or relapsed following prior treatment\n5. Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization\n6. Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy\n7. Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mucosal appearance (determined by endoscopy exam) score of 1 or 2 (mild/moderate)\n8. Able and willing to have kept a daily diary during the study\n\nExclusion Criteria:\n\n1. Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine) within the 90 days immediately preceding Screening\n2. Use of rectal - administered aminosalicylates within 7 days of randomization\n3. Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization\n4. Crohn's disease, ischemic colitis, or disease of bacterial origin\n5. Known allergy or hypersensitivity to aspirin or salicylate compounds\n6. History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments\n7. History of cancer other than basal cell carcinoma within the five years immediately preceding study entry\n8. In relapse for \\> 3 weeks prior to the screening visit\n9. Proctitis below 15 cm from the anal verge\n10. History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis\n11. History of bleeding disorder\n12. Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract\n13. Previous colonic surgery\n14. History of alcohol or other substance abuse within the year immediately preceding anticipated study entry\n15. HIV positive\n16. \\> 6 bloody stools per day\n17. Positive stool culture for ova and/or parasites, enteric pathogens including Salmonella, Shigella, Yersinia, and Campylobacter, or positive stool assay for C. difficile toxin\n18. Pregnant or breast feeding\n19. Used an investigational drug in the 30 days prior to randomization\n20. BUN or serum creatinine levels of 1.5 times the upper limit of normal (ULN) or liver enzyme levels \\> 2 times the ULN", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "gastrointestinal obstruction including severe constipation, or anatomic abnormality of the gi tract", "unit": null, "evidence_text": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Crohn's disease, ischemic colitis, or disease of bacterial origin", "unit": null, "evidence_text": "Crohn's disease, ischemic colitis, or disease of bacterial origin"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "alcohol or other substance abuse within the year immediately preceding anticipated study entry", "unit": null, "evidence_text": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bleeding disorder", "unit": null, "evidence_text": "History of bleeding disorder"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cancer other than basal cell carcinoma within the five years immediately preceding study entry", "unit": null, "evidence_text": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis", "unit": null, "evidence_text": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments", "unit": null, "evidence_text": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "HIV positive"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract", "unit": null, "evidence_text": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry", "unit": null, "evidence_text": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of bleeding disorder", "unit": null, "evidence_text": "History of bleeding disorder"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry", "unit": null, "evidence_text": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis", "unit": null, "evidence_text": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator pr", "unit": null, "evidence_text": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "In relapse for \\> 3 weeks prior to the screening visit", "unit": null, "evidence_text": "In relapse for \\> 3 weeks prior to the screening visit"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization", "unit": null, "evidence_text": "Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Use of rectal - administered aminosalicylates within 7 days of randomization", "unit": null, "evidence_text": "Use of rectal - administered aminosalicylates within 7 days of randomization"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2", "unit": "times", "evidence_text": "BUN or serum creatinine levels of 1.5 times the upper limit of normal (ULN) or liver enzyme levels \\> 2 times the ULN"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine)", "unit": null, "evidence_text": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine) within the 90 days immediately preceding Screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Used an investigational drug in the 30 days prior to randomization", "unit": null, "evidence_text": "Used an investigational drug in the 30 days prior to randomization"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Previous colonic surgery", "unit": null, "evidence_text": "Previous colonic surgery"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "18 years of age or older"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "confirming biopsy", "unit": null, "evidence_text": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a partner who had undergone a vasectomy", "unit": null, "evidence_text": "Male or, if female, had undergone sterilization (hysterectomy or bilateral tubal ligation), was post-menopausal (defined as 1 year without menses) or has a negative pregnancy test at screening and, if heterosexually active, had used and agreed to continue to use: double-barrier method of contraception (condom and spermicide), oral or patch contraceptives, intrauterine device, or was in a monogamous relationship with a partner who had undergone a vasectomy."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mu", "unit": null, "evidence_text": "Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mucosal appearance (determined by endoscopy exam) score of 1 or 2 (mild/moderate)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ulcerative colitis or relapsed following prior treatment", "unit": null, "evidence_text": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Adults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation", "unit": null, "evidence_text": "Adults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation in the study:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "IRB approved consent form signed and dated prior to any study-related activities", "unit": null, "evidence_text": "IRB approved consent form signed and dated prior to any study-related activities"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment", "unit": null, "evidence_text": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization", "unit": null, "evidence_text": "Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Able and willing to have kept a daily diary during the study", "unit": null, "evidence_text": "Able and willing to have kept a daily diary during the study"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy", "unit": null, "evidence_text": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Male or, if female, had undergone sterilization (hysterectomy or bilateral tubal ligation), was post-menopausal (defined as 1 year without menses) or has a negative pregnancy test at screening and, if heterosexually active, had used and agreed to continue to use: double-barrier method of contraception (condom and spermicide), oral or patch contraceptives, intrauterine device, or was in a monogamous relationship with a partner who had undergone a vasectomy."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Crohn's disease, ischemic colitis, or disease of bacterial origin", "unit": null, "evidence_text": "Crohn's disease, ischemic colitis, or disease of bacterial origin"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract", "unit": null, "evidence_text": "Active peptic ulcer disease, history of gastrointestinal obstruction including severe constipation, or anatomic abnormality of the GI tract"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry", "unit": null, "evidence_text": "History of alcohol or other substance abuse within the year immediately preceding anticipated study entry"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of bleeding disorder", "unit": null, "evidence_text": "History of bleeding disorder"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry", "unit": null, "evidence_text": "History of cancer other than basal cell carcinoma within the five years immediately preceding study entry"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis", "unit": null, "evidence_text": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator pr", "unit": null, "evidence_text": "History of or laboratory results showing significant hepatic or renal disease or other significant medical condition which in the opinion of the investigator precluded participation in the study based on efficacy/safety assessments"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "In relapse for \\> 3 weeks prior to the screening visit", "unit": null, "evidence_text": "In relapse for \\> 3 weeks prior to the screening visit"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization", "unit": null, "evidence_text": "Patient had taken greater than 1.6 g/day of mesalamine or equivalent within 14 days of randomization"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Use of rectal - administered aminosalicylates within 7 days of randomization", "unit": null, "evidence_text": "Use of rectal - administered aminosalicylates within 7 days of randomization"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2", "unit": "times", "evidence_text": "BUN or serum creatinine levels of 1.5 times the upper limit of normal (ULN) or liver enzyme levels \\> 2 times the ULN"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine)", "unit": null, "evidence_text": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g. azathioprine, 6-mercaptopurine) within the 90 days immediately preceding Screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Used an investigational drug in the 30 days prior to randomization", "unit": null, "evidence_text": "Used an investigational drug in the 30 days prior to randomization"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Previous colonic surgery", "unit": null, "evidence_text": "Previous colonic surgery"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mu", "unit": null, "evidence_text": "Mild to moderate ulcerative colitis, defined as a Disease Activity Index (DAI) score between 4 and 9, inclusive, at study entry, and with a PGA of 1 or 2 and mucosal appearance (determined by endoscopy exam) score of 1 or 2 (mild/moderate)"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Adults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation", "unit": null, "evidence_text": "Adults with newly diagnosed ulcerative colitis or with relapse following prior treatment and who met all the following criteria were eligible for participation in the study:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "IRB approved consent form signed and dated prior to any study-related activities", "unit": null, "evidence_text": "IRB approved consent form signed and dated prior to any study-related activities"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment", "unit": null, "evidence_text": "Newly diagnosed with ulcerative colitis or relapsed following prior treatment"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization", "unit": null, "evidence_text": "Patient had not taken \\> 1.6 g/day of mesalamine or equivalent for 14 days prior to randomization"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Able and willing to have kept a daily diary during the study", "unit": null, "evidence_text": "Able and willing to have kept a daily diary during the study"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy", "unit": null, "evidence_text": "Disease extending ≥ 15 cm above the anal verge on screening sigmoidoscopy or colonoscopy with confirming biopsy"}], "rule_v1_extra_rules": [{"id": "rule-6d67a2a1-0482-4490-a3f8-fd936aecdb6f", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "topical rectal", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Treatment with topical rectal, oral, or intravenous (IV) corticosteroids within 30 days of screening or immunosuppressives (e.g.", "source_span": {"start": 1401, "end": 1529}}, {"id": "rule-45404e0c-c9b4-47af-8f50-f70903d044f6", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "ulcerative colitis", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of or current gastrointestinal bleeding other than bloody stools associated with ulcerative colitis", "source_span": {"start": 2389, "end": 2496}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00004", "nct_id": "NCT00942331", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 172.0, "priority_reasons": ["missing_critical_rules=15", "rule_v1_missing=18", "rule_v1_extra=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 7, "lab": 3, "procedure": 5, "sex": 1}, "extra_rules_by_field": {"age": 1, "condition": 3, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "procedure", "lab", "condition", "sex", "age"], "eligibility_text": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with metastatic or locally advanced disease (T4b, N2, N3, or M1); patients must not be candidates for potentially curative surgery or radiotherapy\n\n  * For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post-surgical scans\n* Prior treatment for transitional cell carcinoma (TCC)\n\n  * Patients may not have received combination systemic chemotherapy for metastatic disease\n  * For the purposes of this study, radiosensitizing single agent chemotherapy is not considered prior systemic therapy\n  * Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 year\n  * \\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered\n  * \\>= 7 days since any minor surgery such as port placement\n  * \\>= 4 weeks since any intravesical therapy\n  * No prior treatment with bevacizumab or other angiogenesis inhibitors\n* No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required\n* No current congestive heart failure; New York Heart Association (NYHA) class II, III or IV\n* Patients with history of hypertension must be well controlled (\\< 150/90) on a regimen of anti-hypertensive therapy\n* Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range international normalized ratio (INR) (usually between 2 and 3) or be on a stable dose of low molecular weight (LMW) heparin; patients receiving anti-platelet agents are also eligible; in addition, patients who are on daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligible\n* No significant history of bleeding events or gastrointestinal (GI) perforation\n\n  * Patients with a history of a significant bleeding episode (e.g. hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months of registration are not eligible\n  * Patients with a history of GI perforation within 12 months of registration are not eligible\n  * Patients with a history of peritoneal carcinomatosis are not eligible\n* No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible\n* Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolled to this study\n* No serious or non-healing wound, ulcer, or bone fracture\n* No sensory or motor peripheral neuropathy \\>= grade 2\n* Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies are not eligible\n* Patients that are pregnant or nursing are not eligible; women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 72 hours prior to registration\n\n  * For women of child-bearing potential with an elevated beta-HCG that is believed to be related to cancer and not pregnancy, a negative trans-vaginal ultrasound and gynecological examination are required\n  * Women of child-bearing potential include any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea \\>= 12 consecutive months; or women on hormone replacement therapy \\[HRT\\] with documented serum follicle stimulating hormone \\[FSH\\] level \\> 35 mIU/mL); even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (or Karnofsky performance status \\[KPS\\] \\>= 80)\n* Absolute neutrophil count (ANC) \\>= 1,500/uL\n* Platelet count \\>= 100,000/uL\n* Calculated or measured creatinine clearance \\>= 50 mL/minute\n* Bilirubin =\\< 1.25 times upper limits of normal; for patients with Gilbert's disease, =\\< 2.5 x upper limit of normal (ULN) is allowed\n* Aspartate aminotransferase (AST) =\\< 2.0 x upper limits of normal\n* Urine protein to creatinine ratio \\< 1.0 or urine protein =\\< 1+ or 24-hour urine protein =\\< 1 gram", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "an elevated beta hcg that is believed", "unit": null, "evidence_text": "For women of child-bearing potential with an elevated beta-HCG that is believed to be related to cancer and not pregnancy, a negative trans-vaginal ultrasound and gynecological examination are required"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pe", "unit": null, "evidence_text": "Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with metastatic or locally advanced disease (T4b, N2, N3, or M1);"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible", "unit": null, "evidence_text": "patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "systemic chemotherapy is permissible provided the interval", "unit": null, "evidence_text": "Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 year"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months o", "unit": null, "evidence_text": "hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months of registration are not eligible"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "No significant history of bleeding events or gastrointestinal (GI) perforation", "unit": null, "evidence_text": "No significant history of bleeding events or gastrointestinal (GI) perforation"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolle", "unit": null, "evidence_text": "Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolled to this study"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patients with a history of a significant bleeding episode (e.g.", "unit": null, "evidence_text": "Patients with a history of a significant bleeding episode (e.g."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with a history of GI perforation within 12 months of registration are not eligible", "unit": null, "evidence_text": "Patients with a history of GI perforation within 12 months of registration are not eligible"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with a history of peritoneal carcinomatosis are not eligible", "unit": null, "evidence_text": "Patients with a history of peritoneal carcinomatosis are not eligible"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Prior treatment for transitional cell carcinoma (TCC)", "unit": null, "evidence_text": "Prior treatment for transitional cell carcinoma (TCC)"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.25", "unit": "times", "evidence_text": "Bilirubin =\\< 1.25 times upper limits of normal; for patients with Gilbert's disease, =\\< 2.5 x upper limit of normal (ULN) is allowed"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "50", "unit": "ml/minute", "evidence_text": "Calculated or measured creatinine clearance \\>= 50 mL/minute"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": null, "evidence_text": "Platelet count \\>= 100,000/uL"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "\\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered", "unit": null, "evidence_text": "\\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "\\>= 7 days since any minor surgery such as port placement", "unit": null, "evidence_text": "\\>= 7 days since any minor surgery such as port placement"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post", "unit": null, "evidence_text": "For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post-surgical scans"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial th", "unit": null, "evidence_text": "No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI);"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required", "unit": null, "evidence_text": "No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 72 hours prior to registration"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pe", "unit": null, "evidence_text": "Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with metastatic or locally advanced disease (T4b, N2, N3, or M1);"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible", "unit": null, "evidence_text": "patients with clinically significant peripheral artery disease (i.e., claudication on less than one block) are ineligible"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolle", "unit": null, "evidence_text": "Patients who have experienced a deep venous thrombosis or pulmonary embolus within the past 6 months must be on stable therapeutic anticoagulation to be enrolled to this study"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patients with a history of a significant bleeding episode (e.g.", "unit": null, "evidence_text": "Patients with a history of a significant bleeding episode (e.g."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Prior treatment for transitional cell carcinoma (TCC)", "unit": null, "evidence_text": "Prior treatment for transitional cell carcinoma (TCC)"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months o", "unit": null, "evidence_text": "hemoptysis, upper or lower GI bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months of registration are not eligible"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "No significant history of bleeding events or gastrointestinal (GI) perforation", "unit": null, "evidence_text": "No significant history of bleeding events or gastrointestinal (GI) perforation"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with a history of GI perforation within 12 months of registration are not eligible", "unit": null, "evidence_text": "Patients with a history of GI perforation within 12 months of registration are not eligible"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with a history of peritoneal carcinomatosis are not eligible", "unit": null, "evidence_text": "Patients with a history of peritoneal carcinomatosis are not eligible"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.25", "unit": "times", "evidence_text": "Bilirubin =\\< 1.25 times upper limits of normal; for patients with Gilbert's disease, =\\< 2.5 x upper limit of normal (ULN) is allowed"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": null, "evidence_text": "Platelet count \\>= 100,000/uL"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "50", "unit": "ml/minute", "evidence_text": "Calculated or measured creatinine clearance \\>= 50 mL/minute"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "\\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered", "unit": null, "evidence_text": "\\>= 4 weeks since any prior radiation (including palliative) or major surgery and fully recovered"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "\\>= 7 days since any minor surgery such as port placement", "unit": null, "evidence_text": "\\>= 7 days since any minor surgery such as port placement"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post", "unit": null, "evidence_text": "For patients that have had surgical resection prior to study enrollment, residual or unresected disease (measurable and/or unmeasurable) must be evident on post-surgical scans"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial th", "unit": null, "evidence_text": "No arterial thrombotic events within 6 months of registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the past 6 months, or myocardial infarction (MI);"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required", "unit": null, "evidence_text": "No known history of brain metastases; brain imaging (magnetic resonance imaging \\[MRI\\]/computed tomography \\[CT\\]) is not required"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential"}], "rule_v1_extra_rules": [{"id": "rule-7c294130-07f7-42ec-b428-43c5f4285145", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Prior neoadjuvant or adjuvant systemic chemotherapy is permissible provided the interval from end of therapy to diagnosis of metastatic disease is at least 1 year", "source_span": {"start": 830, "end": 992}}, {"id": "rule-de92eba9-a3fb-4294-aefd-d1fcb2c292bd", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a history of gi perforation within 12", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a history of GI perforation within 12 months of registration are not eligible", "source_span": {"start": 2365, "end": 2456}}, {"id": "rule-166f9b03-143e-4dbe-afe4-ad63eee20045", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a history of peritoneal carcinomatosis are not", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a history of peritoneal carcinomatosis are not eligible", "source_span": {"start": 2461, "end": 2530}}, {"id": "rule-bba7aa83-e385-4f94-9b83-b359fdddcc8f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "bevacizumab or other angiogenesis inhibitors", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No prior treatment with bevacizumab or other angiogenesis inhibitors", "source_span": {"start": 1208, "end": 1276}}, {"id": "rule-0baa6078-3e8d-4ffa-8dfd-7f501ad329b1", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 72 hours prior to registration", "source_span": {"start": 3429, "end": 3640}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00005", "nct_id": "NCT01253265", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 170.0, "priority_reasons": ["missing_critical_rules=15", "rule_v1_missing=18", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3, "history": 6, "lab": 1, "medication": 4, "other": 2, "procedure": 2}, "extra_rules_by_field": {"condition": 2, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "medication", "condition", "other", "procedure", "lab", "sex"], "eligibility_text": "Inclusion Criteria:\n\n* Ambulatory male or female patients between the ages of 20 and 75 years\n* Male patients: Agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing. Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding. Women of child bearing potential must agree to use a reliable method of birth control during the study.\n* Patients who are between the body weight of 40 and 105 kilogram (kg)\n* Patients who have an established diagnosis of Rheumatoid Arthritis (RA)\n* Patients who have C reactive protein (CRP) measurement greater than the upper limit of normal or erythrocyte sedimentation rate of at least 28 millimeters per hour (mm/hr)\n* Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks\n* Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site\n* Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n\nExclusion Criteria:\n\n* Patients who use oral corticosteroids at average daily doses of \\>10 mg/day of prednisone or its equivalent or use of variable doses of oral corticosteroids within the last 4 weeks\n* Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks\n* Patients who have a diagnosis of any systemic inflammatory condition other than RA\n* Patients who have evidence of active vasculitis or uveitis\n* Patients who have a diagnosis of Felty's syndrome\n* Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study\n* Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease\n* Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection\n* Patients who have an evidence or suspicion of active tuberculosis (TB) by medical history, physical examination, and/or chest radiograph or documentation of TB by a positive purified protein derivative (PPD) test\n* Patients who have uncontrolled arterial hypertension characterized by a systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg\n* Patients who have an evidence of positive hepatitis B (HBV) surface antigen, positive hepatitis B surface antibody, positive hepatitis B core antibody, or hepatitis B DNA (HBV DNA); an evidence of human immunodeficiency virus (HIV), evidence of hepatitis B; or an evidence of hepatitis C\n* Patients who have clinical laboratory test results at entry that are outside the normal reference range, or results with unacceptable deviations that are considered clinically significant by the investigator\n* Patients who have a serum creatinine \\>2.0 milligrams per deciliter (mg/dL)\n* Patients who have known hypogammaglobulinemia or a serum immunoglobulin (Ig) G (IgG), IgM, or IgA concentration less than the lower limit of normal\n* Patients who have an abnormality in the 12 lead electrocardiogram (ECG).\n* Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days\n* Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer\n* Patients who previously completed or withdrawn from this study or any other study investigating LY2439821\n* Patients who have been treated with any biologic DMARD currently or previously for 5 half lives\n* Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)\n* Patients who have received non biologics DMARDs (other than MTX, sulfasalazine, bucillamine or hydroxychloroquine)", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "an evidence of human immunodeficiency virus (HIV), evidence of hepatitis B;"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients who have a diagnosis of any systemic inflammatory condition other than RA", "unit": null, "evidence_text": "Patients who have a diagnosis of any systemic inflammatory condition other than RA"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients who have a diagnosis of Felty's syndrome", "unit": null, "evidence_text": "Patients who have a diagnosis of Felty's syndrome"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives", "unit": null, "evidence_text": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days", "unit": null, "evidence_text": "Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in", "unit": null, "evidence_text": "Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that hav", "unit": null, "evidence_text": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection", "unit": null, "evidence_text": "Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who previously completed or withdrawn from this study or any other study investigating LY2439821", "unit": null, "evidence_text": "Patients who previously completed or withdrawn from this study or any other study investigating LY2439821"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2.0", "unit": "milligrams", "evidence_text": "Patients who have a serum creatinine \\>2.0 milligrams per deciliter (mg/dL)"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer", "unit": null, "evidence_text": "For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or", "unit": null, "evidence_text": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)", "unit": null, "evidence_text": "Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients who have an abnormality in the 12 lead electrocardiogram (ECG).", "unit": null, "evidence_text": "Patients who have an abnormality in the 12 lead electrocardiogram (ECG)."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study", "unit": null, "evidence_text": "Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a partner who is not child bearing", "unit": null, "evidence_text": "Male patients: Agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients who have an established diagnosis of Rheumatoid Arthritis (RA)", "unit": null, "evidence_text": "Patients who have an established diagnosis of Rheumatoid Arthritis (RA)"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) f", "unit": null, "evidence_text": "Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site", "unit": null, "evidence_text": "Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures", "unit": null, "evidence_text": "Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Male patients: Agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients who have a diagnosis of any systemic inflammatory condition other than RA", "unit": null, "evidence_text": "Patients who have a diagnosis of any systemic inflammatory condition other than RA"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients who have a diagnosis of Felty's syndrome", "unit": null, "evidence_text": "Patients who have a diagnosis of Felty's syndrome"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives", "unit": null, "evidence_text": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days", "unit": null, "evidence_text": "Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in", "unit": null, "evidence_text": "Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that hav", "unit": null, "evidence_text": "Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection", "unit": null, "evidence_text": "Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients who previously completed or withdrawn from this study or any other study investigating LY2439821", "unit": null, "evidence_text": "Patients who previously completed or withdrawn from this study or any other study investigating LY2439821"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2.0", "unit": "milligrams", "evidence_text": "Patients who have a serum creatinine \\>2.0 milligrams per deciliter (mg/dL)"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer", "unit": null, "evidence_text": "For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or", "unit": null, "evidence_text": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)", "unit": null, "evidence_text": "Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients who have an abnormality in the 12 lead electrocardiogram (ECG).", "unit": null, "evidence_text": "Patients who have an abnormality in the 12 lead electrocardiogram (ECG)."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study", "unit": null, "evidence_text": "Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients who have an established diagnosis of Rheumatoid Arthritis (RA)", "unit": null, "evidence_text": "Patients who have an established diagnosis of Rheumatoid Arthritis (RA)"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) f", "unit": null, "evidence_text": "Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site", "unit": null, "evidence_text": "Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures", "unit": null, "evidence_text": "Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures"}], "rule_v1_extra_rules": [{"id": "rule-07d7fdc1-7d64-4579-ad07-953166d681ef", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any biologic dmard", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients who have been treated with any biologic DMARD currently or previously for 5 half lives", "source_span": {"start": 4251, "end": 4346}}, {"id": "rule-a35553c4-6698-41f1-b5c8-256977566555", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "this study", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.", "source_span": {"start": 3682, "end": 3989}}, {"id": "rule-3c71c56e-354a-4184-a31e-1adf7013f4fd", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding.", "source_span": {"start": 279, "end": 412}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00006", "nct_id": "NCT00843024", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 169.0, "priority_reasons": ["missing_critical_rules=14", "rule_v1_missing=19", "rule_v1_extra=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4, "history": 8, "medication": 4, "procedure": 2, "sex": 1}, "extra_rules_by_field": {"condition": 3, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition", "medication", "procedure", "sex"], "eligibility_text": "Inclusion Criteria: Subjects eligible for enrollment in the study must meet all of the following criteria:\n\n1. Subject is \\>/=12 years of age and \\</=17 years of age at the Screening Visit.\n2. Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required. Attacks should last a minimum of three hours and be associated with moderate-to-severe headache pain.\n3. Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).\n4. Male or female subjects. Female subjects are eligible for participation in the study if they are:\n\n   1. Females of non-childbearing potential; or\n   2. Females of childbearing potential, and who have a negative urine pregnancy test at screening, and agree to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy\n5. Any subject taking oral contraceptives at enrollment must be on a stable regimen for at least 2 months prior to screening.\n6. Subject and subject's parent or legal guardian are able to read and write English or Spanish.\n7. Subject is able to read, comprehend, and complete subject diaries.\n8. Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.\n9. Subject is willing and able to provide Informed Assent prior to entry into the study (if required).\n\n   \\-\n\nExclusion Criteria:\n\n* Subjects meeting any of the following criteria must not be enrolled in the study:\n\n  1. Subject is \\< 74 pounds (33.3 kg).\n  2. Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches.\n  3. Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.\n  4. Subject has uncontrolled hypertension at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.\n  5. Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study.\n  6. Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above.\n  7. Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening.\n  8. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.\n  9. Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma.\n  10. Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized.\n  11. Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of 4 days per month over the last 6 months.\n  12. Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.\n  13. Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.\n  14. Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.\n  15. Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy test(s).\n  16. Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.\n  17. Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any bleeding disorder or is currently taking any anti coagulant or any antiplatelet agent", "unit": null, "evidence_text": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study", "unit": null, "evidence_text": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study", "unit": null, "evidence_text": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "regular use of opioids or barbiturates for treatment of their migraine headache and/or other non migraine pain", "unit": null, "evidence_text": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any gastrointestinal surgery, gi ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease", "unit": null, "evidence_text": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above", "unit": null, "evidence_text": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "central nervous system pathology including stroke and/or transient ischemic attacks (tias), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening", "unit": null, "evidence_text": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic m", "unit": null, "evidence_text": "Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.", "unit": null, "evidence_text": "Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.", "unit": null, "evidence_text": "John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.", "unit": null, "evidence_text": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.", "unit": null, "evidence_text": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain.", "unit": null, "evidence_text": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease,", "unit": null, "evidence_text": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above."}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormal", "unit": null, "evidence_text": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesi", "unit": null, "evidence_text": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.", "unit": null, "evidence_text": "Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dos", "unit": null, "evidence_text": "Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past yea", "unit": null, "evidence_text": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medica", "unit": null, "evidence_text": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial."}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "Subject is \\>/=12 years of age and \\</=17 years of age at the Screening Visit."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe headache pain", "unit": null, "evidence_text": "Attacks should last a minimum of three hours and be associated with moderate-to-severe headache pain."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1).", "unit": null, "evidence_text": "Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1)."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).", "unit": null, "evidence_text": "Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches)."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required.", "unit": null, "evidence_text": "A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subject is willing and able to provide Informed Assent prior to entry into the study (if required).", "unit": null, "evidence_text": "Subject is willing and able to provide Informed Assent prior to entry into the study (if required)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.", "unit": null, "evidence_text": "Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female subjects are eligible for participation in the study if they are:"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females of non-childbearing potential; or"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic m", "unit": null, "evidence_text": "Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.", "unit": null, "evidence_text": "Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.", "unit": null, "evidence_text": "John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.", "unit": null, "evidence_text": "Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.", "unit": null, "evidence_text": "Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain.", "unit": null, "evidence_text": "Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease,", "unit": null, "evidence_text": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormal", "unit": null, "evidence_text": "Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesi", "unit": null, "evidence_text": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.", "unit": null, "evidence_text": "Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dos", "unit": null, "evidence_text": "Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past yea", "unit": null, "evidence_text": "Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medica", "unit": null, "evidence_text": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1).", "unit": null, "evidence_text": "Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1)."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).", "unit": null, "evidence_text": "Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subject is willing and able to provide Informed Assent prior to entry into the study (if required).", "unit": null, "evidence_text": "Subject is willing and able to provide Informed Assent prior to entry into the study (if required)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.", "unit": null, "evidence_text": "Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required.", "unit": null, "evidence_text": "A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female subjects are eligible for participation in the study if they are:"}], "rule_v1_extra_rules": [{"id": "rule-cf121daf-64dc-4dc8-b0f8-6ea4d767a75a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an antiepileptic drug for seizure control within", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening.", "source_span": {"start": 2587, "end": 2890}}, {"id": "rule-c6233cfd-d487-4dff-9713-526e3e712ee2", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any of the above", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above.", "source_span": {"start": 2370, "end": 2581}}, {"id": "rule-1d011112-c867-4fbc-aee1-50160276c3ce", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the study conduct", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.", "source_span": {"start": 4509, "end": 4929}}, {"id": "rule-f91494ed-dac9-455c-8975-86d420e75491", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Female subjects are eligible for participation in the study if they are:", "source_span": {"start": 625, "end": 697}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00007", "nct_id": "NCT01158274", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 165.0, "priority_reasons": ["missing_critical_rules=13", "rule_v1_missing=19", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"condition": 5, "history": 3, "lab": 4, "medication": 3, "other": 2, "procedure": 1, "sex": 1}, "extra_rules_by_field": {"condition": 4, "sex": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "lab", "history", "medication", "other", "sex", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\>= 20 mm with conventional techniques or as \\>= 10 mm with spiral CT scan\n* Patients must be at least 4 weeks since prior chemotherapy, 6 weeks if the last regimen included BCNU or mitomycin C; prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated\n* Life expectancy of greater than 3 months\n* ECOG performance status =\\< 2 (Karnofsky \\>= 60%)\n* Hemoglobin \\>= 9 g/dL\n* Leukocytes \\>= 3,000/mcL\n* Absolute neutrophil count \\>= 1,500/mcL\n* Platelets \\>= 100,000/mcL\n* Total bilirubin within normal institutional limits\n* AST (SGOT)/ALT (SGPT) =\\< 2.5 X institutional upper limit of normal\n* Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal; a 24 hour urine collection and creatinine clearance can be measured if indicated\n* Treated, stable brain metastases are allowed; patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not metabolized by cytochrome P450\n* Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study and for 12 months after study participation, the patient should inform the treating physician immediately\n* Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of RO4929097 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of RO4929097; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing RO4929097, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of RO4929097\n* Female patients of childbearing potential are defined as follows:\n\n  * Patients with regular menses\n  * Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding\n  * Women who have had tubal ligation\n* Female patients may be considered NOT to be of childbearing potential for the following reasons:\n\n  * The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy\n  * The patient is medically confirmed to be menopausal (no menstrual period) for 24 consecutive months\n  * Pre-pubertal females. The parent or guardian of young female patients who have not yet started menstruation should verify that menstruation has not begun. If a young female patient reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward\n* Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document\n* Preclinical studies indicate that RO4929097 is a substrate of CYP3A4 and inducer of CYP3A4 enzyme activity; caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates, inducers, and/or inhibitors; furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk; if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study\n* PART 2A (MTD EXPANSION COLORECTAL CANCER):\n* For this cohort patients must have histologically or cytologically documented advanced or metastatic colorectal cancer; patients must have had at least one prior chemotherapy regimen for their disease but no more than 2\n* All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial\n* PART 2B (MTD EXPANSION BREAST CANCER):\n* For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer\n* Patient must be HER2/neu negative; HER2 negative will be defined as HER2 neither over-expressed or amplified; HER2 will be considered NOT over-expressed if the tumor stains as 0 or 1+ for HER2 by immunohistochemistry (IHC); if the IHC for HER2 is 2+, fluorescence in-site hybridization (FISH) ratio must be less than 2 to be considered NOT amplified; any tumor for which only FISH was performed must have a ratio of less than 2 to be considered NOT amplified\n* All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial\n\nExclusion Criteria:\n\n* Patients may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine\n* Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®) are ineligible\n* Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow tablets\n* Patients who are serologically positive for Hepatitis A, B or C, or have a history of liver disease, other forms of hepatitis or cirrhosis are ineligible\n* Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study; note: it is acceptable to use corrected calcium when interpreting calcium levels\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and a history of torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study; breastfeeding should be discontinued\n* HIV-positive patients, who are not on anti-retroviral therapy but have CD4 cells less than 200, should be excluded; HIV-positive patients are eligible if they are on HAART (highly active anti-retroviral therapy) which are not CYP3A4 substrates, inducers and/or inhibitors and meet all other criteria\n* Cardiovascular: baseline QTcF \\> 450 msec\n* Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency enzyme are excluded\n* Patients who have not recovered to \\< CTCAE grade 2 toxicities related to prior therapy are not eligible to participate in this study\n* A requirement for antiarrhythmics or other medications known to prolong QTc\n* PART2B (MTD EXPANSION BREAST CANCER):\n* Patients may not have had more than 1 prior cytotoxic chemotherapy for metastatic disease; prior endocrine or immunotherapy regimens for metastatic disease will not be counted as cytotoxic", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reactions attributed to compounds of similar chemical or biologic composition to ro4929097 or capecitabine", "unit": null, "evidence_text": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "HIV-positive patients are eligible if they are on HAART (highly active anti-retroviral therapy) which are not CYP3A4 substrates, inducers and/or inhibitors and meet all other criteria"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "liver disease, other forms of hepatitis or cirrhosis are ineligible", "unit": null, "evidence_text": "Patients who are serologically positive for Hepatitis A, B or C, or have a history of liver disease, other forms of hepatitis or cirrhosis are ineligible"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements", "unit": null, "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and a history of torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine", "unit": null, "evidence_text": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women are excluded from this study;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "this trial", "unit": null, "evidence_text": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this tr", "unit": null, "evidence_text": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "cyp3a4 substrates", "unit": null, "evidence_text": "caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates, inducers, and/or inhibitors;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "creatinine levels above institutional normal", "unit": null, "evidence_text": "Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer", "unit": null, "evidence_text": "For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "PART 2A (MTD EXPANSION COLORECTAL CANCER):", "unit": null, "evidence_text": "PART 2A (MTD EXPANSION COLORECTAL CANCER):"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "PART 2B (MTD EXPANSION BREAST CANCER):", "unit": null, "evidence_text": "PART 2B (MTD EXPANSION BREAST CANCER):"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stable brain imaging and off any medications", "unit": null, "evidence_text": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not metabolized by cytochrome P450"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible", "unit": null, "evidence_text": "Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "spiral ct scan", "unit": null, "evidence_text": "Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\>= 20 mm with conventional techniques or as \\>= 10 mm with spiral CT scan"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "lymphoma will be eligible", "unit": null, "evidence_text": "patients with lymphoma will be eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "regular menses", "unit": null, "evidence_text": "Patients with regular menses"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "amenorrhea", "unit": null, "evidence_text": "Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "bilateral salpingo oophorectomy or bilateral oophorectomy", "unit": null, "evidence_text": "The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Total bilirubin within normal institutional limits", "unit": null, "evidence_text": "Total bilirubin within normal institutional limits"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks", "unit": null, "evidence_text": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment;"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "2.5", "unit": "x", "evidence_text": "AST (SGOT)/ALT (SGPT) =\\< 2.5 X institutional upper limit of normal"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "60", "unit": "ml/min/1", "evidence_text": "Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal;"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "9", "unit": "g/dl", "evidence_text": "Hemoglobin \\>= 9 g/dL"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": null, "evidence_text": "Platelets \\>= 100,000/mcL"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medica", "unit": null, "evidence_text": "furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk;"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study", "unit": null, "evidence_text": "if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not", "unit": null, "evidence_text": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not metabolized by cytochrome P450"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial", "unit": null, "evidence_text": "All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document", "unit": null, "evidence_text": "Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated", "unit": null, "evidence_text": "prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female patients may be considered NOT to be of childbearing potential for the following reasons:"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine", "unit": null, "evidence_text": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to RO4929097 or capecitabine"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women are excluded from this study;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this tr", "unit": null, "evidence_text": "All 5 patients in this breast cancer cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer", "unit": null, "evidence_text": "For this cohort, patients must have histologically or cytologically documented advanced or metastatic breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "PART 2A (MTD EXPANSION COLORECTAL CANCER):", "unit": null, "evidence_text": "PART 2A (MTD EXPANSION COLORECTAL CANCER):"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "PART 2B (MTD EXPANSION BREAST CANCER):", "unit": null, "evidence_text": "PART 2B (MTD EXPANSION BREAST CANCER):"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible", "unit": null, "evidence_text": "Patients must have histologically or cytologically confirmed advanced or metastatic solid tumor; patients with lymphoma will be eligible"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Total bilirubin within normal institutional limits", "unit": null, "evidence_text": "Total bilirubin within normal institutional limits"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks", "unit": null, "evidence_text": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment;"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": null, "evidence_text": "Platelets \\>= 100,000/mcL"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "2.5", "unit": "x", "evidence_text": "AST (SGOT)/ALT (SGPT) =\\< 2.5 X institutional upper limit of normal"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "60", "unit": "ml/min/1", "evidence_text": "Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal;"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "9", "unit": "g/dl", "evidence_text": "Hemoglobin \\>= 9 g/dL"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medica", "unit": null, "evidence_text": "furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk;"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study", "unit": null, "evidence_text": "if such patients cannot be switched to alternative medications, they will be ineligible to participate in this study"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not", "unit": null, "evidence_text": "patients must be four weeks from radiation with stable brain imaging and off any medications used to treat brain metastases, excepting those anti-epileptics not metabolized by cytochrome P450"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial", "unit": null, "evidence_text": "All 5 patients in this cohort must be willing and able to have tumor biopsies performed as part of the correlative studies associated with this trial"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document", "unit": null, "evidence_text": "Patients must demonstrate an ability to understand and the willingness to sign a written informed consent document"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated", "unit": null, "evidence_text": "prior radiation is allowed as long as the radiation was completed 4 weeks prior to study treatment and no more than 35% of marrow irradiated"}], "rule_v1_extra_rules": [{"id": "rule-6d92db8a-bac8-4da9-bb0f-3f9258ebc7b9", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and a history of torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements", "source_span": {"start": 6523, "end": 6898}}, {"id": "rule-099f38a5-b38b-451b-b527-550035f3738b", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "intestinal absorption", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption;", "source_span": {"start": 5890, "end": 5994}}, {"id": "rule-66a074e4-f532-48ec-88ea-725ec4c88479", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "study requirements", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and a history of torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements", "source_span": {"start": 6523, "end": 6898}}, {"id": "rule-34ae1a42-27bb-4733-8126-87b2c253b93a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled hypocalcemia", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study;", "source_span": {"start": 6194, "end": 6439}}, {"id": "rule-48981b1a-e34b-43da-a23e-93ce90fe8e59", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Pregnant women are excluded from this study;", "source_span": {"start": 6901, "end": 6945}}, {"id": "rule-d8534d9b-b56c-4435-8f9c-154f1e6e161d", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Women of childbearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment;", "source_span": {"start": 1485, "end": 1751}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00008", "nct_id": "NCT01042366", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 151.0, "priority_reasons": ["missing_critical_rules=12", "contract_errors=1", "rule_v1_missing=15", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3, "history": 4, "lab": 2, "medication": 3, "other": 2, "procedure": 1}, "extra_rules_by_field": {"condition": 6}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"LAB_THRESHOLD_VALUE_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition", "medication", "lab", "other", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n* Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC). Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute.\n* All subjects have to be HLA-A2 positive (required for immunologic testing).\n* Subjects must have recovered fully from surgery.\n* Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation.\n* Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7).\n* Sufficient number of DCs of at least 12 X 10 6 for preparation of the autologous tumor dendritic cell vaccine preparation (if less than needed number of cells will be obtained by one course of leukopheresis, the second leukopheresis will be repeated 2 weeks apart).\n* Subjects must not have received any chemotherapy or immunotherapy within the four weeks preceding vaccination (six weeks for nitrosourea, mitomycin).\n* Subjects must have an expected survival of greater than or equal to 12 months.\n* Subjects must have an ECOG performance status 0 or 1.\n* Subjects must have the following initial and subsequent pretreatment\n* laboratory parameters: Granulocytes \\>=2,500/mm3 Lymphocytes \\>=1000/mm3 Platelets \\>100,000/mm3 Serum Creatinine \\<=1.5 X the ULN AST, ALT, GGT, LDH, Alk phos \\<= 2.5 X the ULN Serum Bilirubin \\<=1.5 X ULN\n* Subjects must be \\>= 18 years of age and must be able to understand the written informed consent.\n* No evidence of active infection, regardless of the degree of severity or localization. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.\n* Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment.\n* Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration\n\nExclusion Criteria:\n\n* Subjects currently treated with anti inflammatory agents including glucocorticoid therapy are ineligible.\n* Subjects currently on treatment with steroids are ineligible, but may receive the DC autologous tumor dendritic cell vaccine 4 weeks after steroid cessation. Subjects on maintenance steroids because of adrenal insufficiency are eligible.\n* Subjects with severely abnormal liver function tests \\[AST (SGOT), ALT (SGPT), GGT, Alk.Phos, LDH, and total bilirubin greater than 2 X ULN\\].\n* Subjects with uncontrolled pain.\n* Subjects with autoimmune disease, HIV, and hepatitis\n* Subjects with symptomatic brain metastasis.\n* Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix).\n* Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm.\n* Subjects who are pregnant.\n* Subjects who have sensitivity to drugs to provide local anesthesia.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Subjects with autoimmune disease, HIV, and hepatitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subjects with autoimmune disease, HIV, and hepatitis", "unit": null, "evidence_text": "Subjects with autoimmune disease, HIV, and hepatitis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm.", "unit": null, "evidence_text": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix).", "unit": null, "evidence_text": "Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix)."}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": "2", "unit": "x", "evidence_text": "Subjects with severely abnormal liver function tests \\[AST (SGOT), ALT (SGPT), GGT, Alk.Phos, LDH, and total bilirubin greater than 2 X ULN\\]."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subjects who have sensitivity to drugs to provide local anesthesia.", "unit": null, "evidence_text": "Subjects who have sensitivity to drugs to provide local anesthesia."}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Subjects must be \\>= 18 years of age and must be able to understand the written informed consent."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "each", "unit": null, "evidence_text": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute.", "unit": null, "evidence_text": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC)", "unit": null, "evidence_text": "Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration", "unit": null, "evidence_text": "Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment.", "unit": null, "evidence_text": "Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "2", "unit": null, "evidence_text": "laboratory parameters: Granulocytes \\>=2,500/mm3 Lymphocytes \\>=1000/mm3 Platelets \\>100,000/mm3 Serum Creatinine \\<=1.5 X the ULN AST, ALT, GGT, LDH, Alk phos \\<= 2.5 X the ULN Serum Bilirubin \\<=1.5 X ULN"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.", "unit": null, "evidence_text": "Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection.", "unit": null, "evidence_text": "Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation.", "unit": null, "evidence_text": "Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7).", "unit": null, "evidence_text": "Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7)."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Subjects must have recovered fully from surgery.", "unit": null, "evidence_text": "Subjects must have recovered fully from surgery."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subjects with autoimmune disease, HIV, and hepatitis", "unit": null, "evidence_text": "Subjects with autoimmune disease, HIV, and hepatitis"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm.", "unit": null, "evidence_text": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix).", "unit": null, "evidence_text": "Subjects with active prior malignancy (with exception of non-melanoma skin cancers and carcinoma in situ of the cervix)."}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": "2", "unit": "x", "evidence_text": "Subjects with severely abnormal liver function tests \\[AST (SGOT), ALT (SGPT), GGT, Alk.Phos, LDH, and total bilirubin greater than 2 X ULN\\]."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subjects who have sensitivity to drugs to provide local anesthesia.", "unit": null, "evidence_text": "Subjects who have sensitivity to drugs to provide local anesthesia."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute.", "unit": null, "evidence_text": "Each diagnosis will be confirmed by pathology review at the Melanoma Center of the University of Pittsburgh Cancer Institute."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC)", "unit": null, "evidence_text": "Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (AJCC)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration", "unit": null, "evidence_text": "Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to18 days of subject registration"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment.", "unit": null, "evidence_text": "Subjects with measurable disease must have an evaluation for extent of disease (tumor staging) performed within 30 days of start of treatment."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "2", "unit": null, "evidence_text": "laboratory parameters: Granulocytes \\>=2,500/mm3 Lymphocytes \\>=1000/mm3 Platelets \\>100,000/mm3 Serum Creatinine \\<=1.5 X the ULN AST, ALT, GGT, LDH, Alk phos \\<= 2.5 X the ULN Serum Bilirubin \\<=1.5 X ULN"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.", "unit": null, "evidence_text": "Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection.", "unit": null, "evidence_text": "Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation.", "unit": null, "evidence_text": "Availability of resectable or tissue banked tumor cells for autologous tumor dendritic cell vaccine preparation."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7).", "unit": null, "evidence_text": "Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine preparation (min 2.6 x 10 7)."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Subjects must have recovered fully from surgery.", "unit": null, "evidence_text": "Subjects must have recovered fully from surgery."}], "rule_v1_extra_rules": [{"id": "rule-b9fa8f5a-4c0e-41a5-9855-8118be0c3ccb", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "anti inflammatory agents including glucocorticoid therapy are", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects currently treated with anti inflammatory agents including glucocorticoid therapy are ineligible.", "source_span": {"start": 2236, "end": 2341}}, {"id": "rule-755250f2-3495-495e-b865-e7d1b9ceb3da", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "autoimmune disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with autoimmune disease, HIV, and hepatitis", "source_span": {"start": 2764, "end": 2816}}, {"id": "rule-6f1aab0d-3a06-4ed8-9845-8d23026543d9", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "melanoma vaccine until 10 subjects have been", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects who have been previously immunized with melanoma vaccine until 10 subjects have been registered in each treatment arm.", "source_span": {"start": 2988, "end": 3115}}, {"id": "rule-12ee77bc-2d1b-4779-bf1c-dd6a217e6845", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "steroids are ineligible", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects currently on treatment with steroids are ineligible, but may receive the DC autologous tumor dendritic cell vaccine 4 weeks after steroid cessation.", "source_span": {"start": 2344, "end": 2501}}, {"id": "rule-17113159-95ee-42a2-ae43-988de0bda092", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "symptomatic brain metastasis", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with symptomatic brain metastasis.", "source_span": {"start": 2819, "end": 2862}}, {"id": "rule-d4f7ca3f-f465-41e8-98f2-d852e1f289ce", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled pain", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with uncontrolled pain.", "source_span": {"start": 2729, "end": 2761}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00009", "nct_id": "NCT00811759", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 149.0, "priority_reasons": ["missing_critical_rules=12", "rule_v1_missing=18"], "priority_breakdown": {"missing_rules_by_field": {"condition": 6, "history": 5, "lab": 2, "medication": 3, "procedure": 2}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "medication", "lab", "procedure"], "eligibility_text": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of unresectable or metastatic melanoma\n\n  * Stage III or IV disease\n* Previously treated or untreated metastatic disease\n* At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI\n* No concurrent brain or CNS metastases\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0-1\n* Life expectancy ≥ 3 months\n* ANC ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin \\> 9 g/dL\n* PT, INR, and PTT \\< 1.5 times upper limit of normal (ULN)\n* Transaminases \\< 2.5 times ULN (\\< 5 in the case of liver metastases)\n* Amylase and lipase \\< 1.5 times ULN\n* Bilirubin ≤ 1.5 times ULN\n* Serum creatinine \\< 1.5 times ULN\n* Normal respiratory, cardiac, and neurological function\n* Not pregnant or nursing\n* No history of any of the following cardiac conditions:\n\n  * NYHA class II-IV heart failure\n  * Coronary disease\n  * Myocardial infarction within the past 6 months\n  * Cardiac arrhythmia requiring treatment with something other than beta-blockers or digoxin\n  * Severe uncontrolled hypertension\n* No severe active infection \\> grade 2\n* No epilepsy requiring medical treatment\n* No other cancer except for carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumors, or curatively treated cancer \\> 3 years ago\n* No HIV or hepatitis B or C positivity\n* No lactase or galactokinase deficiency, galactose intolerance, or disease accompanied by malabsorption of glucose or galactose\n* No allergy to the study drugs or to dacarbazine\n* Able to swallow medications\n* No patients deprived of liberty\n* No psychological, familial, social, or geographic conditions that would preclude clinical follow up\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior organ transplantation\n* No prior temozolomide or sorafenib tosylate\n* More than 30 days since other prior antitumor chemotherapy, immunotherapy, hormonal therapy, or investigational agent\n* More than 30 days since prior study drugs\n* More than 3 weeks since prior radiotherapy\n* More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "something other than beta blockers or digoxin", "unit": null, "evidence_text": "Cardiac arrhythmia requiring treatment with something other than beta-blockers or digoxin"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Coronary disease", "unit": null, "evidence_text": "Coronary disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis of unresectable or metastatic melanoma", "unit": null, "evidence_text": "Diagnosis of unresectable or metastatic melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "DISEASE CHARACTERISTICS:", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "NYHA class II-IV heart failure", "unit": null, "evidence_text": "NYHA class II-IV heart failure"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "See Disease Characteristics", "unit": null, "evidence_text": "See Disease Characteristics"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Stage III or IV disease", "unit": null, "evidence_text": "Stage III or IV disease"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])", "unit": null, "evidence_text": "More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Myocardial infarction within the past 6 months", "unit": null, "evidence_text": "Myocardial infarction within the past 6 months"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "No history of any of the following cardiac conditions:", "unit": null, "evidence_text": "No history of any of the following cardiac conditions:"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "No prior temozolomide or sorafenib tosylate", "unit": null, "evidence_text": "No prior temozolomide or sorafenib tosylate"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Previously treated or untreated metastatic disease", "unit": null, "evidence_text": "Previously treated or untreated metastatic disease"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "9", "unit": "g/dl", "evidence_text": "Hemoglobin \\> 9 g/dL"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "times", "evidence_text": "Serum creatinine \\< 1.5 times ULN"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Able to swallow medications", "unit": null, "evidence_text": "Able to swallow medications"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "More than 30 days since prior study drugs", "unit": null, "evidence_text": "More than 30 days since prior study drugs"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "No allergy to the study drugs or to dacarbazine", "unit": null, "evidence_text": "No allergy to the study drugs or to dacarbazine"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI", "unit": null, "evidence_text": "At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "No prior organ transplantation", "unit": null, "evidence_text": "No prior organ transplantation"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Coronary disease", "unit": null, "evidence_text": "Coronary disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis of unresectable or metastatic melanoma", "unit": null, "evidence_text": "Diagnosis of unresectable or metastatic melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "DISEASE CHARACTERISTICS:", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "NYHA class II-IV heart failure", "unit": null, "evidence_text": "NYHA class II-IV heart failure"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "See Disease Characteristics", "unit": null, "evidence_text": "See Disease Characteristics"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Stage III or IV disease", "unit": null, "evidence_text": "Stage III or IV disease"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])", "unit": null, "evidence_text": "More than 3 weeks since prior biological response modifiers (i.e., filgrastim \\[G-CSF\\])"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Myocardial infarction within the past 6 months", "unit": null, "evidence_text": "Myocardial infarction within the past 6 months"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Previously treated or untreated metastatic disease", "unit": null, "evidence_text": "Previously treated or untreated metastatic disease"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "No history of any of the following cardiac conditions:", "unit": null, "evidence_text": "No history of any of the following cardiac conditions:"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "No prior temozolomide or sorafenib tosylate", "unit": null, "evidence_text": "No prior temozolomide or sorafenib tosylate"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "times", "evidence_text": "Serum creatinine \\< 1.5 times ULN"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "9", "unit": "g/dl", "evidence_text": "Hemoglobin \\> 9 g/dL"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Able to swallow medications", "unit": null, "evidence_text": "Able to swallow medications"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "More than 30 days since prior study drugs", "unit": null, "evidence_text": "More than 30 days since prior study drugs"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "No allergy to the study drugs or to dacarbazine", "unit": null, "evidence_text": "No allergy to the study drugs or to dacarbazine"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI", "unit": null, "evidence_text": "At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "No prior organ transplantation", "unit": null, "evidence_text": "No prior organ transplantation"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00010", "nct_id": "NCT01001234", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 143.0, "priority_reasons": ["missing_critical_rules=12", "rule_v1_missing=16", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3, "history": 5, "medication": 6, "other": 1, "sex": 1}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "history", "condition", "sex", "other"], "eligibility_text": "Inclusion Criteria:\n\n* Patient weighs at least 20 kg (44 pounds)\n* Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior to screening Visit 1\n* Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions\n* Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication\n* Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment\n* The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and\n\npatient assent\n\n\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1.\n\nExclusion Criteria:\n\n* Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation\n* Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours\n* Patient has basilar or hemiplegic migraine headaches\n* Patient has \\>15 headache-days per month OR has taken medication for acute\n\nheadache on more than 10 days per month in any of the 3 months prior to screening\n\n* Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any\n\ncancer, or any other significant disease\n\n* Patient has a history or clinical evidence of cardiovascular problems or stroke\n* Patient has either demonstrated hypersensitivity to or experienced a serious\n\nadverse event in response to rizatriptan\n\n* Patient did not experience satisfactory relief from migraine pain to prior treatment with 2 or more adequate courses of 5-hydroxytryptamine 1 (5HT1) agonists\n* Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs\n* Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required\n* Patient is currently participating or has participated in a study with an\n\ninvestigational compound or device within 30 days of screening\n\n\\- Patient is legally or mentally incapacitated.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cancer, or any other significant disease", "unit": null, "evidence_text": "cancer, or any other significant disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mild migraine attacks or migraines that resolve in less than 2 hours", "unit": null, "evidence_text": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patient has basilar or hemiplegic migraine headaches", "unit": null, "evidence_text": "Patient has basilar or hemiplegic migraine headaches"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any", "unit": null, "evidence_text": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "headache on more than 10 days per month in any of the 3 months prior to screening", "unit": null, "evidence_text": "headache on more than 10 days per month in any of the 3 months prior to screening"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "investigational compound or device within 30 days of screening", "unit": null, "evidence_text": "investigational compound or device within 30 days of screening"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours", "unit": null, "evidence_text": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patient has \\>15 headache-days per month OR has taken medication for acute", "unit": null, "evidence_text": "Patient has \\>15 headache-days per month OR has taken medication for acute"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs", "unit": null, "evidence_text": "Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inh", "unit": null, "evidence_text": "Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions", "unit": null, "evidence_text": "Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior t", "unit": null, "evidence_text": "Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior to screening Visit 1"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1.", "unit": null, "evidence_text": "\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment", "unit": null, "evidence_text": "Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication", "unit": null, "evidence_text": "Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and", "unit": null, "evidence_text": "The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cancer, or any other significant disease", "unit": null, "evidence_text": "cancer, or any other significant disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patient has basilar or hemiplegic migraine headaches", "unit": null, "evidence_text": "Patient has basilar or hemiplegic migraine headaches"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any", "unit": null, "evidence_text": "Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "headache on more than 10 days per month in any of the 3 months prior to screening", "unit": null, "evidence_text": "headache on more than 10 days per month in any of the 3 months prior to screening"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "investigational compound or device within 30 days of screening", "unit": null, "evidence_text": "investigational compound or device within 30 days of screening"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours", "unit": null, "evidence_text": "Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patient has \\>15 headache-days per month OR has taken medication for acute", "unit": null, "evidence_text": "Patient has \\>15 headache-days per month OR has taken medication for acute"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs", "unit": null, "evidence_text": "Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a \"recreational user\" of illicit drugs"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inh", "unit": null, "evidence_text": "Patient is currently taking monoamine oxidase inhibitors, methysergide, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions", "unit": null, "evidence_text": "Patient has a history of migraine defined by International Headache Society (IHS) migraine definitions"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior t", "unit": null, "evidence_text": "Patient has had a history of migraine with or without aura \\> 6 months with \\>= 1 to \\<= 8 moderate or severe migraine attacks per month in the 2 months prior to screening Visit 1"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1.", "unit": null, "evidence_text": "\\- For patients taking migraine prophylactic medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment", "unit": null, "evidence_text": "Patient has not experienced satisfactory relief from migraine pain with nonsteroidal anti-inflammatory drugs (NSAIDs) or N-acetyl-p-aminophenol (APAP) treatment"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication", "unit": null, "evidence_text": "Patient is willing to stay awake for at least 2 hours after administration of the first dose of study medication"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and", "unit": null, "evidence_text": "The parent or guardian and patient agree to the patient's participation in the study as indicated by parental/guardian signature on the consent form and"}], "rule_v1_extra_rules": [{"id": "rule-a4527cee-ce07-42af-9deb-561ba5aa3b82", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation", "source_span": {"start": 970, "end": 1098}}, {"id": "rule-803a5734-bc70-4f1e-9a73-423123250ae4", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00011", "nct_id": "NCT00737789", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 142.0, "priority_reasons": ["missing_critical_rules=10", "contract_errors=1", "rule_v1_missing=16", "rule_v1_extra=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 5, "history": 1, "lab": 1, "medication": 3, "other": 3, "procedure": 2, "sex": 1}, "extra_rules_by_field": {"condition": 4, "sex": 1}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication", "other", "procedure", "sex", "history", "lab"], "eligibility_text": "Inclusion Criteria:\n\nPatients will be included if they comply with the following inclusion criteria determined at baseline, prior to first drug administration:\n\n* Aged over 18 years.\n* Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction). All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).\n* Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8).\n* Men or non pregnant women.\n* Women with childbearing potential must be using a contraceptive method judged effective by the investigator.\n* Oral maintenance treatment with azathioprine or 6-mercaptopurine (taken for at least 6 months at stable dose and continued at the same dose throughout the study) is permitted.\n* Informed consent given.\n\nExclusion Criteria:\n\nThe patients will not be included in the study if one of the following exclusion criteria is fulfilled at baseline, prior to first drug administration:\n\n* Proctitis (less than 12-18 cm from the anorectal junction).\n* Previous colonic surgery.\n* Previously failed to respond to steroids within the previous year.\n* Non-response to rectal 5-Amino Salicylic Acid (5-ASA) therapy or to oral 5-ASA therapy at a dose \\> 3g/day for induction of remission within the previous year.\n* Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).\n* Severe/fulminant ulcerative colitis.\n* Evidence of other forms of inflammatory bowel disease or infectious disease.\n* Allergy to aspirin or salicylate derivatives.\n* The following treatment will be forbidden during the study (if present at selection, a wash-out will be necessary):\n* Loperamide and other antidiarrheal agents, mucilages, antibiotics: 1 week wash-out.\n* Oral steroids: 4 weeks wash-out.\n* Rectal steroids: 2 weeks wash-out\n* Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardioprotection is allowed).\n* Sulfasalazine \\> 4g/day or mesalazine or 4-ASA at a higher dose than what is permitted in the local formulary or standard care for maintenance treatment: 4 weeks wash-out\n* Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above).\n* Known significant hepatic or renal function abnormalities.\n* Moderate/severe abnormal renal, hepatic or blood count tests defined as: creatinine plasma value \\> 1.5 x Upper Limit of Normal (ULN) or white blood cells \\< 3500/mm˄3 or \\> 15000/mm˄3 or Platelets \\< 100000/mm˄3 or \\> 800000/mm˄3 or aspartate aminotransferase/alanine Aminotransferase (ASAT/ALAT) \\> 3 x ULN or Gamma glutamyl transpeptidase (GGT)/Alkaline Phosphatase's \\> 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria).\n* History or physical examination findings indicative of active alcohol or drug abuse,\n* Pregnancy or breast-feeding,\n* History of disease, including mental/emotional disorder, that might interfere with their participation in the study,\n* Participation in another clinical study in the last 3 months.\n* Inability to comply with the protocol requirements.\n* Inability to fill in the diary cards.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).", "unit": null, "evidence_text": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says)."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Evidence of other forms of inflammatory bowel disease or infectious disease.", "unit": null, "evidence_text": "Evidence of other forms of inflammatory bowel disease or infectious disease."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "disease, including mental/emotional disorder, that might interfere with their participation in the study", "unit": null, "evidence_text": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Severe/fulminant ulcerative colitis.", "unit": null, "evidence_text": "Severe/fulminant ulcerative colitis."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,", "unit": null, "evidence_text": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "x", "evidence_text": "Moderate/severe abnormal renal, hepatic or blood count tests defined as: creatinine plasma value \\> 1.5 x Upper Limit of Normal (ULN) or white blood cells \\< 3500/mm˄3 or \\> 15000/mm˄3 or Platelets \\< 100000/mm˄3 or \\> 800000/mm˄3 or aspartate aminotransferase/alanine Aminotransferase (ASAT/ALAT) \\> 3 x ULN or Gamma glutamyl transpeptidase (GGT)/Alkaline Phosphatase's \\> 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria)."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "History or physical examination findings indicative of active alcohol or drug abuse,", "unit": null, "evidence_text": "History or physical examination findings indicative of active alcohol or drug abuse,"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above).", "unit": null, "evidence_text": "Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above)."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardi", "unit": null, "evidence_text": "Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardioprotection is allowed)."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to comply with the protocol requirements.", "unit": null, "evidence_text": "Inability to comply with the protocol requirements."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to fill in the diary cards.", "unit": null, "evidence_text": "Inability to fill in the diary cards."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Previous colonic surgery.", "unit": null, "evidence_text": "Previous colonic surgery."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score wi", "unit": null, "evidence_text": "Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8)."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction).", "unit": null, "evidence_text": "Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction)."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Informed consent given.", "unit": null, "evidence_text": "Informed consent given."}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).", "unit": null, "evidence_text": "All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years)."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Men or non pregnant women."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Men or non pregnant women."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Women with childbearing potential must be using a contraceptive method judged effective by the investigator."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).", "unit": null, "evidence_text": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says)."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Evidence of other forms of inflammatory bowel disease or infectious disease.", "unit": null, "evidence_text": "Evidence of other forms of inflammatory bowel disease or infectious disease."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Severe/fulminant ulcerative colitis.", "unit": null, "evidence_text": "Severe/fulminant ulcerative colitis."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,", "unit": null, "evidence_text": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "x", "evidence_text": "Moderate/severe abnormal renal, hepatic or blood count tests defined as: creatinine plasma value \\> 1.5 x Upper Limit of Normal (ULN) or white blood cells \\< 3500/mm˄3 or \\> 15000/mm˄3 or Platelets \\< 100000/mm˄3 or \\> 800000/mm˄3 or aspartate aminotransferase/alanine Aminotransferase (ASAT/ALAT) \\> 3 x ULN or Gamma glutamyl transpeptidase (GGT)/Alkaline Phosphatase's \\> 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria)."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "History or physical examination findings indicative of active alcohol or drug abuse,", "unit": null, "evidence_text": "History or physical examination findings indicative of active alcohol or drug abuse,"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above).", "unit": null, "evidence_text": "Immunomodulating/suppressing drugs: 3 month for wash out (except for patients maintained on azathioprine or 6-mercaptopurine -see above)."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardi", "unit": null, "evidence_text": "Repeated treatment (\\> 3days of use) of non steroidal anti-inflammatory drugs (NSAID) oral or rectal route: 1 week wash-out (aspirin ≤ 325 mg/day used for cardioprotection is allowed)."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to comply with the protocol requirements.", "unit": null, "evidence_text": "Inability to comply with the protocol requirements."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to fill in the diary cards.", "unit": null, "evidence_text": "Inability to fill in the diary cards."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Previous colonic surgery.", "unit": null, "evidence_text": "Previous colonic surgery."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score wi", "unit": null, "evidence_text": "Disease activity will be assessed on the 15 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8)."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction).", "unit": null, "evidence_text": "Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction)."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Informed consent given.", "unit": null, "evidence_text": "Informed consent given."}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).", "unit": null, "evidence_text": "All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years)."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Men or non pregnant women."}], "rule_v1_extra_rules": [{"id": "rule-7c95b0cd-ee83-43d3-86d8-8136721c0f90", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "for patient recently diagnosed the period of", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Current relapse lasting more than 6 weeks (for patient recently diagnosed the period of 6 weeks runs from the endoscopic diagnosis)(from what patient says).", "source_span": {"start": 1505, "end": 1661}}, {"id": "rule-dde43160-c002-4341-a44f-1f64d46dbf8a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the protocol requirements", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Inability to comply with the protocol requirements.", "source_span": {"start": 3414, "end": 3465}}, {"id": "rule-618dbd2c-98af-4e0b-b685-fb487a97e567", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "their participation in the study", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of disease, including mental/emotional disorder, that might interfere with their participation in the study,", "source_span": {"start": 3231, "end": 3347}}, {"id": "rule-619865c8-2dfa-4858-985a-6270d0cc0a5f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the following inclusion criteria determined at baseline", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients will be included if they comply with the following inclusion criteria determined at baseline, prior to first drug administration:", "source_span": {"start": 21, "end": 159}}, {"id": "rule-0a60343a-4585-4d69-b4a5-ed8c9eb090b9", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Women with childbearing potential must be using a contraceptive method judged effective by the investigator.", "source_span": {"start": 694, "end": 802}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00012", "nct_id": "NCT00843154", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 140.0, "priority_reasons": ["missing_critical_rules=10", "contract_errors=3", "rule_v1_missing=13", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 4, "lab": 3, "medication": 2, "procedure": 1, "sex": 1}, "extra_rules_by_field": {"condition": 3}, "contract_error_count": 3, "contract_warning_count": 0, "contract_error_codes": {"LAB_THRESHOLD_VALUE_INVALID": 3}, "contract_warning_codes": {}}, "focus_fields": ["history", "lab", "condition", "medication", "procedure", "sex"], "eligibility_text": "Inclusion Criteria:\n\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n* Stable, symptomatic New York Heart Association II-IV Chronic Heart Failure with Left Ventricular Ejection Fraction less than or greater than or greater than or equal to 40% treated with standard therapy including Angiotensin Converting Enzyme-inhibitors and/or beta-blockers. Patients with Left Ventricular Ejection Fraction greater than or equal to 40% had to be hospitalized for cardiovascular events during the past 12 months.\n\nExclusion Criteria:\n\n* History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first.\n* Severe or malignant hypertension (Systolic Blood Pressure / Diastolic Blood Pressure greater than 180/110 mmHg).\n* Symptomatic hypotension.\n* Acute myocardial infarction within one month from first visit.\n* Stroke or transient ischemic attack within one month from first visit.\n* Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit.\n* Hemodynamically relevant arrhythmias.\n* Implant of pacemakers, cardiac resynchronization therapy or cardioverters within 6 months prior the randomization.\n* Hemodynamically relevant cardiac valvular defect.\n* Constrictive pericarditis or active myocarditis.\n* Likelihood of cardiac surgical intervention (of any type) during the overall treatment period.\n* Evidence of angina pectoris in the previous month.\n* Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated hemoglobin greater than 8% obtained within three months from the study initiation).\n* Untreated thyroid dysfunction.\n* Renal artery stenosis.\n* Angioedema of any etiology.\n* Significant liver (aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase greater than twice the upper limit of normal range) or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0 mmol/L) impairment.\n* Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other clinically relevant hematological disease.\n* Any disease with malabsorption.\n* Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy.\n* History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance.\n* Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients.\n* Participation in another trial in the month preceding study entry.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Any disease with malabsorption.", "unit": null, "evidence_text": "Any disease with malabsorption."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance", "unit": null, "evidence_text": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "prior treatment with angiotensin receptor blockers within two weeks from first", "unit": null, "evidence_text": "History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy.", "unit": null, "evidence_text": "Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Acute myocardial infarction within one month from first visit.", "unit": null, "evidence_text": "Acute myocardial infarction within one month from first visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Evidence of angina pectoris in the previous month.", "unit": null, "evidence_text": "Evidence of angina pectoris in the previous month."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit.", "unit": null, "evidence_text": "Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Stroke or transient ischemic attack within one month from first visit.", "unit": null, "evidence_text": "Stroke or transient ischemic attack within one month from first visit."}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": "10.5", "unit": "g/dl", "evidence_text": "Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other clinically relevant hematological disease."}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": "140", "unit": "mg/ml", "evidence_text": "Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated hemoglobin greater than 8% obtained within three months from the study initiation)."}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": "2.0", "unit": "mg/dl", "evidence_text": "Significant liver (aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase greater than twice the upper limit of normal range) or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0 mmol/L) impairment."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance.", "unit": null, "evidence_text": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients.", "unit": null, "evidence_text": "Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Likelihood of cardiac surgical intervention (of any type) during the overall treatment period.", "unit": null, "evidence_text": "Likelihood of cardiac surgical intervention (of any type) during the overall treatment period."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Any disease with malabsorption.", "unit": null, "evidence_text": "Any disease with malabsorption."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy.", "unit": null, "evidence_text": "Presence of any non-cardiac (e.g. cancer) disease that is likely to significantly (i.e. below 1 year from randomization) shorten life expectancy."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Acute myocardial infarction within one month from first visit.", "unit": null, "evidence_text": "Acute myocardial infarction within one month from first visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Evidence of angina pectoris in the previous month.", "unit": null, "evidence_text": "Evidence of angina pectoris in the previous month."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit.", "unit": null, "evidence_text": "Percutaneous transluminal coronary angioplasty or coronary artery by-pass graft within one month from first visit."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Stroke or transient ischemic attack within one month from first visit.", "unit": null, "evidence_text": "Stroke or transient ischemic attack within one month from first visit."}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": "10.5", "unit": "g/dl", "evidence_text": "Anemia of any etiology (defined as hemoglobin levels less than 10.5 g/dL) or any other clinically relevant hematological disease."}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": "140", "unit": "mg/ml", "evidence_text": "Poorly controlled diabetes mellitus (glycemia greater than 140mg/mL or glycosylated hemoglobin greater than 8% obtained within three months from the study initiation)."}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": "2.0", "unit": "mg/dl", "evidence_text": "Significant liver (aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase greater than twice the upper limit of normal range) or renal (serum creatinine greater than 2.0 mg/dL or serum potassium greater than 5.0 mmol/L) impairment."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance.", "unit": null, "evidence_text": "History of chronic alcohol or drug/substance abuse, or presence of other conditions potentially able to affect study subjects' compliance."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients.", "unit": null, "evidence_text": "Known allergy, sensitivity or intolerance to study drugs and/or study drugs' formulation ingredients."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Likelihood of cardiac surgical intervention (of any type) during the overall treatment period.", "unit": null, "evidence_text": "Likelihood of cardiac surgical intervention (of any type) during the overall treatment period."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study."}], "rule_v1_extra_rules": [{"id": "rule-97bbf991-f880-4d55-8c31-dd504d2f3935", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "angiotensin receptor blockers within two weeks from", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of prior treatment with Angiotensin-Receptor Blockers within two weeks from first.", "source_span": {"start": 674, "end": 764}}, {"id": "rule-e6d6e189-f762-42d2-8380-71f97f919b3b", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "malabsorption", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Any disease with malabsorption.", "source_span": {"start": 2237, "end": 2268}}, {"id": "rule-c032585c-5b82-462b-80ce-44e4ebb9aaf4", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00013", "nct_id": "NCT01206322", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 138.0, "priority_reasons": ["missing_critical_rules=10", "contract_errors=1", "rule_v1_missing=16", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 5, "history": 3, "medication": 2, "other": 2, "procedure": 3, "sex": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "procedure", "medication", "other", "sex"], "eligibility_text": "Inclusion Criteria:\n\nDiabetes group:\n\n* 30 men and women aged \\>50 years old diagnosed with T2DM and treated \\> 5 years with oral agents\n* Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels.\n\nControl group:\n\n* 30 healthy men and women aged \\>50 years selected to have the same age and sex distributions as the diabetic subjects\n* Normotensive, not treated for any systemic disease, and have normal fasting blood glucose.\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus\n* History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring\n* Positive stress test for CAD or other ischemic conditions\n* Carotid stenosis \\> 50% by medical history\n* History of a clinically documented stroke\n* Treatment with any medications administered intranasally including intranasal steroids\n* Any previous adverse or allergic reactions to insulin\n* Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months\n* Liver or renal failure or transplant\n* Uncontrolled hypertension (systolic BP \\>180 and/or diastolic BP \\>100 mm Hg or subjects taking more than 3 antihypertensive medications)\n* Seizure disorders\n* Malignant tumors\n* Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the subject's age group and education level, or ≤ 24)\n* Current recreational drug or alcohol abuse\n* Morbid obesity (BMI \\>40)\n* Inability to obtain permission for participation from the primary care physician\n* Transcranial Doppler (TCD) exclusion criterion - poor insonation window and TCD signal\n* MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia\n* Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis", "unit": null, "evidence_text": "Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically documented stroke", "unit": null, "evidence_text": "History of a clinically documented stroke"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe hypoglycemia or hypoglycemic episode during home baseline monitoring", "unit": null, "evidence_text": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Type 1 Diabetes Mellitus", "unit": null, "evidence_text": "Type 1 Diabetes Mellitus"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Any previous adverse or allergic reactions to insulin", "unit": null, "evidence_text": "Any previous adverse or allergic reactions to insulin"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of a clinically documented stroke", "unit": null, "evidence_text": "History of a clinically documented stroke"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring", "unit": null, "evidence_text": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current recreational drug or alcohol abuse", "unit": null, "evidence_text": "Current recreational drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Treatment with any medications administered intranasally including intranasal steroids", "unit": null, "evidence_text": "Treatment with any medications administered intranasally including intranasal steroids"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value", "unit": null, "evidence_text": "Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the subject's age group and education level, or ≤ 24)"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to obtain permission for participation from the primary care physician", "unit": null, "evidence_text": "Inability to obtain permission for participation from the primary care physician"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months", "unit": null, "evidence_text": "Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Liver or renal failure or transplant", "unit": null, "evidence_text": "Liver or renal failure or transplant"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia", "unit": null, "evidence_text": "MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "oral agents", "unit": null, "evidence_text": "30 men and women aged \\>50 years old diagnosed with T2DM and treated \\> 5 years with oral agents"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diabetes group:", "unit": null, "evidence_text": "Diabetes group:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels.", "unit": null, "evidence_text": "Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Normotensive, not treated for any systemic disease, and have normal fasting blood glucose.", "unit": null, "evidence_text": "Normotensive, not treated for any systemic disease, and have normal fasting blood glucose."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "30 men and women aged \\>50 years old diagnosed with T2DM and treated \\> 5 years with oral agents"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis", "unit": null, "evidence_text": "Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Type 1 Diabetes Mellitus", "unit": null, "evidence_text": "Type 1 Diabetes Mellitus"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Any previous adverse or allergic reactions to insulin", "unit": null, "evidence_text": "Any previous adverse or allergic reactions to insulin"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of a clinically documented stroke", "unit": null, "evidence_text": "History of a clinically documented stroke"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring", "unit": null, "evidence_text": "History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current recreational drug or alcohol abuse", "unit": null, "evidence_text": "Current recreational drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Treatment with any medications administered intranasally including intranasal steroids", "unit": null, "evidence_text": "Treatment with any medications administered intranasally including intranasal steroids"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value", "unit": null, "evidence_text": "Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the subject's age group and education level, or ≤ 24)"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to obtain permission for participation from the primary care physician", "unit": null, "evidence_text": "Inability to obtain permission for participation from the primary care physician"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months", "unit": null, "evidence_text": "Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Liver or renal failure or transplant", "unit": null, "evidence_text": "Liver or renal failure or transplant"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia", "unit": null, "evidence_text": "MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diabetes group:", "unit": null, "evidence_text": "Diabetes group:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels.", "unit": null, "evidence_text": "Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Normotensive, not treated for any systemic disease, and have normal fasting blood glucose.", "unit": null, "evidence_text": "Normotensive, not treated for any systemic disease, and have normal fasting blood glucose."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "30 men and women aged \\>50 years old diagnosed with T2DM and treated \\> 5 years with oral agents"}], "rule_v1_extra_rules": [{"id": "rule-3bfd02bb-c8d5-490e-88b4-1ce5e5d9746b", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any medications administered intranasally including intranasal steroids", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Treatment with any medications administered intranasally including intranasal steroids", "source_span": {"start": 761, "end": 847}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00014", "nct_id": "NCT00736970", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 135.0, "priority_reasons": ["missing_critical_rules=10", "contract_errors=1", "rule_v1_missing=14", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4, "history": 3, "lab": 1, "medication": 2, "other": 3, "procedure": 1}, "extra_rules_by_field": {"condition": 6}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"LAB_THRESHOLD_VALUE_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "other", "medication", "lab", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n* Female, 18 years of age or older\n* Histologically confirmed HER2-positive metastatic breast cancer\n* Trastuzumab-resistance\n* Measurable disease, according to RECIST guidelines\n* ECOG performance status less than or equal to 1\n* Life expectancy greater than 3 months\n* No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor\n* At least 4 weeks must have lapsed between prior investigational therapy, chemotherapy or radiotherapy, and the first dose of ridaforolimus\n* Left ventricular ejection greater than or equal to 50%\n* Adequate cardiovascular function\n* Adequate hematological, hepatic, and renal function\n* Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL\n* Negative pregnancy test within 7 days prior to first dose of study drug and must use an approved contraceptive method from screening to 30 days after the last dose of study drug\n* Availability and patient consent to obtain archival tissue samples\n* Signed informed consent\n\nExclusion Criteria:\n\n* Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry\n* Grade 1 or Grade 2 hypersensitivity reactions to prior trastuzumab therapy if these reactions prevented further trastuzumab administration\n* Grade 3 or Grade 4 hypersensitivity reaction to prior trastuzumab\n* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest\n* Known allergy to macrolide antibiotics\n* Pregnant or breast-feeding\n* Know history of HIV\n* Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months\n* Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin\n* Active infection requiring prescription intervention\n* Newly diagnosed or poorly controlled Type 1 or 2 diabetes\n* Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug\n* Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.\n* Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Active infection requiring prescription intervention"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Know history of HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Newly diagnosed or poorly controlled Type 1 or 2 diabetes", "unit": null, "evidence_text": "Newly diagnosed or poorly controlled Type 1 or 2 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest", "unit": null, "evidence_text": "Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months", "unit": null, "evidence_text": "Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Know history of HIV", "unit": null, "evidence_text": "Know history of HIV"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin", "unit": null, "evidence_text": "Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.", "unit": null, "evidence_text": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of t", "unit": null, "evidence_text": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol", "unit": null, "evidence_text": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry", "unit": null, "evidence_text": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Female, 18 years of age or older"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Histologically confirmed HER2-positive metastatic breast cancer", "unit": null, "evidence_text": "Histologically confirmed HER2-positive metastatic breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Measurable disease, according to RECIST guidelines", "unit": null, "evidence_text": "Measurable disease, according to RECIST guidelines"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": "350", "unit": "mg/dl", "evidence_text": "Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Availability and patient consent to obtain archival tissue samples", "unit": null, "evidence_text": "Availability and patient consent to obtain archival tissue samples"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Signed informed consent", "unit": null, "evidence_text": "Signed informed consent"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Newly diagnosed or poorly controlled Type 1 or 2 diabetes", "unit": null, "evidence_text": "Newly diagnosed or poorly controlled Type 1 or 2 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest", "unit": null, "evidence_text": "Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months", "unit": null, "evidence_text": "Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Know history of HIV", "unit": null, "evidence_text": "Know history of HIV"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin", "unit": null, "evidence_text": "Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.", "unit": null, "evidence_text": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of t", "unit": null, "evidence_text": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol", "unit": null, "evidence_text": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry", "unit": null, "evidence_text": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Histologically confirmed HER2-positive metastatic breast cancer", "unit": null, "evidence_text": "Histologically confirmed HER2-positive metastatic breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Measurable disease, according to RECIST guidelines", "unit": null, "evidence_text": "Measurable disease, according to RECIST guidelines"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": "350", "unit": "mg/dl", "evidence_text": "Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Availability and patient consent to obtain archival tissue samples", "unit": null, "evidence_text": "Availability and patient consent to obtain archival tissue samples"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Signed informed consent", "unit": null, "evidence_text": "Signed informed consent"}], "rule_v1_extra_rules": [{"id": "rule-909365ca-c48f-4a86-a268-37cacb76127c", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Know history of HIV", "source_span": {"start": 1587, "end": 1606}}, {"id": "rule-cb6f9771-9cb9-4fec-8683-d6fd33619c30", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "medications that strongly induce or inhibit cytochrome", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.", "source_span": {"start": 2129, "end": 2215}}, {"id": "rule-ae861497-d5c8-45e0-85df-4d24006077d5", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the evaluation of the safety of the", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug", "source_span": {"start": 1953, "end": 2126}}, {"id": "rule-39f98c14-ffe8-4fc6-a3f6-d4b9615f452f", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the protocol", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol", "source_span": {"start": 2218, "end": 2340}}, {"id": "rule-6e181fae-5ae4-4922-8f02-33d0d92634c1", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "undergone any major surgery within 2 weeks", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry", "source_span": {"start": 1069, "end": 1194}}, {"id": "rule-e1b87d2d-bb04-487e-ad9b-010d776554d4", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "temsirolimus", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor", "source_span": {"start": 292, "end": 380}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00015", "nct_id": "NCT00861705", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 132.0, "priority_reasons": ["missing_critical_rules=10", "rule_v1_missing=16", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 5, "history": 2, "lab": 3, "procedure": 5, "sex": 1}, "extra_rules_by_field": {"condition": 2, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "procedure", "lab", "history", "sex"], "eligibility_text": "Inclusion Criteria:\n\n* Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)\n* The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10% of invasive cancer cells by immunohistochemistry (IHC)\n* The invasive tumor must be HER2-negative, defined as IHC 0-1+ or with a fluorescent in situ hybridization (FISH) ratio (HER2 gene copy/chromosome 17) of \\< 2.0 if IHC 2+\n* Clinical stage II-III invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy; patients with inflammatory breast cancer are not eligible; staging to rule out metastatic disease is recommended for clinical stage III patients\n* Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria\n* Patient agrees to undergo pretreatment research biopsies\n* No prior chemotherapy, hormone therapy, or radiation therapy with therapeutic intent for this cancer\n* The target lesion in the breast must be \\>= 1 cm, clinically or radiographically; palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint; patients with axillary disease only (no identifiable tumor in the breast that is \\>= 1 cm on physical exam or radiographic study) are not eligible to participate\n* Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are not eligible\n* No serious or non-healing wound, skin ulcers or bone fracture; no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study\n* The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining the required research needle biopsies; placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection; placement of a port for central venous access; fine needle aspiration of a prominent or suspicious axillary lymph node; needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease; or pretreatment sentinel lymph node sampling\n* No baseline neuropathy grade \\>= 2\n* Zubrod performance status 0-1\n* Pregnant or nursing women are not eligible; all women of reproductive potential must have a negative pregnancy test at baseline and agree to use an effective, non-hormonal method of contraception during the entire period of treatment on the study\n* Patients with congestive heart failure are not eligible, nor are patients with myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack (TIA) within the past 12 months, uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160 or diastolic blood pressure \\[DBP\\] \\> 90), uncontrolled or symptomatic arrhythmia, or grade II or greater peripheral vascular disease\n* Patients must have a pretreatment multi gated acquisition (MUGA) scan or echocardiogram with a left ventricular ejection fraction (LVEF) above the institutional lower limit of normal\n* Granulocytes \\> 1,000/mcl\n* Platelets \\> 100,000/mcl\n* Total bilirubin =\\< 1.5 x upper limits of normal\n* Calculated or measured \\> 30 ml/min\n* Urine protein =\\< 1+ or urine protein to creatinine (UPC) ratio \\< 1\n\n  * Patients discovered to have \\>= 2+ proteinuria at baseline must undergo a 24-hour urine collection that must demonstrate \\< 1 g of protein/24 hr, or UPC ratio \\< 1 to allow participation in the study\n* Serum alanine aminotransferase (ALT) =\\< 2.5 x upper limits of normal\n* Serum beta human chorionic gonadotropin (HCG) negative (for women of child bearing potential)\n* Prothrombin time (PT)/international normalized ratio (INR) =\\< 1.5 x upper limit of normal (ULN)\n\n  * Unless patient is on therapeutic doses of warfarin; if so, the patient must have an INR =\\< 3 on a stable dose of warfarin, must have not active bleeding or pathologic condition that is associated with a high risk of bleeding", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "intent to perform surgical resection after neoadjuvant", "unit": null, "evidence_text": "Clinical stage II-III invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a high risk of bleeding", "unit": null, "evidence_text": "if so, the patient must have an INR =\\< 3 on a stable dose of warfarin, must have not active bleeding or pathologic condition that is associated with a high risk of bleeding"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint;", "unit": null, "evidence_text": "palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "congestive heart failure are not eligible", "unit": null, "evidence_text": "Patients with congestive heart failure are not eligible, nor are patients with myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack (TIA) within the past 12 months, uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160 or diastolic blood pressure \\[DBP\\] \\> 90), uncontrolled or symptomatic arrhythmia, or grade II or greater peripheral vascular disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "inflammatory breast cancer are not eligible", "unit": null, "evidence_text": "patients with inflammatory breast cancer are not eligible;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "patients with inflammatory breast cancer are not eligible;", "unit": null, "evidence_text": "patients with inflammatory breast cancer are not eligible;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria", "unit": null, "evidence_text": "Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "staging to rule out metastatic disease is recommended for clinical stage III patients", "unit": null, "evidence_text": "staging to rule out metastatic disease is recommended for clinical stage III patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10%", "unit": null, "evidence_text": "The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10% of invasive cancer cells by immunohistochemistry (IHC)"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months;", "unit": null, "evidence_text": "no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months;"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are", "unit": null, "evidence_text": "Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are not eligible"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": null, "evidence_text": "Platelets \\> 100,000/mcl"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "x", "evidence_text": "Total bilirubin =\\< 1.5 x upper limits of normal"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1", "unit": null, "evidence_text": "Urine protein =\\< 1+ or urine protein to creatinine (UPC) ratio \\< 1"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)", "unit": null, "evidence_text": "Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease;", "unit": null, "evidence_text": "needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease;"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study", "unit": null, "evidence_text": "no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection;", "unit": null, "evidence_text": "placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection;"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining t", "unit": null, "evidence_text": "The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining the required research needle biopsies;"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "all women of reproductive potential must have a negative pregnancy test at baseline and agree to use an effective, non-hormonal method of contraception during the entire period of treatment on the study"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant or nursing women are not eligible;"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint;", "unit": null, "evidence_text": "palpable or radiographically measurable axillary adenopathy will be recorded but will not serve as measurable disease for the primary endpoint;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "patients with inflammatory breast cancer are not eligible;", "unit": null, "evidence_text": "patients with inflammatory breast cancer are not eligible;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria", "unit": null, "evidence_text": "Patients with multicentric or bilateral disease are eligible if the target lesion meets eligibility criteria"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "staging to rule out metastatic disease is recommended for clinical stage III patients", "unit": null, "evidence_text": "staging to rule out metastatic disease is recommended for clinical stage III patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10%", "unit": null, "evidence_text": "The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor (ER) and progesterone receptor (PgR) negative or staining present in =\\< 10% of invasive cancer cells by immunohistochemistry (IHC)"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months;", "unit": null, "evidence_text": "no abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months;"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are", "unit": null, "evidence_text": "Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower gastrointestinal \\[GI\\] bleeding) within 6 months of registration are not eligible"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1", "unit": null, "evidence_text": "Urine protein =\\< 1+ or urine protein to creatinine (UPC) ratio \\< 1"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "x", "evidence_text": "Total bilirubin =\\< 1.5 x upper limits of normal"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": null, "evidence_text": "Platelets \\> 100,000/mcl"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease;", "unit": null, "evidence_text": "needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease;"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection;", "unit": null, "evidence_text": "placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection;"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)", "unit": null, "evidence_text": "Invasive breast cancer, diagnosed by core needle or incisional biopsy (excisional biopsy not permitted)"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study", "unit": null, "evidence_text": "no major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of study"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining t", "unit": null, "evidence_text": "The following are not considered to be major surgical procedures that would be prohibited in the 28 days prior to, or following study randomization: obtaining the required research needle biopsies;"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "all women of reproductive potential must have a negative pregnancy test at baseline and agree to use an effective, non-hormonal method of contraception during the entire period of treatment on the study"}], "rule_v1_extra_rules": [{"id": "rule-177ff2f8-9406-41f1-b076-484975f9e76f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "myocardial infarction", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with congestive heart failure are not eligible, nor are patients with myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack (TIA) within the past 12 months, uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160 or diastolic blood pressure \\[DBP\\] \\> 90), uncontrolled or symptomatic arrhythmia, or grade II or greater peripheral vascular disease", "source_span": {"start": 2800, "end": 3227}}, {"id": "rule-85010480-f401-4796-b76d-97d03d6edf8d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "therapeutic intent for this cancer", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No prior chemotherapy, hormone therapy, or radiation therapy with therapeutic intent for this cancer", "source_span": {"start": 950, "end": 1050}}, {"id": "rule-1391348c-ae98-48d4-bb13-a0186c72a383", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Pregnant or nursing women are not eligible;", "source_span": {"start": 2551, "end": 2594}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00016", "nct_id": "NCT01209000", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 130.0, "priority_reasons": ["missing_critical_rules=11", "rule_v1_missing=14", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 2, "history": 3, "medication": 1, "other": 2, "procedure": 5}, "extra_rules_by_field": {"age": 1, "condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["procedure", "history", "condition", "other", "age", "medication"], "eligibility_text": "Cohort A (biopsy cohort) Inclusion Criteria:\n\nPatients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:\n\n* Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.\n* Scheduled renal biopsy\n\nCohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:\n\n* Age \\<19 years of age\n* Initial presentation with \\<30 days immunosuppression therapy\n* Proteinuria/nephrotic\n\n  * UA\\>2+ and edema OR\n  * UA\\>2+ and serum albumin \\<3 OR\n  * UPC \\> 2g/g and serum albumin \\<3\n\nExclusion Criteria (Cohort A\\&B):\n\n* Prior solid organ transplant\n* A clinical diagnosis of glomerulopathy without diagnostic renal biopsy\n* Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)\n* Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)\n* Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months\n* Unwillingness or inability to give a comprehensive informed consent\n* Unwillingness to comply with study procedures and visit schedule\n* Institutionalized individuals (e.g., prisoners)", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas),", "unit": null, "evidence_text": "Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months", "unit": null, "evidence_text": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Patho", "unit": null, "evidence_text": "Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unwillingness or inability to give a comprehensive informed consent", "unit": null, "evidence_text": "Unwillingness or inability to give a comprehensive informed consent"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unwillingness to comply with study procedures and visit schedule", "unit": null, "evidence_text": "Unwillingness to comply with study procedures and visit schedule"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy", "unit": null, "evidence_text": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Prior solid organ transplant", "unit": null, "evidence_text": "Prior solid organ transplant"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 19, "unit": "years", "evidence_text": "Age \\<19 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a clinical", "unit": null, "evidence_text": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "creatinine ratio equivalent at the time of", "unit": null, "evidence_text": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a life expectancy less than 6 months", "unit": null, "evidence_text": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "patients presenting with an incipient clinical", "unit": null, "evidence_text": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study procedures and visit schedule", "unit": null, "evidence_text": "Unwillingness to comply with study procedures and visit schedule"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening", "unit": null, "evidence_text": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSG", "unit": null, "evidence_text": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Initial presentation with \\<30 days immunosuppression therapy", "unit": null, "evidence_text": "Initial presentation with \\<30 days immunosuppression therapy"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Cohort A (biopsy cohort) Inclusion Criteria:", "unit": null, "evidence_text": "Cohort A (biopsy cohort) Inclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:", "unit": null, "evidence_text": "Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Scheduled renal biopsy", "unit": null, "evidence_text": "Scheduled renal biopsy"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas),", "unit": null, "evidence_text": "Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months", "unit": null, "evidence_text": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Patho", "unit": null, "evidence_text": "Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unwillingness or inability to give a comprehensive informed consent", "unit": null, "evidence_text": "Unwillingness or inability to give a comprehensive informed consent"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unwillingness to comply with study procedures and visit schedule", "unit": null, "evidence_text": "Unwillingness to comply with study procedures and visit schedule"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy", "unit": null, "evidence_text": "A clinical diagnosis of glomerulopathy without diagnostic renal biopsy"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Prior solid organ transplant", "unit": null, "evidence_text": "Prior solid organ transplant"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 19, "unit": "years", "evidence_text": "Age \\<19 years of age"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening", "unit": null, "evidence_text": "Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSG", "unit": null, "evidence_text": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Initial presentation with \\<30 days immunosuppression therapy", "unit": null, "evidence_text": "Initial presentation with \\<30 days immunosuppression therapy"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Cohort A (biopsy cohort) Inclusion Criteria:", "unit": null, "evidence_text": "Cohort A (biopsy cohort) Inclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:", "unit": null, "evidence_text": "Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Scheduled renal biopsy", "unit": null, "evidence_text": "Scheduled renal biopsy"}], "rule_v1_extra_rules": [{"id": "rule-420ca472-1154-49ca-b9eb-263b084dd757", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 19, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Age \\<19 years of age", "source_span": {"start": 524, "end": 545}}, {"id": "rule-65179378-6771-419b-bbf3-d1d8c656e426", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "systemic disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months", "source_span": {"start": 1521, "end": 1617}}, {"id": "rule-20ac86a2-c9df-411c-a39d-27b0c5f901ad", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "with a clinical", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following", "source_span": {"start": 46, "end": 239}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00017", "nct_id": "NCT01138046", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 126.0, "priority_reasons": ["missing_critical_rules=8", "rule_v1_missing=17", "rule_v1_extra=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 7, "history": 3, "medication": 5, "sex": 2}, "extra_rules_by_field": {"age": 1, "condition": 3, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication", "history", "sex", "age"], "eligibility_text": "Inclusion Criteria:\n\n* Prior written consent in participating in the study by the subject or his/her private attorney.\n* Japanese female \\>=18 years of age.\n* Invasive breast cancer with stage IV disease.\n* Documentation by local laboratory of ErbB2 status by immunohistochemistry (IHC) or amplification by fluorescence in situ hybridization (FISH).\n* If a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred \\>12 months after completion of this treatment and the patients recovered from all associated toxicities.\n* Measurable lesion(s) according to RECIST criteria.\n* Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any investigational treatment.\n* For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:\n\n  * Patient with visceral disease that requires chemotherapy (e.g., patients with liver or lung metastases).\n  * Rapidly progressing or life threatening disease that are considered to be inapplicable to hormonal therapy, as determined by the investigator.\n  * Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of investigational treatment.\n  * Subjects recovered from all the associated toxicities by prior endocrine therapy.\n* Eastern cooperative oncology group (ECOG) Performance status (PS) of 0 or 1.\n* Able to swallow and retain oral medication.\n* Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be performed or is inconclusive.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Pregnant or lactating females at anytime during the study.\n* Received prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic disease.\n* History of other malignancy.\n* Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab, in the adjuvant setting.\n* Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment.\n* Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment.\n* Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment.\n* Uncontrolled infection.\n* Patients having at least positive antibody either to HBs or HBc.\n* Patients who have had a positive HCV antibody.\n* Peripheral neuropathy grade 2 or greater.\n* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.\n* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.\n* Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.\n* Concurrent treatment with prohibited medications.\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients.\n* Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the", "unit": null, "evidence_text": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic", "unit": null, "evidence_text": "Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other malignancy", "unit": null, "evidence_text": "History of other malignancy."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.", "unit": null, "evidence_text": "Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.", "unit": null, "evidence_text": "Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis", "unit": null, "evidence_text": "Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of other malignancy.", "unit": null, "evidence_text": "History of other malignancy."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Concurrent treatment with prohibited medications.", "unit": null, "evidence_text": "Concurrent treatment with prohibited medications."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients.", "unit": null, "evidence_text": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment.", "unit": null, "evidence_text": "Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment.", "unit": null, "evidence_text": "Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant or lactating females at anytime during the study."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:", "unit": null, "evidence_text": "For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stage iv disease", "unit": null, "evidence_text": "Invasive breast cancer with stage IV disease."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Invasive breast cancer with stage IV disease.", "unit": null, "evidence_text": "Invasive breast cancer with stage IV disease."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be p", "unit": null, "evidence_text": "Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be performed or is inconclusive."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Prior written consent in participating in the study by the subject or his/her private attorney.", "unit": null, "evidence_text": "Prior written consent in participating in the study by the subject or his/her private attorney."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Able to swallow and retain oral medication.", "unit": null, "evidence_text": "Able to swallow and retain oral medication."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Japanese female \\>=18 years of age."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the", "unit": null, "evidence_text": "Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic", "unit": null, "evidence_text": "Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.", "unit": null, "evidence_text": "Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.", "unit": null, "evidence_text": "Known history or concurrent condition of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis", "unit": null, "evidence_text": "Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of other malignancy.", "unit": null, "evidence_text": "History of other malignancy."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Concurrent treatment with prohibited medications.", "unit": null, "evidence_text": "Concurrent treatment with prohibited medications."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients.", "unit": null, "evidence_text": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their excipients."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment.", "unit": null, "evidence_text": "Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior anti-cancer treatment."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment.", "unit": null, "evidence_text": "Used an investigational drug within 30 days or five half-lives, whichever is longer, preceding the first dose of investigational treatment."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant or lactating females at anytime during the study."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:", "unit": null, "evidence_text": "For those patients whose disease is ER+ and/or PR+ one of the following criteria should be met:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Invasive breast cancer with stage IV disease.", "unit": null, "evidence_text": "Invasive breast cancer with stage IV disease."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Prior written consent in participating in the study by the subject or his/her private attorney.", "unit": null, "evidence_text": "Prior written consent in participating in the study by the subject or his/her private attorney."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be p", "unit": null, "evidence_text": "Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scan is accepted in cases where an echocardiogram cannot be performed or is inconclusive."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Able to swallow and retain oral medication.", "unit": null, "evidence_text": "Able to swallow and retain oral medication."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Japanese female \\>=18 years of age."}], "rule_v1_extra_rules": [{"id": "rule-3c1eba3c-4fde-43d7-a6f5-42e16016531d", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "at least positive antibody either to hbs", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients having at least positive antibody either to HBs or HBc.", "source_span": {"start": 2579, "end": 2643}}, {"id": "rule-851e7a79-2878-4285-be60-ce2bcc51952f", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "prohibited medications", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Concurrent treatment with prohibited medications.", "source_span": {"start": 3471, "end": 3520}}, {"id": "rule-fbd2b55b-aaff-4cd0-9c33-0465984f9077", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "ulcerative colitis are also excluded", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with ulcerative colitis are also excluded.", "source_span": {"start": 2866, "end": 2917}}, {"id": "rule-002e8612-d267-4e3c-9f88-1c21fb68c46a", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Japanese female \\>=18 years of age.", "source_span": {"start": 121, "end": 156}}, {"id": "rule-20cf9124-ce15-41a1-b27c-74ed07c82c24", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Japanese female \\>=18 years of age.", "source_span": {"start": 121, "end": 156}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00018", "nct_id": "NCT00992797", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 123.0, "priority_reasons": ["missing_critical_rules=8", "contract_errors=1", "rule_v1_missing=15", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4, "history": 2, "lab": 1, "medication": 4, "procedure": 1, "sex": 3}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication", "sex", "history", "lab", "procedure"], "eligibility_text": "Inclusion criteria:\n\n1. Moderate (S-25OHD 25-50 nmol/l) to severe (S-25OHD \\< 25 nmol/l) vitamin D deficiency measured at Visit 1.\n2. Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication must be in stable doses during the 4 week lead-in period.\n3. HbA1c \\< 11 % at Visit 1.\n4. Able to communicate in Norwegian.\n5. Men and women ≥ 18 years.\n6. Norwegian or South Asian ethnicity.\n7. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study. All WOCBP must have negative serum or urine pregnancy test at enrollment, randomization, titration visit and final study assessment.\n8. Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are allowed if the subjects adhere to the same regimen during the study\n\nExclusion Criteria:\n\n1. Subjects not having type 2 diabetes.\n2. SBP ≥ 160 or DBP ≥ 95 at Visit 1.\n3. Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min.\n4. Significant liver disease or ASAT or ALAT \\>3x UNL.\n5. Malignancy during the last five years.\n6. Hypercalcemia at Visit 1.\n7. A history of kidney stone disease\n8. WOCBP unwilling or unable to use an acceptable method to avoid pregnancy.\n9. Pregnant or breastfeeding women.\n10. Chronic inflammatory disease in active phase\n11. Long term (\\>2 weeks) use of corticosteroids last 3 months\n12. Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope and possible consequences of the study.\n13. Drug or alcohol abuse.\n14. BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years).\n15. Anemia\n16. Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months.\n17. Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "kidney stone disease", "unit": null, "evidence_text": "A history of kidney stone disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Chronic inflammatory disease in active phase", "unit": null, "evidence_text": "Chronic inflammatory disease in active phase"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Significant liver disease or ASAT or ALAT \\>3x UNL.", "unit": null, "evidence_text": "Significant liver disease or ASAT or ALAT \\>3x UNL."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min.", "unit": null, "evidence_text": "Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subjects not having type 2 diabetes.", "unit": null, "evidence_text": "Subjects not having type 2 diabetes."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of kidney stone disease", "unit": null, "evidence_text": "A history of kidney stone disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months.", "unit": null, "evidence_text": "Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety.", "unit": null, "evidence_text": "Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Drug or alcohol abuse.", "unit": null, "evidence_text": "Drug or alcohol abuse."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years).", "unit": null, "evidence_text": "BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years)."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant or breastfeeding women."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes", "unit": null, "evidence_text": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "11", "unit": "%", "evidence_text": "HbA1c \\< 11 % at Visit 1."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are al", "unit": null, "evidence_text": "Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are allowed if the subjects adhere to the same regimen during the study"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication mus", "unit": null, "evidence_text": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication must be in stable doses during the 4 week lead-in period."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Men and women ≥ 18 years."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Chronic inflammatory disease in active phase", "unit": null, "evidence_text": "Chronic inflammatory disease in active phase"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Significant liver disease or ASAT or ALAT \\>3x UNL.", "unit": null, "evidence_text": "Significant liver disease or ASAT or ALAT \\>3x UNL."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min.", "unit": null, "evidence_text": "Significant renal disease or chronic renal impairment, GFR\\< 30 ml/min."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subjects not having type 2 diabetes.", "unit": null, "evidence_text": "Subjects not having type 2 diabetes."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "A history of kidney stone disease", "unit": null, "evidence_text": "A history of kidney stone disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months.", "unit": null, "evidence_text": "Cardiovascular disease (myocardial infarction, unstable angina pectoris or stroke) during the last 6 months."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety.", "unit": null, "evidence_text": "Any medical condition that in the judgment of the investigator would jeopardize the subject's safety or evaluation of the study drug for efficacy and safety."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Drug or alcohol abuse.", "unit": null, "evidence_text": "Drug or alcohol abuse."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years).", "unit": null, "evidence_text": "BMI \\> 45 kg/m2 or bariatric surgery (\\<5 years)."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant or breastfeeding women."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "11", "unit": "%", "evidence_text": "HbA1c \\< 11 % at Visit 1."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are al", "unit": null, "evidence_text": "Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are allowed if the subjects adhere to the same regimen during the study"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication mus", "unit": null, "evidence_text": "Patients with type 2 diabetes, including drug naïve subjects, subjects using oral anti-diabetic medication and subjects on insulin treatment. All medication must be in stable doses during the 4 week lead-in period."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Men and women ≥ 18 years."}], "rule_v1_extra_rules": [{"id": "rule-c3d12467-cbcf-4952-8553-ae5b0fc434ef", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "type 2 diabetes", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects not having type 2 diabetes.", "source_span": {"start": 1004, "end": 1040}}, {"id": "rule-b921e2cf-dea7-4de3-b98d-4398633fd7c1", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study.", "source_span": {"start": 486, "end": 616}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00019", "nct_id": "NCT00743496", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 118.0, "priority_reasons": ["missing_critical_rules=7", "contract_errors=1", "rule_v1_missing=15", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"age": 2, "condition": 4, "history": 2, "medication": 2, "other": 1, "procedure": 2, "sex": 2}, "extra_rules_by_field": {"age": 2, "condition": 1}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age", "history", "medication", "procedure", "sex", "other"], "eligibility_text": "Inclusion Criteria:\n\n* Diagnosis:\n\n  * Part A: Recurrent or refractory neuroblastoma or melanoma.\n  * Part B: Recurrent or refractory neuroblastoma or melanoma.\n  * Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.\n* Age: ≤ 21 years of age at the time of enrollment (i.e. participants are eligible until they reach their 22nd birthday).\n* Does not have a clinically significant neurologic deficit or objective peripheral neuropathy (greater than or equal to grade 2). Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed.\n* Life expectancy: at least 8 weeks.\n* Organ Function: Must have adequate organ and marrow function\n* Performance status: Karnofsky ≥ 50 for \\> 10 years of age; Lansky ≥ 50 for children \\< 10 years of age.\n* Prior Therapy: Patient must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study.\n\n  * Myelosuppressive Chemotherapy: Must not have received myelosuppressive therapy within 2 weeks prior to study entry (4 weeks if nitrosurea).\n  * Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with biologic agent, including retinoic acid. Participants receiving IVIG are eligible; however, participant must not receive IVIG during the 4 days of antibody infusion.\n  * Radiation therapy: At least 2 weeks since prior local radiation therapy at the time of study entry.\n  * Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry.\n  * Investigational agent: Must not have received investigational agent within 14 days of study entry.\n  * Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of study entry. Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-related allergic reaction will be permitted.\n* Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to study entry (assessment must be made by CT or MRI).\n* Written informed consent following institutional and federal guidelines.\n\nExclusion Criteria:\n\n* Prior monoclonal antibody: Participants having received in vivo monoclonal antibodies for biologic therapy or for tumor imaging are eligible provided they did not experience a severe allergic reaction with the antibody.\n* Pregnancy or Breast Feeding: Study participants who are pregnant are not eligible for this study. Pregnancy tests must be obtained in girls who are \\> 10 years of age or post-menarchal within 7 days prior to study enrollment. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial. Breast feeding should be discontinued if a mother wishes to participate in this study.\n* Allergy: known hypersensitivity to other recombinant human antibodies.\n* An uncontrolled infection.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 10, "unit": "years", "evidence_text": "Pregnancy tests must be obtained in girls who are \\> 10 years of age or post-menarchal within 7 days prior to study enrollment."}, {"type": "EXCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnancy tests must be obtained in girls who are \\> 10 years of age or post-menarchal within 7 days prior to study enrollment."}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 21, "unit": "years", "evidence_text": "Age: ≤ 21 years of age at the time of enrollment (i.e. participants are eligible until they reach their 22nd birthday)."}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 10, "unit": "years", "evidence_text": "Performance status: Karnofsky ≥ 50 for \\> 10 years of age; Lansky ≥ 50 for children \\< 10 years of age."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "biologic agent", "unit": null, "evidence_text": "Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with biologic agent, including retinoic acid."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis:", "unit": null, "evidence_text": "Diagnosis:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Part A: Recurrent or refractory neuroblastoma or melanoma.", "unit": null, "evidence_text": "Part A: Recurrent or refractory neuroblastoma or melanoma."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Part B: Recurrent or refractory neuroblastoma or melanoma.", "unit": null, "evidence_text": "Part B: Recurrent or refractory neuroblastoma or melanoma."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.", "unit": null, "evidence_text": "Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry.", "unit": null, "evidence_text": "Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Investigational agent: Must not have received investigational agent within 14 days of study entry.", "unit": null, "evidence_text": "Investigational agent: Must not have received investigational agent within 14 days of study entry."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of stud", "unit": null, "evidence_text": "Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of study entry."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-rel", "unit": null, "evidence_text": "Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-related allergic reaction will be permitted."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Written informed consent following institutional and federal guidelines.", "unit": null, "evidence_text": "Written informed consent following institutional and federal guidelines."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to st", "unit": null, "evidence_text": "Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to study entry (assessment must be made by CT or MRI)."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed.", "unit": null, "evidence_text": "Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnancy tests must be obtained in girls who are \\> 10 years of age or post-menarchal within 7 days prior to study enrollment."}, {"type": "EXCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial."}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 10, "unit": "years", "evidence_text": "Performance status: Karnofsky ≥ 50 for \\> 10 years of age; Lansky ≥ 50 for children \\< 10 years of age."}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 21, "unit": "years", "evidence_text": "Age: ≤ 21 years of age at the time of enrollment (i.e. participants are eligible until they reach their 22nd birthday)."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis:", "unit": null, "evidence_text": "Diagnosis:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Part A: Recurrent or refractory neuroblastoma or melanoma.", "unit": null, "evidence_text": "Part A: Recurrent or refractory neuroblastoma or melanoma."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Part B: Recurrent or refractory neuroblastoma or melanoma.", "unit": null, "evidence_text": "Part B: Recurrent or refractory neuroblastoma or melanoma."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma.", "unit": null, "evidence_text": "Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry.", "unit": null, "evidence_text": "Growth factors: Must not have received hematopoietic growth factors (G-CSF, GM-CSF) for at least 1 week prior to study entry."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Investigational agent: Must not have received investigational agent within 14 days of study entry.", "unit": null, "evidence_text": "Investigational agent: Must not have received investigational agent within 14 days of study entry."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-rel", "unit": null, "evidence_text": "Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast agent-related allergic reaction will be permitted."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of stud", "unit": null, "evidence_text": "Immune therapy: Must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of study entry."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Written informed consent following institutional and federal guidelines.", "unit": null, "evidence_text": "Written informed consent following institutional and federal guidelines."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to st", "unit": null, "evidence_text": "Patients may have had prior CNS metastasis providing: CNS disease has been previously treated and CNS disease has been clinically stable for 4 weeks prior to study entry (assessment must be made by CT or MRI)."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed.", "unit": null, "evidence_text": "Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed."}], "rule_v1_extra_rules": [{"id": "rule-f58f627c-9fe6-419c-9d11-aa9f23563c91", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the antibody", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Prior monoclonal antibody: Participants having received in vivo monoclonal antibodies for biologic therapy or for tumor imaging are eligible provided they did not experience a severe allergic reaction with the antibody.", "source_span": {"start": 2344, "end": 2563}}, {"id": "rule-db9b287f-ee0f-46a2-8f51-8460371686ba", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 10, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Performance status: Karnofsky ≥ 50 for \\> 10 years of age;", "source_span": {"start": 685, "end": 743}}, {"id": "rule-1166ff67-ae22-4fc2-a385-5999e2eea325", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 21, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Age: ≤ 21 years of age at the time of enrollment (i.e.", "source_span": {"start": 231, "end": 285}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00020", "nct_id": "NCT00889161", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 105.0, "priority_reasons": ["missing_critical_rules=9", "rule_v1_missing=11", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 1, "medication": 6, "procedure": 2}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "condition", "procedure", "history"], "eligibility_text": "Inclusion Criteria:\n\n* Children and adolescents eight to eighteen years old\n* Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology\n* Mild disease or in clinical remission based upon PUCAI or PCDAI score (score \\<34 on the PUCAI or score \\<30 on the PCDAI)\n* Parent/guardian and participant must be able to attend study visits at screening, baseline, and weeks three, six, and nine\n* Patient must be on a stable dose of IBD medications for at least 3 months\n* Patient must be able to swallow study medication\n\nExclusion Criteria:\n\n* Abnormal laboratory values as defined in the protocol\n* History of increased gastrointestinal symptoms (\"flare\") in the last 3 months\n* Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD\n* Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil). Allowed supplementation includes multivitamin, vitamin D \\& calcium, folate and vitamin B12, and Iron.\n* Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.\n* History of gastrointestinal surgery or planned gastrointestinal surgery in the future.\n* Tobacco, alcohol, or illicit drug abuse\n* Planned surgery during the potential study participation time\n* Inability to swallow study medication", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "gastrointestinal surgery or planned gastrointestinal surgery in the future", "unit": null, "evidence_text": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "increased gastrointestinal symptoms (\"flare\") in the last 3 months", "unit": null, "evidence_text": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.", "unit": null, "evidence_text": "Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease."}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months", "unit": null, "evidence_text": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botan", "unit": null, "evidence_text": "Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil)."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD", "unit": null, "evidence_text": "Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Inability to swallow study medication", "unit": null, "evidence_text": "Inability to swallow study medication"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Tobacco, alcohol, or illicit drug abuse", "unit": null, "evidence_text": "Tobacco, alcohol, or illicit drug abuse"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future.", "unit": null, "evidence_text": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Planned surgery during the potential study participation time", "unit": null, "evidence_text": "Planned surgery during the potential study participation time"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies a", "unit": null, "evidence_text": "Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient must be able to swallow study medication", "unit": null, "evidence_text": "Patient must be able to swallow study medication"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient must be on a stable dose of IBD medications for at least 3 months", "unit": null, "evidence_text": "Patient must be on a stable dose of IBD medications for at least 3 months"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease.", "unit": null, "evidence_text": "Other serious medical conditions such as neurological, liver, kidney, auto- immune or systemic disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months", "unit": null, "evidence_text": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botan", "unit": null, "evidence_text": "Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including but not limited to aspirin, NSAID, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil)."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD", "unit": null, "evidence_text": "Current use (past use of these medications is not an exclusion) of medications such as azathioprine, methotrexate or 6-mercaptopurine used to treat IBD"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Inability to swallow study medication", "unit": null, "evidence_text": "Inability to swallow study medication"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Tobacco, alcohol, or illicit drug abuse", "unit": null, "evidence_text": "Tobacco, alcohol, or illicit drug abuse"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future.", "unit": null, "evidence_text": "History of gastrointestinal surgery or planned gastrointestinal surgery in the future."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Planned surgery during the potential study participation time", "unit": null, "evidence_text": "Planned surgery during the potential study participation time"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies a", "unit": null, "evidence_text": "Diagnosis of inflammatory bowel disease (IBD) made by a pediatric gastroenterologist based upon history, physical examination, laboratory/radiological studies and gastrointestinal histology"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient must be able to swallow study medication", "unit": null, "evidence_text": "Patient must be able to swallow study medication"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patient must be on a stable dose of IBD medications for at least 3 months", "unit": null, "evidence_text": "Patient must be on a stable dose of IBD medications for at least 3 months"}], "rule_v1_extra_rules": [{"id": "rule-fdca8fa5-d627-4057-900f-b469af546c3d", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "increased gastrointestinal", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of increased gastrointestinal symptoms (\"flare\") in the last 3 months", "source_span": {"start": 725, "end": 802}}, {"id": "rule-dbeb9223-4d98-437f-9643-12d9832b2357", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00021", "nct_id": "NCT01196455", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 101.0, "priority_reasons": ["missing_critical_rules=8", "rule_v1_missing=12"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 3, "history": 3, "lab": 5}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["lab", "condition", "history", "age"], "eligibility_text": "Inclusion Criteria:\n\n* Histologically/cytologically confirmed breast cancer\n* Metastatic breast cancer, having at least one target lesion according to the RECIST criteria. Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions. Target lesions must be ≥ 10 mm longest diameter measured in one dimension using spiral CT, or ≥ 20 mm longest diameter measured in one dimension using conventional techniques. In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable).\n* Age \\> 18 years\n* Signed informed consent obtained prior to initiation of any study-specific procedures or treatment\n\nExclusion Criteria:\n\n* Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease\n* Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment\n* Life expectancy \\< 3 months\n* Not-ambulatory or with an ECOG performance status \\> 1\n* Insufficient hematological, renal and hepatic functions:\n* hemoglobin \\< 8.0 g/dL\n* absolute neutrophils count (ANC) \\< 1.5 x 109/L\n* platelet count \\< 100 x 109/L\n* serum creatinine \\> 1.25 x N\\*\n* total bilirubin \\> 2.0 x N\\*\n* ASAT and/or ALAT \\> 2.5 x N\\* (in case of liver metastases \\> 5 x N\\*)\n* alkaline phosphatase \\> 2.5 x N\\* (in case of liver metastases \\> 5 x N\\*, in case of bone metastases \\> 10 x N\\*) \\*N = upper limit of standard range\n* Severe renal impairment \\[creatinine clearance \\< 30 mL/min (calculated according to cockcroft and Gault)\\]", "current_labeled_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment", "unit": null, "evidence_text": "Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "8.0", "unit": "g/dl", "evidence_text": "hemoglobin \\< 8.0 g/dL"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": "x", "evidence_text": "platelet count \\< 100 x 109/L"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "1.25", "unit": "x", "evidence_text": "serum creatinine \\> 1.25 x N\\*"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "30", "unit": "ml/min", "evidence_text": "Severe renal impairment \\[creatinine clearance \\< 30 mL/min (calculated according to cockcroft and Gault)\\]"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2.0", "unit": "x", "evidence_text": "total bilirubin \\> 2.0 x N\\*"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age \\> 18 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not a", "unit": null, "evidence_text": "Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Histologically/cytologically confirmed breast cancer", "unit": null, "evidence_text": "Histologically/cytologically confirmed breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least one target lesion according to", "unit": null, "evidence_text": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria.", "unit": null, "evidence_text": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria."}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated", "unit": null, "evidence_text": "In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable)."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Signed informed consent obtained prior to initiation of any study-specific procedures or treatment", "unit": null, "evidence_text": "Signed informed consent obtained prior to initiation of any study-specific procedures or treatment"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment", "unit": null, "evidence_text": "Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "1.25", "unit": "x", "evidence_text": "serum creatinine \\> 1.25 x N\\*"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "100", "unit": "x", "evidence_text": "platelet count \\< 100 x 109/L"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2.0", "unit": "x", "evidence_text": "total bilirubin \\> 2.0 x N\\*"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "30", "unit": "ml/min", "evidence_text": "Severe renal impairment \\[creatinine clearance \\< 30 mL/min (calculated according to cockcroft and Gault)\\]"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "8.0", "unit": "g/dl", "evidence_text": "hemoglobin \\< 8.0 g/dL"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age \\> 18 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not a", "unit": null, "evidence_text": "Bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Histologically/cytologically confirmed breast cancer", "unit": null, "evidence_text": "Histologically/cytologically confirmed breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria.", "unit": null, "evidence_text": "Metastatic breast cancer, having at least one target lesion according to the RECIST criteria."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Signed informed consent obtained prior to initiation of any study-specific procedures or treatment", "unit": null, "evidence_text": "Signed informed consent obtained prior to initiation of any study-specific procedures or treatment"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated", "unit": null, "evidence_text": "In addition to the definitions pertaining to the target lesion(s) from the RECIST criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable)."}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00022", "nct_id": "NCT01080677", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 91.0, "priority_reasons": ["missing_critical_rules=6", "rule_v1_missing=12", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 6, "history": 3, "medication": 2, "other": 1}, "extra_rules_by_field": {"age": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "medication", "other", "age"], "eligibility_text": "Inclusion Criteria:1. Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for migraine with or without aura 2. Subject is between 18-50 years of age. 3. Subject experiences an average of 2-8 migraines per month. 4. If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation.\n\n5\\. Subject is able to communicate adequately and comply with the requirements of the study as determined by the investigator.\n\n6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form.\n\nExclusion Criteria:1. Subject#s age of migraine onset is greater than 50 years. 2. Subject has more than 6 non-migraine headache days per month. 3. Subject has less than 48 hours of freedom from headache between attacks of migraine.\n\n4\\. Subject meets the criteria for complicated and/or brainstem migraines. 5. Subject is pregnant or lactating. 6. Subject has history of alcohol or drug abuse within the past 2 years. 7. Subject has existing systolic blood pressure \\< 100mm Hg, existing systolic blood pressure \\> 150mm Hg, and or heart rate \\<50 beats per minute.\n\n8\\. Subject has heart block greater than 1st degree without a functioning pacemaker 9. Subject has a history of tachyarrythmias 10. Subject has uncompensated congestive heart failure (CHF) 11. Subject has severe chronic obstructive pulmonary disease or severe asthma. 12. Subject has consumed caffeine within 6 hours. 13. Subjects with existing generalized anxiety disorder (GAD) and/or panic disorder.\n\n14\\. Subjects with existing severe hepatic and/or renal insufficiency. 15. Subjects with existing Raynaud#s disease. 16. Subject is participating in another clinical trial during or within 30 days prior to study enrollment.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "tachyarrythmias 10", "unit": null, "evidence_text": "Subject has a history of tachyarrythmias 10."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "alcohol or drug abuse within the past 2 years", "unit": null, "evidence_text": "Subject has history of alcohol or drug abuse within the past 2 years."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject has severe chronic obstructive pulmonary disease or severe asthma.", "unit": null, "evidence_text": "Subject has severe chronic obstructive pulmonary disease or severe asthma."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject has uncompensated congestive heart failure (CHF) 11.", "unit": null, "evidence_text": "Subject has uncompensated congestive heart failure (CHF) 11."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject meets the criteria for complicated and/or brainstem migraines.", "unit": null, "evidence_text": "Subject meets the criteria for complicated and/or brainstem migraines."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subjects with existing Raynaud#s disease.", "unit": null, "evidence_text": "Subjects with existing Raynaud#s disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a history of tachyarrythmias 10.", "unit": null, "evidence_text": "Subject has a history of tachyarrythmias 10."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has consumed caffeine within 6 hours.", "unit": null, "evidence_text": "Subject has consumed caffeine within 6 hours."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject is participating in another clinical trial during or within 30 days prior to study enrollment.", "unit": null, "evidence_text": "Subject is participating in another clinical trial during or within 30 days prior to study enrollment."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has history of alcohol or drug abuse within the past 2 years.", "unit": null, "evidence_text": "Subject has history of alcohol or drug abuse within the past 2 years."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject experiences an average of 2-8 migraines per month.", "unit": null, "evidence_text": "Subject experiences an average of 2-8 migraines per month."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without aura 2", "unit": null, "evidence_text": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for migraine with or without aura 2."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for", "unit": null, "evidence_text": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for migraine with or without aura 2."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of the study as determined", "unit": null, "evidence_text": "Subject is able to communicate adequately and comply with the requirements of the study as determined by the investigator."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation.", "unit": null, "evidence_text": "If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form.", "unit": null, "evidence_text": "6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject has severe chronic obstructive pulmonary disease or severe asthma.", "unit": null, "evidence_text": "Subject has severe chronic obstructive pulmonary disease or severe asthma."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject has uncompensated congestive heart failure (CHF) 11.", "unit": null, "evidence_text": "Subject has uncompensated congestive heart failure (CHF) 11."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subject meets the criteria for complicated and/or brainstem migraines.", "unit": null, "evidence_text": "Subject meets the criteria for complicated and/or brainstem migraines."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Subjects with existing Raynaud#s disease.", "unit": null, "evidence_text": "Subjects with existing Raynaud#s disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has a history of tachyarrythmias 10.", "unit": null, "evidence_text": "Subject has a history of tachyarrythmias 10."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject has consumed caffeine within 6 hours.", "unit": null, "evidence_text": "Subject has consumed caffeine within 6 hours."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Subject is participating in another clinical trial during or within 30 days prior to study enrollment.", "unit": null, "evidence_text": "Subject is participating in another clinical trial during or within 30 days prior to study enrollment."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Subject has history of alcohol or drug abuse within the past 2 years.", "unit": null, "evidence_text": "Subject has history of alcohol or drug abuse within the past 2 years."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject experiences an average of 2-8 migraines per month.", "unit": null, "evidence_text": "Subject experiences an average of 2-8 migraines per month."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for", "unit": null, "evidence_text": "Subject has a minimum 12-month migraine history that the investigator determines meets the International Headache Society (IHS) Migraine Diagnostic Criteria for migraine with or without aura 2."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation.", "unit": null, "evidence_text": "If on preventive migraine therapy, medication regimen has been stable for 30 days and will remain stable for the duration of participation."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form.", "unit": null, "evidence_text": "6\\. Subject is able to read and understand the informed consent written in English and voluntarily consents to sign the informed consent form."}], "rule_v1_extra_rules": [{"id": "rule-ec81f3e5-e0b3-4255-8da9-ea7ee5ed6d51", "type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Subject is between 18-50 years of age.", "source_span": {"start": 216, "end": 254}}, {"id": "rule-be143534-bcf4-471f-a159-a21cbccf93d6", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Subject is between 18-50 years of age.", "source_span": {"start": 216, "end": 254}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00023", "nct_id": "NCT00890253", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 91.0, "priority_reasons": ["missing_critical_rules=7", "rule_v1_missing=9", "rule_v1_extra=10"], "priority_breakdown": {"missing_rules_by_field": {"lab": 3, "other": 2, "procedure": 2, "sex": 2}, "extra_rules_by_field": {"condition": 8, "sex": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["lab", "sex", "other", "procedure", "condition"], "eligibility_text": "Inclusion Criteria:\n\n1. Patients undergoing primary liver transplantation.\n2. Patients older than 18 years.\n3. Patients with a hepatorenal syndrome.\n4. Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation.\n5. eGFR \\< 50 ml/min at the time point of transplantation.\n6. Serum creatinine levels \\> 1.5 mg/dL at the time-point of transplantation.\n\nExclusion Criteria:\n\n1. Patients with pre-transplant renal replacement therapy \\> 14 days.\n2. Patients with a reason for renal impairment other than a hepatorenal syndrome.\n3. Patients with a known hypersensitivity to mTOR-inhibitors.\n4. Patients with a known hypersensitivity to mycophenolate acid.\n5. Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.\n6. Patients with platelets \\< 50.000/nl prior to initiation of therapy with mTOR inhibition.\n7. Patients with triglycerides \\> 350 mg/dl and cholesterol \\> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition.\n8. Severe systemic infections and wound-healing disturbances.\n9. Multiple organ graft recipients.\n10. Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with everolimus.\n11. Pregnant women will not be included in the study.\n12. Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.\n13. Patients under guardianship (e.g., individuals who are not able to freely give their informed consent).", "current_labeled_rules": [{"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "50.000", "unit": "/nl", "evidence_text": "Patients with platelets \\< 50.000/nl prior to initiation of therapy with mTOR inhibition."}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "350", "unit": "mg/dl", "evidence_text": "Patients with triglycerides \\> 350 mg/dl and cholesterol \\> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients under guardianship (e.g., individuals who are not able to freely give their informed consent).", "unit": null, "evidence_text": "Patients under guardianship (e.g., individuals who are not able to freely give their informed consent)."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.", "unit": null, "evidence_text": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women will not be included in the study."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a hepatorenal syndrome", "unit": null, "evidence_text": "Patients with a hepatorenal syndrome."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "mg/dl", "evidence_text": "Serum creatinine levels \\> 1.5 mg/dL at the time-point of transplantation."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "eGFR \\< 50 ml/min at the time point of transplantation.", "unit": null, "evidence_text": "eGFR \\< 50 ml/min at the time point of transplantation."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients undergoing primary liver transplantation.", "unit": null, "evidence_text": "Patients undergoing primary liver transplantation."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "350", "unit": "mg/dl", "evidence_text": "Patients with triglycerides \\> 350 mg/dl and cholesterol \\> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition."}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "50.000", "unit": "/nl", "evidence_text": "Patients with platelets \\< 50.000/nl prior to initiation of therapy with mTOR inhibition."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients under guardianship (e.g., individuals who are not able to freely give their informed consent).", "unit": null, "evidence_text": "Patients under guardianship (e.g., individuals who are not able to freely give their informed consent)."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.", "unit": null, "evidence_text": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women will not be included in the study."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "1.5", "unit": "mg/dl", "evidence_text": "Serum creatinine levels \\> 1.5 mg/dL at the time-point of transplantation."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "eGFR \\< 50 ml/min at the time point of transplantation.", "unit": null, "evidence_text": "eGFR \\< 50 ml/min at the time point of transplantation."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients undergoing primary liver transplantation.", "unit": null, "evidence_text": "Patients undergoing primary liver transplantation."}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation."}], "rule_v1_extra_rules": [{"id": "rule-c2e3e6de-1c2c-4d20-ba48-59316dee33b9", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a known hypersensitivity to anti cd 25", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.", "source_span": {"start": 758, "end": 833}}, {"id": "rule-4d5f29d9-b3ae-4dbb-ab60-f5adfefa7745", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a known hypersensitivity to mtor inhibitors", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a known hypersensitivity to mTOR-inhibitors.", "source_span": {"start": 631, "end": 689}}, {"id": "rule-d063bde5-b2eb-47e9-8912-75a350b807c9", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a known hypersensitivity to mycophenolate acid", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a known hypersensitivity to mycophenolate acid.", "source_span": {"start": 693, "end": 754}}, {"id": "rule-18c13928-e99e-4384-896c-f50060272c3e", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a psychological", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.", "source_span": {"start": 1359, "end": 1515}}, {"id": "rule-98954f0f-ba60-43be-ae24-2d8deb4069b1", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a reason for renal impairment other than", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a reason for renal impairment other than a hepatorenal syndrome.", "source_span": {"start": 549, "end": 627}}, {"id": "rule-060c83b9-dedf-4437-bda7-41d9786a7e3c", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "everolimus", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with everolimus.", "source_span": {"start": 1195, "end": 1300}}, {"id": "rule-f84c3096-7898-4d55-a23c-cd032aceacc7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mtor inhibition", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with platelets \\< 50.000/nl prior to initiation of therapy with mTOR inhibition.", "source_span": {"start": 837, "end": 926}}, {"id": "rule-40758f4f-c338-4eeb-87f5-f14868f392fa", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the study protocol and follow up schedule", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.", "source_span": {"start": 1359, "end": 1515}}, {"id": "rule-6a2a4f90-764d-45f9-8adc-e7ca1f5fdc57", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Pregnant women will not be included in the study.", "source_span": {"start": 1305, "end": 1354}}, {"id": "rule-0dc5b6cb-3e1e-401f-b7b7-932f2ea0f070", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation.", "source_span": {"start": 152, "end": 316}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00024", "nct_id": "NCT00947674", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 85.0, "priority_reasons": ["missing_critical_rules=4", "contract_errors=2", "rule_v1_missing=9", "rule_v1_extra=8"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4, "lab": 2, "medication": 2, "sex": 1}, "extra_rules_by_field": {"condition": 7, "sex": 1}, "contract_error_count": 2, "contract_warning_count": 0, "contract_error_codes": {"LAB_THRESHOLD_VALUE_INVALID": 2}, "contract_warning_codes": {}}, "focus_fields": ["condition", "lab", "medication", "sex"], "eligibility_text": "Inclusion Criteria:\n\n* Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy\n* Patients with pancolitis type or left-sided colitis type lesion of 15 cm or longer observed endoscopically\n* Patients with Mayo score between 5 and 10\n* Patients with Mayo sub-score (findings from flexible sigmoidoscopy) of 2 or 3\n* Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks\n\nExclusion Criteria:\n\n* Patients with a difficulty in peripheral vascular access\n* Patients having received ACE inhibitor (at least 10 times of its half-life time for interval needed before initiating the treatment)\n* Patients with toxic megacolon\n* Patients with a malignant disease or its experience\n* Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))\n* Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)\n* Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria\n* Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN\n* Pregnant women or patients with possible pregnancy\n* Breast feeding women\n* Patients weighing 40 kg or less\n* Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)\n* Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)\n* Patients with white blood cell count of less than 3.5 x 109/L (3,500/mm3)\n* Patients with hypotension (with systolic blood pressure of 80 mmHg or less)", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of nor", "unit": null, "evidence_text": "Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with a malignant disease or its experience", "unit": null, "evidence_text": "Patients with a malignant disease or its experience"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))", "unit": null, "evidence_text": "Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": "6.5", "unit": "mmol/l", "evidence_text": "Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": "150", "unit": "x", "evidence_text": "Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN", "unit": null, "evidence_text": "Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Breast feeding women"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women or patients with possible pregnancy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "patients diagnosed to have uc in the", "unit": null, "evidence_text": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy", "unit": null, "evidence_text": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "mayo score between 5 and 10", "unit": null, "evidence_text": "Patients with Mayo score between 5 and 10"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks", "unit": null, "evidence_text": "Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of nor", "unit": null, "evidence_text": "Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with a malignant disease or its experience", "unit": null, "evidence_text": "Patients with a malignant disease or its experience"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))", "unit": null, "evidence_text": "Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": "150", "unit": "x", "evidence_text": "Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": "6.5", "unit": "mmol/l", "evidence_text": "Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN", "unit": null, "evidence_text": "Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Breast feeding women"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy", "unit": null, "evidence_text": "Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks", "unit": null, "evidence_text": "Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks"}], "rule_v1_extra_rules": [{"id": "rule-0653863d-cfac-4b79-9acc-c4c8445e86a7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a difficulty in peripheral vascular access", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a difficulty in peripheral vascular access", "source_span": {"start": 519, "end": 575}}, {"id": "rule-5f7f5423-57f3-4faa-8384-baa640e85d39", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a malignant disease or its experience", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a malignant disease or its experience", "source_span": {"start": 745, "end": 796}}, {"id": "rule-c73e325b-7dc5-4202-8bca-670b74644365", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hbv or hcv or hiv or pathogenic", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria", "source_span": {"start": 1147, "end": 1224}}, {"id": "rule-1a3d1821-6e9b-4d11-8057-8fff3ecbec5a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hemoglobin level of less than 6", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)", "source_span": {"start": 1487, "end": 1553}}, {"id": "rule-b11ff1e1-5f1d-43b9-9155-0ddfad932fbe", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "possible pregnancy", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Pregnant women or patients with possible pregnancy", "source_span": {"start": 1377, "end": 1427}}, {"id": "rule-c266f542-db21-4221-8879-bf99ee5a778d", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "toxic megacolon", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with toxic megacolon", "source_span": {"start": 713, "end": 742}}, {"id": "rule-80012f30-fecd-4517-b0f0-2e05f6dbbb58", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "white blood cell count of less than", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with white blood cell count of less than 3.5 x 109/L (3,500/mm3)", "source_span": {"start": 1642, "end": 1715}}, {"id": "rule-6c5093d3-c82a-4aaa-b470-9b32f134f159", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Pregnant women or patients with possible pregnancy", "source_span": {"start": 1377, "end": 1427}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00025", "nct_id": "NCT00910689", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 80.0, "priority_reasons": ["missing_critical_rules=5", "rule_v1_missing=10", "rule_v1_extra=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4, "history": 1, "medication": 3, "other": 1, "sex": 1}, "extra_rules_by_field": {"age": 2, "condition": 2, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication", "sex", "history", "other", "age"], "eligibility_text": "Inclusion Criteria:\n\n* 18 to 65 years\n* Diagnosis of migraine with or without aura (International Classification of Headache Disorders)\n* 3 or more migraine episodes/month with disability for the past 6 months\n* Less than 20 total headache days/month for the past 6 months\n\nExclusion Criteria:\n\n* Medication overuse headaches\n* Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw\n* Concurrently undergoing counseling/psychotherapy treatment\n* Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.\n* Unable/unwilling to give written informed consent\n* History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease.\n* Uncontrolled hypertension at screening (sitting systolic pressure \\> 160 mmHg, diastolic pressure \\> 95 mmHg)\n* Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception.\n* Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality.\n* Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)\n* Has a substance abuse problem or a psychological disorder that prevents participation in study (e.g., unmanaged severe depression that requires immediate treatment or limits participation in home-based treatment)\n* Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol, Sumatriptan, or Rizatriptan", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease", "unit": null, "evidence_text": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)", "unit": null, "evidence_text": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.", "unit": null, "evidence_text": "Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stro", "unit": null, "evidence_text": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw", "unit": null, "evidence_text": "Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or mul", "unit": null, "evidence_text": "Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Medication overuse headaches", "unit": null, "evidence_text": "Medication overuse headaches"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unable/unwilling to give written informed consent", "unit": null, "evidence_text": "Unable/unwilling to give written informed consent"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "disability for the past 6 months", "unit": null, "evidence_text": "3 or more migraine episodes/month with disability for the past 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "3 or more migraine episodes/month with disability for the past 6 months", "unit": null, "evidence_text": "3 or more migraine episodes/month with disability for the past 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis of migraine with or without aura (International Classification of Headache Disorders)", "unit": null, "evidence_text": "Diagnosis of migraine with or without aura (International Classification of Headache Disorders)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)", "unit": null, "evidence_text": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual.", "unit": null, "evidence_text": "Unable to read, understand or record information in study diaries, questionnaires, and migraine management manual."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stro", "unit": null, "evidence_text": "History of exclusionary medical condition such as, but not limited to, epilepsy, heart disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic abdominal syndromes, peripheral vascular disease."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw", "unit": null, "evidence_text": "Currently taking medications contraindicated by study protocol and unable or unwilling to withdraw"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or mul", "unit": null, "evidence_text": "Has exclusionary medical condition such as but not limited to diabetes (insulin dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple risk factors for heart disease), angina pectoris, documented silent ischemia, or cardiac arrythmias requiring medication, or a clinically significant EKG abnormality."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Medication overuse headaches", "unit": null, "evidence_text": "Medication overuse headaches"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unable/unwilling to give written informed consent", "unit": null, "evidence_text": "Unable/unwilling to give written informed consent"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "3 or more migraine episodes/month with disability for the past 6 months", "unit": null, "evidence_text": "3 or more migraine episodes/month with disability for the past 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosis of migraine with or without aura (International Classification of Headache Disorders)", "unit": null, "evidence_text": "Diagnosis of migraine with or without aura (International Classification of Headache Disorders)"}], "rule_v1_extra_rules": [{"id": "rule-c852598a-387a-45c9-afea-14e264dd4ef7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "fertile", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception.", "source_span": {"start": 996, "end": 1130}}, {"id": "rule-5cfa5390-493c-487e-a05b-96dacef8f538", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other pain", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)", "source_span": {"start": 1468, "end": 1539}}, {"id": "rule-9736bce0-aaa1-43a4-95b6-9589985bff62", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Fertile female who is breastfeeding, pregnant planning a pregnancy within the next year or is unwilling to use adequate contraception.", "source_span": {"start": 996, "end": 1130}}, {"id": "rule-9eba62c8-366f-498d-9ed0-31d37c23b9f8", "type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "18 to 65 years", "source_span": {"start": 23, "end": 37}}, {"id": "rule-fb74695a-4c13-4fd1-ba3c-55cf91913667", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "18 to 65 years", "source_span": {"start": 23, "end": 37}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00026", "nct_id": "NCT00785083", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 74.0, "priority_reasons": ["missing_critical_rules=7", "rule_v1_missing=7", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 3, "medication": 4}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "history", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Forced Expiratory Volume in 1 second of at least 60%\n* History of asthma for at least 6 months\n* Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)\n\nExclusion Criteria:\n\n* History of lung disease other than asthma\n* Smokers\n* Use of inhaled corticosteroid above specified dose\n* Use of oral beta agonists or corticosteroids or other asthma medications\n* Hypersensitivity to the drug\n* Respiratory tract infections within 1 month of the study\n\nOther protocol-defined inclusion/exclusion criteria may apply", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "lung disease other than asthma", "unit": null, "evidence_text": "History of lung disease other than asthma"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of lung disease other than asthma", "unit": null, "evidence_text": "History of lung disease other than asthma"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Respiratory tract infections within 1 month of the study", "unit": null, "evidence_text": "Respiratory tract infections within 1 month of the study"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Hypersensitivity to the drug", "unit": null, "evidence_text": "Hypersensitivity to the drug"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Use of inhaled corticosteroid above specified dose", "unit": null, "evidence_text": "Use of inhaled corticosteroid above specified dose"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Use of oral beta agonists or corticosteroids or other asthma medications", "unit": null, "evidence_text": "Use of oral beta agonists or corticosteroids or other asthma medications"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "History of asthma for at least 6 months", "unit": null, "evidence_text": "History of asthma for at least 6 months"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)", "unit": null, "evidence_text": "Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of lung disease other than asthma", "unit": null, "evidence_text": "History of lung disease other than asthma"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Respiratory tract infections within 1 month of the study", "unit": null, "evidence_text": "Respiratory tract infections within 1 month of the study"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Hypersensitivity to the drug", "unit": null, "evidence_text": "Hypersensitivity to the drug"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Use of inhaled corticosteroid above specified dose", "unit": null, "evidence_text": "Use of inhaled corticosteroid above specified dose"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Use of oral beta agonists or corticosteroids or other asthma medications", "unit": null, "evidence_text": "Use of oral beta agonists or corticosteroids or other asthma medications"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "History of asthma for at least 6 months", "unit": null, "evidence_text": "History of asthma for at least 6 months"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)", "unit": null, "evidence_text": "Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)"}], "rule_v1_extra_rules": [{"id": "rule-28b2c85d-77ee-4ff7-b039-3a64ea7994bf", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00027", "nct_id": "NCT01054118", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 74.0, "priority_reasons": ["missing_critical_rules=7", "rule_v1_missing=7", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 2, "medication": 2, "other": 1, "procedure": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "medication", "procedure", "other", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Body Mass Index (BMI) between 27.0 and 38.0 kg/m2 (inclusive)\n* Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests\n* Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication\n\nExclusion Criteria:\n\n* History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant\n* Smoker or tobacco user within the past 6 months\n* History of recent major surgery (within 6 months of study start)\n* Positive test for alcohol and/or drugs of abuse\n* Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements\n* Any condition that, in the opinion of the investigator, would compromise the well being of the volunteer or the study or prevent the volunteer from meeting or performing study requirements", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "recent major surgery (within 6 months of study start)", "unit": null, "evidence_text": "History of recent major surgery (within 6 months of study start)"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "evidence_text": "History of recent major surgery (within 6 months of study start)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant", "unit": null, "evidence_text": "History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Smoker or tobacco user within the past 6 months", "unit": null, "evidence_text": "Smoker or tobacco user within the past 6 months"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Positive test for alcohol and/or drugs of abuse", "unit": null, "evidence_text": "Positive test for alcohol and/or drugs of abuse"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study require", "unit": null, "evidence_text": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "History of recent major surgery (within 6 months of study start)", "unit": null, "evidence_text": "History of recent major surgery (within 6 months of study start)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "diaphragm", "unit": null, "evidence_text": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauter", "unit": null, "evidence_text": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests", "unit": null, "evidence_text": "Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant", "unit": null, "evidence_text": "History of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Smoker or tobacco user within the past 6 months", "unit": null, "evidence_text": "Smoker or tobacco user within the past 6 months"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Positive test for alcohol and/or drugs of abuse", "unit": null, "evidence_text": "Positive test for alcohol and/or drugs of abuse"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study require", "unit": null, "evidence_text": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "History of recent major surgery (within 6 months of study start)", "unit": null, "evidence_text": "History of recent major surgery (within 6 months of study start)"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauter", "unit": null, "evidence_text": "Men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests", "unit": null, "evidence_text": "Healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests"}], "rule_v1_extra_rules": [{"id": "rule-1999b9a3-7451-424d-be7f-a1dafbf00315", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the study requirements", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements", "source_span": {"start": 931, "end": 1096}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00028", "nct_id": "NCT00738023", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 71.0, "priority_reasons": ["missing_critical_rules=5", "contract_errors=1", "rule_v1_missing=7", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"history": 1, "lab": 2, "other": 1, "procedure": 1, "sex": 2}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["sex", "lab", "history", "other", "procedure", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Males or females between the ages of 18 and 70 years.\n* Subjects must have a BMI of ≥ 30 kg/m2.\n* Subjects must have a BP \\< 130/80 mm Hg and no prior history of hypertension.\n* A known history of type 2 diabetes mellitus \\< 3 years (now 5 years).\n* Subjects must have an HbA1c of \\< 9%.\n* Diabetic subjects must have been receiving as their only current anti-diabetic therapy stable doses of sulfonylureas for the last 2 months.\n* Subjects must be able to understand and willing to adhere to the study protocol.\n\nExclusion Criteria:\n\n* Subjects with history of hypertension (BP \\> 140/90 mm HG) or who have received antihypertensive drug therapy prior to the study.\n* Obese nondiabetic controls with impaired glucose tolerance (2-hour glucose between 140 - 199 mg/dl) during a 75-g OGTT.\n* Diabetic subjects who require insulin therapy or have received an insulin sensitizer agent (metformin, rosiglitazone, pioglitazone) within 3 months of entering the study (at SV1, week-2).\n* Subjects with fasting triglyceride levels \\> 250 mg/dL prior to the study (at SV1, week-2).\n* Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness.\n* Renal failure, as shown by a serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for females.\n* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\n* Female subjects are pregnant or breast feeding at time of enrollment into the study.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypertension (bp \\> 140/90 mm hg) or who have received antihypertensive drug therapy prior to the study", "unit": null, "evidence_text": "Subjects with history of hypertension (BP \\> 140/90 mm HG) or who have received antihypertensive drug therapy prior to the study."}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "250", "unit": "mg/dl", "evidence_text": "Subjects with fasting triglyceride levels \\> 250 mg/dL prior to the study (at SV1, week-2)."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness.", "unit": null, "evidence_text": "Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female subjects are pregnant or breast feeding at time of enrollment into the study."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "A known history of type 2 diabetes mellitus \\< 3 years (now 5 years).", "unit": null, "evidence_text": "A known history of type 2 diabetes mellitus \\< 3 years (now 5 years)."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "9", "unit": "%", "evidence_text": "Subjects must have an HbA1c of \\< 9%."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Subjects must be able to understand and willing to adhere to the study protocol.", "unit": null, "evidence_text": "Subjects must be able to understand and willing to adhere to the study protocol."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Males or females between the ages of 18 and 70 years."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "250", "unit": "mg/dl", "evidence_text": "Subjects with fasting triglyceride levels \\> 250 mg/dL prior to the study (at SV1, week-2)."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness.", "unit": null, "evidence_text": "Clinically relevant hepatic disease (ALT 2.5x \\> upper limit of normal), or other significant medical or surgical illness."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female subjects are pregnant or breast feeding at time of enrollment into the study."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "A known history of type 2 diabetes mellitus \\< 3 years (now 5 years).", "unit": null, "evidence_text": "A known history of type 2 diabetes mellitus \\< 3 years (now 5 years)."}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "9", "unit": "%", "evidence_text": "Subjects must have an HbA1c of \\< 9%."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Subjects must be able to understand and willing to adhere to the study protocol.", "unit": null, "evidence_text": "Subjects must be able to understand and willing to adhere to the study protocol."}, {"type": "INCLUSION", "field": "sex", "operator": "IN", "value": "male", "unit": null, "evidence_text": "Males or females between the ages of 18 and 70 years."}], "rule_v1_extra_rules": [{"id": "rule-2f26edb3-8d13-47d2-ab54-a8675d8c4561", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Female subjects are pregnant or breast feeding at time of enrollment into the study.", "source_span": {"start": 1442, "end": 1526}}, {"id": "rule-f9ebd55d-ab3e-4a0b-8f00-e5a419292a01", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00029", "nct_id": "NCT01126177", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 70.0, "priority_reasons": ["missing_critical_rules=5", "rule_v1_missing=9", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3, "medication": 2, "other": 2, "procedure": 1, "sex": 1}, "extra_rules_by_field": {"age": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication", "other", "procedure", "sex", "age"], "eligibility_text": "1. Male or female aged 18 to 65 years of age at the time of screening.\n2. Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:\n\n   1. ≥12% and 200mL bronchodilator reversibility at screening or documented in the past, OR,\n   2. evidence of bronchial hyper-responsiveness at screening or documented in the past, OR,\n   3. a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR.\n   4. documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18\n3. Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\"\n4. To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion.\n5. Must be taking regular inhaled corticosteroids.\n6. Pre-bronchodilator FEV1 ≥ 40 % predicted at screening.\n7. Post-bronchodilator FEV1 ≥ 50 % predicted at screening.\n8. Provide written informed consent.\n9. Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study.\n10. Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "Male or female aged 18 to 65 years of age at the time of screening."}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Male or female aged 18 to 65 years of age at the time of screening."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR.", "unit": null, "evidence_text": "a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "for worsening of asthma", "unit": null, "evidence_text": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\"", "unit": null, "evidence_text": "Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\""}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:", "unit": null, "evidence_text": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "antibiotics on one or more occasion", "unit": null, "evidence_text": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Must be taking regular inhaled corticosteroids.", "unit": null, "evidence_text": "Must be taking regular inhaled corticosteroids."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids", "unit": null, "evidence_text": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding t", "unit": null, "evidence_text": "Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Provide written informed consent.", "unit": null, "evidence_text": "Provide written informed consent."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since", "unit": null, "evidence_text": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study."}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR.", "unit": null, "evidence_text": "a documented hospital admission (including an Accident and Emergency admission) for asthma since the age of 18, OR."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\"", "unit": null, "evidence_text": "Must answer \"Yes\" to the question \"Does a cold make your asthma worse?\""}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:", "unit": null, "evidence_text": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Must be taking regular inhaled corticosteroids.", "unit": null, "evidence_text": "Must be taking regular inhaled corticosteroids."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids", "unit": null, "evidence_text": "To have had at least one asthma exacerbation suspected to have been caused by a respiratory virus in the last 24 months which required the use of oral steroids and/or additional treatment with antibiotics on one or more occasion."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding t", "unit": null, "evidence_text": "Motivation (in the Investigator\"s opinion) to complete all study visits, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment including its risks and benefits."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Provide written informed consent.", "unit": null, "evidence_text": "Provide written informed consent."}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since", "unit": null, "evidence_text": "documented evidence that they have attended their GP surgery, out-of-hours clinic (or alternative health care provider) for worsening of asthma symptoms, since the age of 18"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Females of childbearing potential must be using a medically acceptable adequate form of birth control and agree to maintain this usage throughout the duration of and four weeks post the Treatment Phase of the study."}], "rule_v1_extra_rules": [{"id": "rule-0fd18296-d6ff-4121-91be-5ac6b0101ffc", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a medical history and:", "source_span": {"start": 74, "end": 180}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00030", "nct_id": "NCT00872794", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 68.0, "priority_reasons": ["missing_critical_rules=5", "rule_v1_missing=7", "rule_v1_extra=7"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "medication": 1, "other": 2, "procedure": 2, "sex": 1}, "extra_rules_by_field": {"condition": 6, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["other", "procedure", "condition", "sex", "medication"], "eligibility_text": "Inclusion Criteria:\n\ni) Male or female subjects, aged between 18 and 65 years inclusive.\n\nii) Subjects with current indications for standard MoM hip resurfacing arthroplasty suitable for cementless fixation in the acetabulum. These include pain, deformity, and loss of function, which are not responsive to medical treatment.\n\niii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.\n\niv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.\n\nExclusion Criteria:\n\ni) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.\n\nii) Subjects with proven significant osteoporosis and poor bone quality.\n\niii) Subjects with compromised renal function.\n\niv) Subjects with proven metal sensitivity.\n\nv) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.\n\nvi) Women who are pregnant.\n\nvii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.\n\nviii) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).\n\nix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.\n\nx) Subjects who are currently involved in any injury litigation claims.\n\nAdditional Exclusion Criteria for Subjects Undergoing Blood Analysis\n\n1. Subjects who currently have other metallic foreign bodies including trauma products and joint arthroplasties unless known to be pure titanium, titanium alloy.\n2. Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision operations", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.", "unit": null, "evidence_text": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.", "unit": null, "evidence_text": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.", "unit": null, "evidence_text": "ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision ope", "unit": null, "evidence_text": "Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision operations"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "vi) Women who are pregnant."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.", "unit": null, "evidence_text": "iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing", "unit": null, "evidence_text": "iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.", "unit": null, "evidence_text": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.", "unit": null, "evidence_text": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.", "unit": null, "evidence_text": "ix) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision ope", "unit": null, "evidence_text": "Subjects who, in the opinion of the investigator, will possibly require a separate joint replacement operation within the next two years, including revision operations"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "vi) Women who are pregnant."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.", "unit": null, "evidence_text": "iii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing", "unit": null, "evidence_text": "iv) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups."}], "rule_v1_extra_rules": [{"id": "rule-b55ec64b-1892-4e50-a5cd-d420c6913c6a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "compromised renal function", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "iii) Subjects with compromised renal function.", "source_span": {"start": 960, "end": 1006}}, {"id": "rule-19e2bbd7-34e7-4d3d-a0dc-f48d32df56b2", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "infectious", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "v) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e.", "source_span": {"start": 1053, "end": 1142}}, {"id": "rule-1f4dd547-485f-474c-bad3-a87a8a37b263", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "proven metal sensitivity", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "iv) Subjects with proven metal sensitivity.", "source_span": {"start": 1008, "end": 1051}}, {"id": "rule-fbc2fa2e-5f16-4515-83b4-b4d5e8d3b9c5", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "proven significant osteoporosis and poor bone quality", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "ii) Subjects with proven significant osteoporosis and poor bone quality.", "source_span": {"start": 886, "end": 958}}, {"id": "rule-3cd2ff5c-b9fd-41ea-a305-98a2ca1e9abd", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "psychological disorders that could affect follow up", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "vii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.", "source_span": {"start": 1241, "end": 1380}}, {"id": "rule-6cbf57b5-6e9a-40d5-a427-b44f7bc6069a", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "vi) Women who are pregnant.", "source_span": {"start": 1212, "end": 1239}}, {"id": "rule-c786206d-93af-44b2-8a82-f550d93ba569", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00031", "nct_id": "NCT01040910", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 67.0, "priority_reasons": ["missing_critical_rules=5", "rule_v1_missing=8", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "medication": 3, "other": 1, "procedure": 1, "sex": 1}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "condition", "sex", "other", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n1. Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study.\n2. Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo.\n3. Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC.\n4. Age above 20.\n\nExclusion Criteria:\n\n1. Patients with a known mental disorder\n2. Patients who are deemed to be at a high risk of abuse or addiction to the study drug.\n3. Pregnant women\n4. Patients who are sensitive to any of the ingredients of the study medication.\n5. Patients who are unable to give informed consent.\n6. Patients who may need surgery in the near future.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are deemed to be at a high risk of abuse or addiction to the study drug.", "unit": null, "evidence_text": "Patients who are deemed to be at a high risk of abuse or addiction to the study drug."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are sensitive to any of the ingredients of the study medication.", "unit": null, "evidence_text": "Patients who are sensitive to any of the ingredients of the study medication."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who are unable to give informed consent.", "unit": null, "evidence_text": "Patients who are unable to give informed consent."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients who may need surgery in the near future.", "unit": null, "evidence_text": "Patients who may need surgery in the near future."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC.", "unit": null, "evidence_text": "Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study.", "unit": null, "evidence_text": "Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active disease", "unit": null, "evidence_text": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will b", "unit": null, "evidence_text": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are deemed to be at a high risk of abuse or addiction to the study drug.", "unit": null, "evidence_text": "Patients who are deemed to be at a high risk of abuse or addiction to the study drug."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are sensitive to any of the ingredients of the study medication.", "unit": null, "evidence_text": "Patients who are sensitive to any of the ingredients of the study medication."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who are unable to give informed consent.", "unit": null, "evidence_text": "Patients who are unable to give informed consent."}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients who may need surgery in the near future.", "unit": null, "evidence_text": "Patients who may need surgery in the near future."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant women"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC.", "unit": null, "evidence_text": "Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study.", "unit": null, "evidence_text": "Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will b", "unit": null, "evidence_text": "Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo."}], "rule_v1_extra_rules": [{"id": "rule-8629648c-0a83-4bc8-8a7a-781db66a4e09", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a known mental disorder", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a known mental disorder", "source_span": {"start": 592, "end": 629}}, {"id": "rule-d2b07bd6-770a-4d95-a90d-944e252e8b01", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Pregnant women", "source_span": {"start": 722, "end": 736}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00032", "nct_id": "NCT00878527", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 65.0, "priority_reasons": ["missing_critical_rules=4", "contract_warnings=2", "rule_v1_missing=8", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 3, "history": 1, "other": 1, "procedure": 2}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["condition", "procedure", "age", "history", "other"], "eligibility_text": "Inclusion Criteria:\n\n* Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers\n* NYHA Class III or IV despite maximal tolerable medical therapy\n* Ambulatory (inpatient or outpatient)\n* Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)\n* Life expectancy of at least 6 months without full VAD support\n\nExclusion Criteria:\n\n* Age \\>75 years\n* Exercise tolerance limited by factors other than heart failure\n* Presence of intra-atrial thrombus\n* Clinically significant right heart failure\n* Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months\n* Evidence of intrinsic hepatic disease\n* Previous episode of resuscitated sudden death without subsequent treatment with AICD\n* Subclavian artery stenosis\n* Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation", "current_labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 75, "unit": "years", "evidence_text": "Age \\>75 years"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinically significant right heart failure", "unit": null, "evidence_text": "Clinically significant right heart failure"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Evidence of intrinsic hepatic disease", "unit": null, "evidence_text": "Evidence of intrinsic hepatic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Exercise tolerance limited by factors other than heart failure", "unit": null, "evidence_text": "Exercise tolerance limited by factors other than heart failure"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation", "unit": null, "evidence_text": "Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months", "unit": null, "evidence_text": "Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months"}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)", "unit": null, "evidence_text": "Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 75, "unit": "years", "evidence_text": "Age \\>75 years"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinically significant right heart failure", "unit": null, "evidence_text": "Clinically significant right heart failure"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Evidence of intrinsic hepatic disease", "unit": null, "evidence_text": "Evidence of intrinsic hepatic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Exercise tolerance limited by factors other than heart failure", "unit": null, "evidence_text": "Exercise tolerance limited by factors other than heart failure"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation", "unit": null, "evidence_text": "Low platelet count, INR that cannot be corrected prior to implant or contraindication to anticoagulation"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months", "unit": null, "evidence_text": "Serum creatinine \\>/= 2.5 mg/dl or any dialysis in previous 3 months"}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Maximum tolerable medical therapy including ACE inhibitors and Beta Blockers"}, {"type": "INCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)", "unit": null, "evidence_text": "Patients on the heart transplant list (or, not currently listed but otherwise suitable for heart transplant)"}], "rule_v1_extra_rules": [{"id": "rule-515cb1f0-98c0-45dd-bd73-363ec5c29b83", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "aicd", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Previous episode of resuscitated sudden death without subsequent treatment with AICD", "source_span": {"start": 677, "end": 761}}, {"id": "rule-5a169a3a-4305-4b36-a1e3-20a73dda55ed", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00033", "nct_id": "NCT00937703", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 62.0, "priority_reasons": ["missing_critical_rules=4", "contract_warnings=2", "rule_v1_missing=7", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3, "lab": 1, "medication": 1, "other": 1, "procedure": 1}, "extra_rules_by_field": {"condition": 3}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["condition", "lab", "medication", "other", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n* Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;\n* Patients treated since at least 3 months, by metformin and secreting insulinic (KNOWN or glinide);\n* Patients uncontrolled with HbA1c ≥ 7.5% and \\< 10% at the inclusion.\n* BMI \\< 40 ;\n* Patients requiring a insulin treatment\n* Patients agree to start a slow insulin treatment\n* Patients already practising the glycemic self-monitoring or agree to learn it and practise it;\n* Patients able to include/understand operation and to use the PDA-phone and/or the SVI;\n* Patient not taking part in another biomedical research study\n* Patients agree to carry out at least 2 finger sticks per day;\n* More than 18 years, there is no higher age limit.\n\nExclusion Criteria:\n\n* Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;\n* Patients in a situation which justifies of a clinical follow-up diabetologic more frequent than that (quarterly) envisaged by the study\n* Patients requiring a transitory passage to insulin;\n* Patients needing a hospitalization for the adaptation of insulin doses;\n* Patients presenting a cardiologic event\n* Patients presenting a hemoglobinopathy interfering with the proportioning of HbA1c;\n* Patients suffering from drug-addiction, alcoholism or psychological troubles\n* Type 1 or secondary diabetes\n* Patients who don't need strict metabolic objectives;\n* Pregnant or parturient patients\n* person with no freedom.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;", "unit": null, "evidence_text": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Type 1 or secondary diabetes", "unit": null, "evidence_text": "Type 1 or secondary diabetes"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients suffering from drug-addiction, alcoholism or psychological troubles", "unit": null, "evidence_text": "Patients suffering from drug-addiction, alcoholism or psychological troubles"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;", "unit": null, "evidence_text": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "10", "unit": "%", "evidence_text": "Patients uncontrolled with HbA1c ≥ 7.5% and \\< 10% at the inclusion."}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;", "unit": null, "evidence_text": "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;", "unit": null, "evidence_text": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Type 1 or secondary diabetes", "unit": null, "evidence_text": "Type 1 or secondary diabetes"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients suffering from drug-addiction, alcoholism or psychological troubles", "unit": null, "evidence_text": "Patients suffering from drug-addiction, alcoholism or psychological troubles"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;", "unit": null, "evidence_text": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "10", "unit": "%", "evidence_text": "Patients uncontrolled with HbA1c ≥ 7.5% and \\< 10% at the inclusion."}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;", "unit": null, "evidence_text": "Patients able to include/understand operation and to use the PDA-phone and/or the SVI;"}], "rule_v1_extra_rules": [{"id": "rule-1bdb104a-da72-4efa-ba7e-1cedcfde9b66", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an uncontrolled diabetes during the year to", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;", "source_span": {"start": 770, "end": 913}}, {"id": "rule-e79b9b48-120f-43c8-8bec-e7fcda54584f", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the proportioning of hba1c", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients presenting a hemoglobinopathy interfering with the proportioning of HbA1c;", "source_span": {"start": 1224, "end": 1307}}, {"id": "rule-8f6021c8-8411-48a7-ba17-4276f48f92da", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00034", "nct_id": "NCT01120561", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 61.0, "priority_reasons": ["missing_critical_rules=3", "rule_v1_missing=9", "rule_v1_extra=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 6, "history": 2, "procedure": 1}, "extra_rules_by_field": {"condition": 4}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n* Histologically or cytologically documented breast cancer\n* Locally advanced or metastatic breast cancer\n* HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment\n* Histologically or cytologically confirmed invasive breast cancer: incurable, unresectable, locally advanced breast cancer previously treated with multimodality therapy or metastatic breast cancer\n* Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both: a taxane, alone or in combination with another agent, and Trastuzumab, alone or in combination with another agent in the adjuvant, unresectable, locally advanced, or metastatic setting\n* Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen\n* Progression must occur during or after most recent treatment for locally advanced/metastatic breast cancer or within 6 months after completing adjuvant therapy\n* Adequate hematologic and end organ function\n* Agreement to use an effective form of birth control throughout the study\n* Life expectancy ≥ 90 days as assessed by the investigator\n\nExclusion Criteria:\n\n* Less than 14 days from the first study treatment since the last anti-cancer therapy, including chemotherapy, biologic, experimental, immune, hormonal or endocrine therapy\n* Prior T-DM1 therapy\n* History of exposure to cumulative doses of select anthracyclines\n* History of intolerance or hypersensitivity to trastuzumab, murine proteins, or any of the excipients, that resulted in trastuzumab being permanently discontinued\n* Brain metastases that are untreated or progressive or currently require any type of therapy, including radiation, surgery, and/or steroids to control symptoms from brain metastases within 30 days before the first study treatment\n* Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the first study treatment\n* History of clinically significant cardiac dysfunction\n* Current known active infection with HIV, hepatitis B virus, or hepatitis C virus\n* Current severe, uncontrolled systemic disease\n* Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment\n* Pregnancy or lactation\n\nNOTE: The site selection process has been completed. Patients can enroll at participating sites.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Current known active infection with HIV, hepatitis B virus, or hepatitis C virus"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Current severe, uncontrolled systemic disease", "unit": null, "evidence_text": "Current severe, uncontrolled systemic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant cardiac dysfunction", "unit": null, "evidence_text": "History of clinically significant cardiac dysfunction"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "exposure to cumulative doses of select anthracyclines", "unit": null, "evidence_text": "History of exposure to cumulative doses of select anthracyclines"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "intolerance or hypersensitivity to trastuzumab, murine proteins, or any of the excipients, that resulted in trastuzumab being permanently discontinued", "unit": null, "evidence_text": "History of intolerance or hypersensitivity to trastuzumab, murine proteins, or any of the excipients, that resulted in trastuzumab being permanently discontinued"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the fir", "unit": null, "evidence_text": "Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the first study treatment"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of clinically significant cardiac dysfunction", "unit": null, "evidence_text": "History of clinically significant cardiac dysfunction"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of exposure to cumulative doses of select anthracyclines", "unit": null, "evidence_text": "History of exposure to cumulative doses of select anthracyclines"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment", "unit": null, "evidence_text": "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen", "unit": null, "evidence_text": "Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment", "unit": null, "evidence_text": "HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "multimodality therapy or metastatic breast cancer", "unit": null, "evidence_text": "Histologically or cytologically confirmed invasive breast cancer: incurable, unresectable, locally advanced breast cancer previously treated with multimodality therapy or metastatic breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Histologically or cytologically documented breast cancer", "unit": null, "evidence_text": "Histologically or cytologically documented breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Locally advanced or metastatic breast cancer", "unit": null, "evidence_text": "Locally advanced or metastatic breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "another agent in the adjuvant", "unit": null, "evidence_text": "Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both: a taxane, alone or in combination with another agent, and Trastuzumab, alone or in combination with another agent in the adjuvant, unresectable, locally advanced, or metastatic setting"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Current severe, uncontrolled systemic disease", "unit": null, "evidence_text": "Current severe, uncontrolled systemic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the fir", "unit": null, "evidence_text": "Peripheral neuropathy of Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, at the time of the first study treatment"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of clinically significant cardiac dysfunction", "unit": null, "evidence_text": "History of clinically significant cardiac dysfunction"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of exposure to cumulative doses of select anthracyclines", "unit": null, "evidence_text": "History of exposure to cumulative doses of select anthracyclines"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment", "unit": null, "evidence_text": "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen", "unit": null, "evidence_text": "Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer during their most recent treatment regimen"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment", "unit": null, "evidence_text": "HER2-positive breast cancer documented as FISH-positive, IHC 3 + or CISH-positive by local laboratory assessment"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Histologically or cytologically documented breast cancer", "unit": null, "evidence_text": "Histologically or cytologically documented breast cancer"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Locally advanced or metastatic breast cancer", "unit": null, "evidence_text": "Locally advanced or metastatic breast cancer"}], "rule_v1_extra_rules": [{"id": "rule-a66c0bd4-1f43-42d2-aaaa-d07fc6e28774", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Current known active infection with HIV, hepatitis B virus, or hepatitis C virus", "source_span": {"start": 2153, "end": 2233}}, {"id": "rule-925a7964-0ffe-409d-9b1e-25c16017c629", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Current known active infection with HIV, hepatitis B virus, or hepatitis C virus", "source_span": {"start": 2153, "end": 2233}}, {"id": "rule-8d30c634-f2c5-424e-b2ba-6af917121b1d", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or steroids to control", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Brain metastases that are untreated or progressive or currently require any type of therapy, including radiation, surgery, and/or steroids to control symptoms from brain metastases within 30 days before the first study treatment", "source_span": {"start": 1685, "end": 1913}}, {"id": "rule-29eb1165-762f-4a4d-b4fc-c046f9d13997", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "another agent", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both: a taxane, alone or in combination with another agent, and Trastuzumab, alone or in combination with another agent in the adjuvant, unresectable, locally advanced, or metastatic setting", "source_span": {"start": 442, "end": 750}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00035", "nct_id": "NCT01242722", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 50.0, "priority_reasons": ["missing_critical_rules=4", "rule_v1_missing=5", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"other": 4, "sex": 1}, "extra_rules_by_field": {"condition": 2, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["other", "sex", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Patients who have a COGNIS CRT-D device implanted for at least 24 hours, with or without a right atrial lead\n* Patients who have an active LV bipolar lead\n* Patients who have an active right ventricular (RV) defibrillation lead\n* Patients who are willing and capable of participating in all testing associated with this Clinical Investigation\n* Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law\n\nExclusion Criteria:\n\n* Patients who have a COGNIS CRT-D that has less than or equal to one year of battery life remaining\n* Patients who are pacemaker-dependent\n* Patients who will not tolerate a pacing pause of up to 6 seconds\n* Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or more leads)\n* Patients with pre-existing leads other than those specified in this investigational plan\n* Patients with a pre-existing unipolar pacemaker\n* Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes\n* Patients enrolled in any concurrent study, without Boston Scientific written approval\n* Women who are pregnant", "current_labeled_rules": [{"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes", "unit": null, "evidence_text": "Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or mo", "unit": null, "evidence_text": "Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or more leads)"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Women who are pregnant"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "this clinical investigation", "unit": null, "evidence_text": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without a right atrial lead", "unit": null, "evidence_text": "Patients who have a COGNIS CRT-D device implanted for at least 24 hours, with or without a right atrial lead"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law", "unit": null, "evidence_text": "Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation", "unit": null, "evidence_text": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes", "unit": null, "evidence_text": "Patients who are unable or unwilling to maintain a supine or sitting position for 40-50 minutes"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or mo", "unit": null, "evidence_text": "Patients who have a unipolar LV pace/sense lead, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or more leads)"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Women who are pregnant"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law", "unit": null, "evidence_text": "Patients who are age 18 or above, or of legal age to give informed consent specific to state and national law"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation", "unit": null, "evidence_text": "Patients who are willing and capable of participating in all testing associated with this Clinical Investigation"}], "rule_v1_extra_rules": [{"id": "rule-5bb0e756-5455-4d92-a2f9-293d77d78c32", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a pre existing unipolar pacemaker", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with a pre-existing unipolar pacemaker", "source_span": {"start": 972, "end": 1019}}, {"id": "rule-5908ac56-d691-4707-a426-a19e1456098b", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pre existing leads other than those specified", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with pre-existing leads other than those specified in this investigational plan", "source_span": {"start": 881, "end": 969}}, {"id": "rule-71fcfa9b-5de6-41b3-b9e3-8edbd9d6a0f0", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Women who are pregnant", "source_span": {"start": 1208, "end": 1230}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00036", "nct_id": "NCT00270907", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 39.0, "priority_reasons": ["rule_v1_missing=9", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"age": 2, "condition": 5, "sex": 2}, "extra_rules_by_field": {"condition": 3}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age", "sex"], "eligibility_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 24, "unit": "years", "evidence_text": "Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "central nervous system metastases", "unit": null, "evidence_text": "History of central nervous system metastases"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "stem cell transplantation", "unit": null, "evidence_text": "Previous history of stem cell transplantation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "typical paclitaxel- or docetaxel-induced grade 1-2 hypersensitivity", "unit": null, "evidence_text": "History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "exceptions to this would include", "unit": null, "evidence_text": "Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "requirements", "unit": null, "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "while there is no strict exclusion based", "unit": null, "evidence_text": "While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "institutional policy", "unit": null, "evidence_text": "Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "creatinine levels above institutional normal", "unit": null, "evidence_text": "creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "within normal limits unless", "unit": null, "evidence_text": "coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "exceptions to this would include", "unit": null, "evidence_text": "Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "requirements", "unit": null, "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "typical paclitaxel- or docetaxel-induced grade 1-2 hypersensitivity", "unit": null, "evidence_text": "History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "while there is no strict exclusion based", "unit": null, "evidence_text": "While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 24, "unit": "years", "evidence_text": "Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "within normal limits unless", "unit": null, "evidence_text": "coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.)"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control"}], "rule_v1_extra_rules": [{"id": "rule-615c8317-637b-4535-950c-ffa24c7960c0", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reactions attributed to compounds of similar chemical or biologic composition to ct 2103, gemcitabine or other agents used in study", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study.", "source_span": {"start": 2498, "end": 2650}}, {"id": "rule-ae05042c-c4be-484a-98b7-5a063f1714fd", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "study requirements", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements..", "source_span": {"start": 2758, "end": 3030}}, {"id": "rule-4e30cf07-a91a-44c1-8e8c-6f1b12408397", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "typical paclitaxel or docetaxel induced grade 1 2 hypersensitivity reactions is permitted", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted..", "source_span": {"start": 2651, "end": 2754}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00037", "nct_id": "NCT00811486", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 39.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=6"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4, "lab": 1, "other": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "lab", "other"], "eligibility_text": "Inclusion Criteria:\n\n1\\. Patients with World Health Organization (WHO) group 1 pulmonary arterial hypertension \\[51\\], excluding patients with portal hypertension, meeting the following hemodynamic parameters:\n\n* Mean pulmonary artery pressure (mPAP) \\>35 mmHg at rest, and\n* Pulmonary capillary wedge pressure (PCWP) \\<15 mmHg, and\n* Pulmonary vascular resistance (PVR) \\>1.5 wood units, and 2. Age 18 to 75 years 3. Right ventricular failure defined by right atrial pressure \\>7 mmHg along with either dilated right ventricle, or absence of inferior vena cava collapse or BNP \\>100 pg/ml 4. Patients of childbearing age must be practicing effective birth control. 5. Normal left ventricular function as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography.\n\nExclusion Criteria:\n\n1\\. Group 2-5 pulmonary hypertension as defined by WHO.\n\n* Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography).\n* Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g. chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndrome.\n* Pulmonary hypertension due to chronic thrombotic and/or embolic diseases\n* Miscellaneous such as sarcoidosis, compression of pulmonary vessels by adenopathy, tumor 2. Systemic hypertension, defined as a systolic pressure \\>140 mmHg or a diastolic blood pressure \\>90 mmHg 3. Patients taking angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARBs) 4. Pregnancy 5. Chronic kidney disease (serum creatinine \\> 2.5mg/dl, proteinuria \\>500 mg/day, hematuria) 6. Cirrhosis or portal hypertension 7. Inability to provide informed consent. 8. Allergy to conivaptan or spironolactone. 9. Active malignancy 10. Patients receiving spironolactone 11. Enrollment in other interventional studies. 12. Patients on Highly Active Antiretroviral Therapy (HAART)", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndro", "unit": null, "evidence_text": "chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndrome."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g.", "unit": null, "evidence_text": "Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Pulmonary hypertension due to chronic thrombotic and/or embolic diseases", "unit": null, "evidence_text": "Pulmonary hypertension due to chronic thrombotic and/or embolic diseases"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography", "unit": null, "evidence_text": "Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography)."}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2.5", "unit": "mg/dl", "evidence_text": "Chronic kidney disease (serum creatinine \\> 2.5mg/dl, proteinuria \\>500 mg/day, hematuria) 6."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to provide informed consent.", "unit": null, "evidence_text": "Inability to provide informed consent."}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "Age 18 to 75 years 3."}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Pulmonary vascular resistance (PVR) \\>1.5 wood units, and 2. Age 18 to 75 years 3. Right ventricular failure defined by right atrial pressure \\>7 mmHg along with either dilated right ventricle, or absence of inferior vena cava collapse or BNP \\>100 pg/ml 4. Patients of childbearing age must be practicing effective birth control. 5. Normal left ventricular function as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "portal hypertension", "unit": null, "evidence_text": "Patients with World Health Organization (WHO) group 1 pulmonary arterial hypertension \\[51\\], excluding patients with portal hypertension, meeting the following hemodynamic parameters:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "either dilated right ventricle", "unit": null, "evidence_text": "Right ventricular failure defined by right atrial pressure \\>7 mmHg along with either dilated right ventricle, or absence of inferior vena cava collapse or BNP \\>100 pg/ml 4."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndro", "unit": null, "evidence_text": "chronic obstructive pulmonary disease, interstitial lung disease, sleep disordered breathing, chronic exposure to high altitude, alveolar hypoventilation syndrome."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g.", "unit": null, "evidence_text": "Pulmonary hypertension associated with lung disease and/or hypoxemia (e.g."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Pulmonary hypertension due to chronic thrombotic and/or embolic diseases", "unit": null, "evidence_text": "Pulmonary hypertension due to chronic thrombotic and/or embolic diseases"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography", "unit": null, "evidence_text": "Pulmonary hypertension with left heart failure (as assessed by echocardiogram, multiple gated acquisition (MUGA) cardiac scan, or invasive left ventriculography)."}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "2.5", "unit": "mg/dl", "evidence_text": "Chronic kidney disease (serum creatinine \\> 2.5mg/dl, proteinuria \\>500 mg/day, hematuria) 6."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Inability to provide informed consent.", "unit": null, "evidence_text": "Inability to provide informed consent."}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00038", "nct_id": "NCT00791557", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 38.0, "priority_reasons": ["missing_critical_rules=3", "rule_v1_missing=4", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "history": 1, "medication": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "condition", "history"], "eligibility_text": "Inclusion Criteria:\n\n* Must Be ages 18-75\n* Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum\n* Must never have received Infliximab for the treatment of pyoderma gangrenosum\n\nExclusion Criteria:\n\n* Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.\n* Have a history of serious infections", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "serious infections", "unit": null, "evidence_text": "Have a history of serious infections"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Have a history of serious infections", "unit": null, "evidence_text": "Have a history of serious infections"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.", "unit": null, "evidence_text": "Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum", "unit": null, "evidence_text": "Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Must never have received Infliximab for the treatment of pyoderma gangrenosum", "unit": null, "evidence_text": "Must never have received Infliximab for the treatment of pyoderma gangrenosum"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Have a history of serious infections", "unit": null, "evidence_text": "Have a history of serious infections"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.", "unit": null, "evidence_text": "Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum", "unit": null, "evidence_text": "Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Must never have received Infliximab for the treatment of pyoderma gangrenosum", "unit": null, "evidence_text": "Must never have received Infliximab for the treatment of pyoderma gangrenosum"}], "rule_v1_extra_rules": [{"id": "rule-2adad681-5690-4267-b669-0468bca15e63", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00039", "nct_id": "NCT00928031", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 38.0, "priority_reasons": ["missing_critical_rules=3", "contract_warnings=2", "rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1, "other": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["other", "history", "condition"], "eligibility_text": "Inclusion Criteria:\n\n1. Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.\n2. Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.\n3. For subjects who have died or have been lost to follow-up(the subject status at end of original ipilimumab study), approval from the appropriate site IRB, specifying or limiting appropriate means for obtaining information, must be granted prior to collection of any information.", "current_labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.", "unit": null, "evidence_text": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insu", "unit": null, "evidence_text": "Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained."}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15."}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.", "unit": null, "evidence_text": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15."}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insu", "unit": null, "evidence_text": "Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained."}], "rule_v1_extra_rules": [{"id": "rule-2b59e223-19f3-49f7-9d45-cad0c1ec95b4", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00040", "nct_id": "NCT00776945", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 37.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=5", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 1, "history": 1, "other": 1, "sex": 1}, "extra_rules_by_field": {"age": 1, "condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["age", "condition", "history", "other", "sex"], "eligibility_text": "Inclusion Criteria:\n\n* Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.\n\nExclusion Criteria:\n\n* Patients with melanomas \\< 1mm.\n* Pregnant females.\n* Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with melanomas \\< 1mm.", "unit": null, "evidence_text": "Patients with melanomas \\< 1mm."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent.", "unit": null, "evidence_text": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant females."}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.", "unit": null, "evidence_text": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent."}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with melanomas \\< 1mm.", "unit": null, "evidence_text": "Patients with melanomas \\< 1mm."}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent.", "unit": null, "evidence_text": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent."}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Pregnant females."}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.", "unit": null, "evidence_text": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent."}], "rule_v1_extra_rules": [{"id": "rule-dd20d0f4-b328-4ee0-a542-2456a7db34b2", "type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Children and young adults \\< 18 yrs of age and patients who are unable to give informed consent.", "source_span": {"start": 238, "end": 334}}, {"id": "rule-4be94ccf-1529-4ddc-8c21-4bd867124550", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "recently diagnosed or a history of", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Adult patients (\\> 18 yrs of age) with recently diagnosed or a history of, Stage I - III melanoma who are able to give informed consent.", "source_span": {"start": 23, "end": 159}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00041", "nct_id": "NCT00966043", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 37.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=5", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 1, "other": 1, "sex": 1}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex", "history", "other"], "eligibility_text": "Inclusion Criteria:\n\n* Female \\> 18 years of age\n* Written and voluntary informed consent understood signed and dated\n* Histologically or cytologically confirmed measurable invasive adenocarcinoma of the breast, amenable to curative therapy.\n* Patients must be postmenopausal as defined by criteria in appendix 1.\n* Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathologist\n* Prior endocrine tamoxifen therapy is not allowed\n* Patients are not previously treated with an endocrine agent or hormone replacement therapy needs being stopped for at least 6 months.\n* Prior chemotherapy and radiotherapy is allowed\n* Adequate renal and liver function Serum creatinine and serum bilirubin ≤ 1.5 X ULN Serum ALT and AST ≤ 2.5 X ULN (or ≤ 5 in case of liver metastases)\n* Serum calcium should be ≤ 11,6 mg/dl\n* ECOG performance status 0,1,2 (appendix 2)\n\nExclusion Criteria:\n\n* Male\n* Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)\n* Use of any endocrine treatment or recent/current use of hormone replacement therapy.\n* Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin\n* Dementia\n* History of other malignancy that may interfere with at least 6 months of tamoxifen therapy", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "dvt/vaginal bleeding of unknown origin", "unit": null, "evidence_text": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other malignancy that may interfere with at least 6 months of tamoxifen therapy", "unit": null, "evidence_text": "History of other malignancy that may interfere with at least 6 months of tamoxifen therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)", "unit": null, "evidence_text": "Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin", "unit": null, "evidence_text": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Male"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Female \\> 18 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathol", "unit": null, "evidence_text": "Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathologist"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Written and voluntary informed consent understood signed and dated", "unit": null, "evidence_text": "Written and voluntary informed consent understood signed and dated"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female \\> 18 years of age"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)", "unit": null, "evidence_text": "Life threatening disease requiring a quick response (eg, extensive hepatic or pulmonary involvement)"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin", "unit": null, "evidence_text": "Contra indication for tamoxifen: history of DVT/vaginal bleeding of unknown origin"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathol", "unit": null, "evidence_text": "Breast cancer should be considered as oestrogen receptor positive by the clinician using immunohistochemistry readings as is standard procedure for local pathologist"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Written and voluntary informed consent understood signed and dated", "unit": null, "evidence_text": "Written and voluntary informed consent understood signed and dated"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female \\> 18 years of age"}], "rule_v1_extra_rules": [{"id": "rule-2cb55db0-e659-4ee5-8257-13981e7d1cac", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "at least 6 months of tamoxifen therapy", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of other malignancy that may interfere with at least 6 months of tamoxifen therapy", "source_span": {"start": 1271, "end": 1361}}, {"id": "rule-8aabc297-2b57-4666-b4b4-49cbcce0926b", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Female \\> 18 years of age", "source_span": {"start": 23, "end": 48}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00042", "nct_id": "NCT00781456", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 36.0, "priority_reasons": ["missing_critical_rules=3", "rule_v1_missing=3", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"history": 3}, "extra_rules_by_field": {"condition": 3}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Premenopausal, non-pregnant, non-lactating\n* History of migraine headaches without aura for at least 6 months\n* History of migraine headaches associated with menstruation\n* Others as directed by FDA-approved protocol\n\nExclusion Criteria:\n\n* History of migraine headaches with aura or focal neurological symptoms\n* Any contraindication to the use of oral contraceptives\n* Others as dictated by FDA-approved protocol", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "migraine headaches with aura or focal neurological symptoms", "unit": null, "evidence_text": "History of migraine headaches with aura or focal neurological symptoms"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of migraine headaches with aura or focal neurological symptoms", "unit": null, "evidence_text": "History of migraine headaches with aura or focal neurological symptoms"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "History of migraine headaches associated with menstruation", "unit": null, "evidence_text": "History of migraine headaches associated with menstruation"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of migraine headaches without aura for at least 6 months", "unit": null, "evidence_text": "History of migraine headaches without aura for at least 6 months"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of migraine headaches with aura or focal neurological symptoms", "unit": null, "evidence_text": "History of migraine headaches with aura or focal neurological symptoms"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "History of migraine headaches associated with menstruation", "unit": null, "evidence_text": "History of migraine headaches associated with menstruation"}, {"type": "INCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "History of migraine headaches without aura for at least 6 months", "unit": null, "evidence_text": "History of migraine headaches without aura for at least 6 months"}], "rule_v1_extra_rules": [{"id": "rule-4db1935a-f8c5-4291-8a4b-687a60f062e5", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "aura or focal neurological symptoms", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of migraine headaches with aura or focal neurological symptoms", "source_span": {"start": 264, "end": 334}}, {"id": "rule-04635513-9fc1-48da-9d2a-b10136289c49", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "migraine headaches with aura or focal neurological", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of migraine headaches with aura or focal neurological symptoms", "source_span": {"start": 264, "end": 334}}, {"id": "rule-09d7c01c-a0f1-4b45-a44e-bb1ac23c0d37", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "menstruation", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of migraine headaches associated with menstruation", "source_span": {"start": 135, "end": 193}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00043", "nct_id": "NCT00421642", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 35.0, "priority_reasons": ["rule_v1_missing=7", "rule_v1_extra=7"], "priority_breakdown": {"missing_rules_by_field": {"condition": 6, "sex": 1}, "extra_rules_by_field": {"age": 1, "condition": 6}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex", "age"], "eligibility_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent naïve or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female subjects who are pregnant or breast-feeding"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "symptomatic obstructive strictures", "unit": null, "evidence_text": "Subjects with symptomatic obstructive strictures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant drug or alcohol abuse in", "unit": null, "evidence_text": "History of clinically significant drug or alcohol abuse in the prior year"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "previously untreated tb", "unit": null, "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "uc for greater than 3 months", "unit": null, "evidence_text": "A diagnosis of UC for greater than 3 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "exclusion of infectious cause", "unit": null, "evidence_text": "UC diagnosis confirmed by endoscopy with exclusion of infectious cause"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of this protocol", "unit": null, "evidence_text": "Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant drug or alcohol abuse in", "unit": null, "evidence_text": "History of clinically significant drug or alcohol abuse in the prior year"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "previously untreated tb", "unit": null, "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "symptomatic obstructive strictures", "unit": null, "evidence_text": "Subjects with symptomatic obstructive strictures"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female subjects who are pregnant or breast-feeding"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of this protocol", "unit": null, "evidence_text": "Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "uc for greater than 3 months", "unit": null, "evidence_text": "A diagnosis of UC for greater than 3 months"}], "rule_v1_extra_rules": [{"id": "rule-95d2da74-e10c-450e-a88b-3b37cca00bdd", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Males and females 18 years of age and older.", "source_span": {"start": 23, "end": 67}}, {"id": "rule-9ccb2210-e41a-4874-b86e-a716ee2fcda8", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a history of listeria", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB.", "source_span": {"start": 1965, "end": 2155}}, {"id": "rule-716c0a07-0fcd-4ba8-848f-7531958ab067", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "corticosteroids", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications.", "source_span": {"start": 528, "end": 849}}, {"id": "rule-90747ee6-e39e-443e-a98e-964645341f32", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ileorectostomy or colectomy with ileoanal pouch", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication..", "source_span": {"start": 2263, "end": 2503}}, {"id": "rule-b1a5730f-7cae-448b-b0b0-304bc16e4b1f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "infliximab and responded", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose..", "source_span": {"start": 2695, "end": 2888}}, {"id": "rule-edd413fb-89b2-4fd5-a65f-ad6e280dee15", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "symptomatic obstructive strictures", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with symptomatic obstructive strictures.", "source_span": {"start": 2210, "end": 2259}}, {"id": "rule-ec1b1aa4-d7e6-4b0a-8f76-5fbedf08e583", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of this study protocol", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol..", "source_span": {"start": 1438, "end": 1565}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00044", "nct_id": "NCT00897481", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 35.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3, "history": 1, "procedure": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "procedure"], "eligibility_text": "DISEASE CHARACTERISTICS:\n\n* Confirmed diagnosis of cutaneous melanoma\n\n  * Breslow thickness \\> 0.75 mm\n* Has undergone sentinel lymph node biopsy\n* No primary melanoma that has not originated in the skin\n* No multiple primary melanomas\n* Currently under clinical followup OR discharged from follow up within the past 3 months\n\nPATIENT CHARACTERISTICS:\n\n* No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "confirmed", "unit": null, "evidence_text": "Confirmed diagnosis of cutaneous melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Confirmed diagnosis of cutaneous melanoma", "unit": null, "evidence_text": "Confirmed diagnosis of cutaneous melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "DISEASE CHARACTERISTICS:", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "See Disease Characteristics", "unit": null, "evidence_text": "See Disease Characteristics"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Currently under clinical followup OR discharged from follow up within the past 3 months", "unit": null, "evidence_text": "Currently under clinical followup OR discharged from follow up within the past 3 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Has undergone sentinel lymph node biopsy", "unit": null, "evidence_text": "Has undergone sentinel lymph node biopsy"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Confirmed diagnosis of cutaneous melanoma", "unit": null, "evidence_text": "Confirmed diagnosis of cutaneous melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "DISEASE CHARACTERISTICS:", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "See Disease Characteristics", "unit": null, "evidence_text": "See Disease Characteristics"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Currently under clinical followup OR discharged from follow up within the past 3 months", "unit": null, "evidence_text": "Currently under clinical followup OR discharged from follow up within the past 3 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Has undergone sentinel lymph node biopsy", "unit": null, "evidence_text": "Has undergone sentinel lymph node biopsy"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00045", "nct_id": "NCT00685425", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 34.0, "priority_reasons": ["rule_v1_missing=4", "rule_v1_extra=15"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4}, "extra_rules_by_field": {"condition": 11, "history": 3, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "sex"], "eligibility_text": "Inclusion Criteria:. * Subject, male or female, must be at least 12 years of age at the time of consent.. * Female subjects 12-60 years of age must have a negative serum pregnancy test.. * Women of child bearing potential must be using an acceptable method of birth control throughout the study.. * Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start. * Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.. * Subject must have a chest X-ray for the study or within 12 months prior to randomization.. * Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.. Exclusion Criteria:. * Female subject who is pregnant or lactating.. * Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.. * Subject whose schedule prevents him or her from starting study visits before 12 PM.. * Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.. * Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.. * Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.. * Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.. * Subject using any prescription drug with which albuterol sulfate administration is contraindicated.. * Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.. * Subject with a history of cancer (exception: basal cell carcinoma in remission).. * Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol.. * Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start.. * Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.. * Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.. * Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.. * Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.. * Subject who is a staff member or relative of a staff member.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 60, "unit": "years", "evidence_text": "* Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Subject, male or female, must be at least 12 years of age at the time of consent"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female subject who is pregnant or lactating"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Subject, male or female, must be at least 12 years of age at the time of consent"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of child bearing potential must be using an acceptable method of birth control throughout the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "unstable asthma", "unit": null, "evidence_text": "* Subjects with unstable asthma"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a history of substance abuse or drug", "unit": null, "evidence_text": "* Subject with a history of substance abuse or drug abuse within 12 months preceding study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "which albuterol sulfate administration is contraindicated", "unit": null, "evidence_text": "* Subject using any prescription drug with which albuterol sulfate administration is contraindicated"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a documented history of bronchopulmonary aspergillosis or", "unit": null, "evidence_text": "* Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "measurements or compliance or both", "unit": null, "evidence_text": "* Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cigarette smoking or use of any tobacco", "unit": null, "evidence_text": "* Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the successful completion of this protocol", "unit": null, "evidence_text": "* Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest, or hypoxic seizures within", "unit": null, "evidence_text": "* Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a documented history of bronchopulmonary aspergillosis or", "unit": null, "evidence_text": "* Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cigarette smoking or use of any tobacco", "unit": null, "evidence_text": "* Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest, or hypoxic seizures within", "unit": null, "evidence_text": "* Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "measurements or compliance or both", "unit": null, "evidence_text": "* Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both"}], "rule_v1_extra_rules": [{"id": "rule-1310f748-7a57-44ee-972a-a26d8359236f", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a known sensitivity to levalbuterol or racemic", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations..", "source_span": {"start": 1711, "end": 1847}}, {"id": "rule-b08630cc-77a3-4e15-9efe-e8eaab8b0089", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start..", "source_span": {"start": 1953, "end": 2180}}, {"id": "rule-af5c2c31-93d7-44f4-a4c3-aa7ce780deb2", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bronchopulmonary aspergillosis or any form of allergic alveolitis", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis..", "source_span": {"start": 2768, "end": 2872}}, {"id": "rule-bd660d56-fa55-4256-a8f0-b0ea3a5721c2", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cancer (exception: basal cell carcinoma in remission)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with a history of cancer (exception: basal cell carcinoma in remission)..", "source_span": {"start": 2183, "end": 2264}}, {"id": "rule-9867f574-b517-405a-bf58-3a3119c378f7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cigarette smoking or use of any tobacco products within 6 months of study start", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start..", "source_span": {"start": 2634, "end": 2765}}, {"id": "rule-e9a419cb-8625-49cf-96a4-f7b50840ddc1", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in patient hospitalization, including elective surgery during the course of the trial", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial..", "source_span": {"start": 1504, "end": 1708}}, {"id": "rule-56c3d8ce-e61d-408f-b9e8-8e3fbbc199cf", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start..", "source_span": {"start": 1953, "end": 2180}}, {"id": "rule-1cb2aada-2a7c-4664-bdca-92b3727b76d2", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hyperthyroidism", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol..", "source_span": {"start": 2267, "end": 2483}}, {"id": "rule-b228867d-60ed-47e2-ad99-a3c306c95f36", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "substance abuse or drug abuse within 12 months preceding study start", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject with a history of substance abuse or drug abuse within 12 months preceding study start.", "source_span": {"start": 2486, "end": 2581}}, {"id": "rule-8a214fa9-6419-44a1-a1da-ad029e2a0a60", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "trial measurements or compliance or both", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both..", "source_span": {"start": 1381, "end": 1501}}, {"id": "rule-737d0ee7-dc6f-4578-8c98-fb62875e7400", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "time_window": null, "certainty": "medium", "evidence_text": "Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start..", "source_span": {"start": 1953, "end": 2180}}, {"id": "rule-30ba8585-2cea-4115-b315-3b056f31a9a0", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "time_window": null, "certainty": "medium", "evidence_text": "Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial..", "source_span": {"start": 1504, "end": 1708}}, {"id": "rule-0b324708-c304-4d7a-aa88-e0ea4bcfb456", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "time_window": null, "certainty": "medium", "evidence_text": "Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start..", "source_span": {"start": 2634, "end": 2765}}, {"id": "rule-c9c7195c-74e2-46bc-8071-a4fa02b2ffa5", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "these activities", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities..", "source_span": {"start": 812, "end": 951}}, {"id": "rule-9535259d-5d78-471a-bba6-62b15af469cc", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Subject, male or female, must be at least 12 years of age at the time of consent..", "source_span": {"start": 23, "end": 105}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00046", "nct_id": "NCT90000001", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 34.0, "priority_reasons": ["missing_critical_rules=2", "contract_errors=1", "rule_v1_missing=2", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"lab": 1, "procedure": 1}, "extra_rules_by_field": {"age": 1, "lab": 1}, "contract_error_count": 1, "contract_warning_count": 0, "contract_error_codes": {"LAB_THRESHOLD_VALUE_INVALID": 1}, "contract_warning_codes": {}}, "focus_fields": ["lab", "procedure", "age"], "eligibility_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": "HbA1c 8.5", "unit": null, "evidence_text": "HbA1c <= 8.5%"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Exclusion: Active infection or major surgery within the last 3 months"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": "HbA1c 8.5", "unit": null, "evidence_text": "HbA1c <= 8.5%"}], "rule_v1_extra_rules": [{"id": "rule-425a1e21-96c2-417f-bd19-8718f7167498", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Participants must be 18 years or older.", "source_span": {"start": 11, "end": 50}}, {"id": "rule-434f3e5d-dd8c-423c-a8c4-ed6d1f5726f7", "type": "INCLUSION", "field": "lab", "operator": "<=", "value": 8.5, "unit": "%", "time_window": null, "certainty": "medium", "evidence_text": "HbA1c <= 8.5%.", "source_span": {"start": 51, "end": 65}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00047", "nct_id": "NCT01050803", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 33.0, "priority_reasons": ["missing_critical_rules=2", "contract_warnings=2", "rule_v1_missing=3", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "other": 2}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["other", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes (according to the WHO criteria)\n* Older than 18 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Unable to participate in a group program (for example, housebound or unable to communicate in Farsi)\n* Having reduced cognitive ability", "current_labeled_rules": [{"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Having reduced cognitive ability", "unit": null, "evidence_text": "Having reduced cognitive ability"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosed with type 2 diabetes (according to the WHO criteria)", "unit": null, "evidence_text": "Diagnosed with type 2 diabetes (according to the WHO criteria)"}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Diagnosed with type 2 diabetes (according to the WHO criteria)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Having reduced cognitive ability", "unit": null, "evidence_text": "Having reduced cognitive ability"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Diagnosed with type 2 diabetes (according to the WHO criteria)", "unit": null, "evidence_text": "Diagnosed with type 2 diabetes (according to the WHO criteria)"}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Diagnosed with type 2 diabetes (according to the WHO criteria)"}], "rule_v1_extra_rules": [{"id": "rule-f1ee234e-844e-44bb-9141-799c996f5b14", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "reduced cognitive ability", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Having reduced cognitive ability", "source_span": {"start": 247, "end": 279}}, {"id": "rule-9c16deb3-3316-47fc-ab18-0444a1de63ed", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00048", "nct_id": "NCT00923026", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 32.0, "priority_reasons": ["missing_critical_rules=2", "contract_warnings=2", "rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "other": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["other", "age", "condition"], "eligibility_text": "* INCLUSION CRITERIA:\n* Age greater than or equal to 18 years.\n* Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).\n* For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.\n\nEXCLUSION CRITERIA:\n\n-For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age greater than or equal to 18 years."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. Fo", "unit": null, "evidence_text": "For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent."}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "INCLUSION CRITERIA:"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age greater than or equal to 18 years."}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "INCLUSION CRITERIA:"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. Fo", "unit": null, "evidence_text": "For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent."}], "rule_v1_extra_rules": [{"id": "rule-b12cb1a2-0cf8-4c75-9b8d-bc3e849be428", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00049", "nct_id": "NCT00778986", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 31.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "other": 1, "procedure": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "other", "procedure"], "eligibility_text": "Inclusion Criteria:\n\n* Clinical diagnosis of Heart Failure (NYHA Class II-IV)\n* Out-patients attending the University Health Network Heart Failure Clinic\n* English-speaking and able to read English\n* 18 years old or over\n\nExclusion Criteria:\n\n* Awaiting heart transplantation\n* Not expected to survive over a year (as determined by their cardiologist)\n* Unable to read text on a mobile phone due to vision disability\n* Unable to self-care due to anxiety, depression, or decreased cognitive function\n* Lack of manual dexterity to accurately press buttons on the mobile phone", "current_labeled_rules": [{"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unable to read text on a mobile phone due to vision disability", "unit": null, "evidence_text": "Unable to read text on a mobile phone due to vision disability"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Awaiting heart transplantation", "unit": null, "evidence_text": "Awaiting heart transplantation"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "clinical", "unit": null, "evidence_text": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)", "unit": null, "evidence_text": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Out-patients attending the University Health Network Heart Failure Clinic", "unit": null, "evidence_text": "Out-patients attending the University Health Network Heart Failure Clinic"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Unable to read text on a mobile phone due to vision disability", "unit": null, "evidence_text": "Unable to read text on a mobile phone due to vision disability"}, {"type": "EXCLUSION", "field": "procedure", "operator": "NOT_IN", "value": "Awaiting heart transplantation", "unit": null, "evidence_text": "Awaiting heart transplantation"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)", "unit": null, "evidence_text": "Clinical diagnosis of Heart Failure (NYHA Class II-IV)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Out-patients attending the University Health Network Heart Failure Clinic", "unit": null, "evidence_text": "Out-patients attending the University Health Network Heart Failure Clinic"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00050", "nct_id": "NCT01219582", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 31.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "other": 2}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "other"], "eligibility_text": "Inclusion Criteria:\n\n* Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients.\n* The diagnosis will be made based on the ADA criteria by the attending physician.\n* Patients will be defined as included in the study if they have a documented prescription of Glucobay-M by the physician.\n* Patients willing to provide signed \\& dated informed consent.\n* Patients willing to comply with study requirements.\n\nExclusion Criteria:\n\n* According to the local product information", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients.", "unit": null, "evidence_text": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study requirements", "unit": null, "evidence_text": "Patients willing to comply with study requirements."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the", "unit": null, "evidence_text": "The diagnosis will be made based on the ADA criteria by the attending physician."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "The diagnosis will be made based on the ADA criteria by the attending physician.", "unit": null, "evidence_text": "The diagnosis will be made based on the ADA criteria by the attending physician."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients willing to comply with study requirements.", "unit": null, "evidence_text": "Patients willing to comply with study requirements."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients willing to provide signed \\& dated informed consent.", "unit": null, "evidence_text": "Patients willing to provide signed \\& dated informed consent."}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients.", "unit": null, "evidence_text": "Female and male patients ≥ 18 years of age with Type 2 Diabetes where investigator feels that addition of Glucobay®-M would be beneficial to patients."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "The diagnosis will be made based on the ADA criteria by the attending physician.", "unit": null, "evidence_text": "The diagnosis will be made based on the ADA criteria by the attending physician."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients willing to comply with study requirements.", "unit": null, "evidence_text": "Patients willing to comply with study requirements."}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients willing to provide signed \\& dated informed consent.", "unit": null, "evidence_text": "Patients willing to provide signed \\& dated informed consent."}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00051", "nct_id": "NCT01078402", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 30.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=3", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "medication": 2}, "extra_rules_by_field": {"condition": 3}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "condition"], "eligibility_text": "Inclusion Criteria:\n\n\\- Adult patients with active RA, PsA or AS for whom Humira therapy is indicated according to the local product label and who meet the following criteria:\n\n* Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR\n* Completed Abbott sponsored interventional clinical trials and are continuing treatment with commercial Humira thereafter.\n\nExclusion Criteria:\n\n* Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)\n* Patients currently participating in another clinical trial\n* Patients with diagnosis of active tuberculosis", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with diagnosis of active tuberculosis", "unit": null, "evidence_text": "Patients with diagnosis of active tuberculosis"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)", "unit": null, "evidence_text": "Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active ra", "unit": null, "evidence_text": "\\- Adult patients with active RA, PsA or AS for whom Humira therapy is indicated according to the local product label and who meet the following criteria:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "commercial humira thereafter", "unit": null, "evidence_text": "Completed Abbott sponsored interventional clinical trials and are continuing treatment with commercial Humira thereafter."}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR", "unit": null, "evidence_text": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients with diagnosis of active tuberculosis", "unit": null, "evidence_text": "Patients with diagnosis of active tuberculosis"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)", "unit": null, "evidence_text": "Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)"}, {"type": "INCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR", "unit": null, "evidence_text": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR"}], "rule_v1_extra_rules": [{"id": "rule-a28d16fc-896d-488c-a255-9d1302cba815", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "diagnosis of active tuberculosis", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with diagnosis of active tuberculosis", "source_span": {"start": 686, "end": 732}}, {"id": "rule-30cbdd8e-b674-4bba-861a-ae516463a5d8", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "patients with", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with diagnosis of active tuberculosis", "source_span": {"start": 686, "end": 732}}, {"id": "rule-8f9ce5d1-8d75-452f-bff6-c2f21ea3297d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "infliximab or etanercept treatment history or", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR", "source_span": {"start": 179, "end": 329}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00052", "nct_id": "NCT00702611", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 29.0, "priority_reasons": ["rule_v1_missing=5", "rule_v1_extra=8"], "priority_breakdown": {"missing_rules_by_field": {"condition": 5}, "extra_rules_by_field": {"condition": 7, "history": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history"], "eligibility_text": "Inclusion Criteria:. * 18 - 75 years old. * Active ulcerative colitis with documented clinical symptoms and endoscopic findings. * Active disease defined as DAI (Mayo score) ≥ 4 and ≤10 with at least 1 point in flexible sigmoidoscopy. * Steroid dependency as defined by:. A. Inability to withdraw corticosteroids within three months of starting treatment, without recurrent active disease. B. appearance of relapse within 3 months after withdrawal of corticosteroids. * Colonic involvement with ulcerative colitis beyond 15cm of the anal verge. * Stable doses:A. Aminosalicylates for the last 4 weeks B. Prednisolone or equivalent dose ≤ 20 mg/day for the last 2 weeks C. Azathioprine or 6-mercaptopurine at stable dose for the last 12 weeks. * Signed informed consent form. * Agree to participate in the required follow-up visits. * Able to complete the diary. Exclusion Criteria:. * Febrile (\\> 38ºC). * Evidence of toxic megacolon. * Anticipated need for surgery within 24 weeks. * Known obstructive diseases of the gastrointestinal system. * Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis. * A history of allergic reaction to heparin or heparin-induced thrombocytopenia. * A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures. * Requires a central venous access catheter for the apheresis treatments. * Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV. * Hypotension (systolic blood pressure \\<80 mmHg and/or diastolic blood pressure \\<50 mmHg) at screening visit only. * Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>120 mmHg) despite medical therapy. * A history of myocardial infarction or unstable angina within the past 6 months. * A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months. * Prosthetic heart valve, pacemaker or other permanent implant. * Severe cardiovascular or peripheral vascular disease, severe renal disease. * Liver disease defined as levels of SGOT \\[AST\\], SGPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test. * History of cirrhosis. * Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment. * Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis. * Known infection with Hepatitis B or C, or HIV. * Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/μl and a granulocyte count \\< 2,000/μl. * Fibrinogen level \\>700mg/dL. * Major surgery within the past 6 months. * Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections. * Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II). * History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años). * Current drug or alcohol abuse. * Pregnant, lactating or planning to become pregnant during the course of the clinical investigation. * Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic. * Received cyclosporine or tacrolimus within the last 8 weeks. * Received infliximab within the last 8 weeks. * Fulminant ulcerative colitis", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* 18 - 75 years old"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* 18 - 75 years old"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cirrhosis", "unit": null, "evidence_text": "* History of cirrhosis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c, or hiv", "unit": null, "evidence_text": "* Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens, pathogenic ova or parasites, c", "unit": null, "evidence_text": "* Known infection with enteric pathogens, pathogenic ova or parasites, C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reaction to heparin or heparin-induced thrombocytopenia", "unit": null, "evidence_text": "* A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction or unstable angina within the", "unit": null, "evidence_text": "* A history of myocardial infarction or unstable angina within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "coronary artery bypass grafting surgery or angioplasty", "unit": null, "evidence_text": "* A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an apheresis procedure or intolerance of apheresis", "unit": null, "evidence_text": "* A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or carcinoma of the colon or lack", "unit": null, "evidence_text": "* History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ulcerative colitis beyond 15cm of the anal", "unit": null, "evidence_text": "* Colonic involvement with ulcerative colitis beyond 15cm of the anal verge"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented clinical symptoms and endoscopic findings", "unit": null, "evidence_text": "* Active ulcerative colitis with documented clinical symptoms and endoscopic findings"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 point in flexible sigmoidoscopy", "unit": null, "evidence_text": "* Active disease defined as DAI (Mayo score) ≥ 4 and ≤10 with at least 1 point in flexible sigmoidoscopy"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "coronary artery bypass grafting surgery or angioplasty", "unit": null, "evidence_text": "* A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens, pathogenic ova or parasites, c", "unit": null, "evidence_text": "* Known infection with enteric pathogens, pathogenic ova or parasites, C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c, or hiv", "unit": null, "evidence_text": "* Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction or unstable angina within the", "unit": null, "evidence_text": "* A history of myocardial infarction or unstable angina within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or carcinoma of the colon or lack", "unit": null, "evidence_text": "* History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años)"}], "rule_v1_extra_rules": [{"id": "rule-6ab5a056-4155-45b0-a52a-3651da6311aa", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "coronary artery bypass grafting surgery or angioplasty within the past 6 months", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months.", "source_span": {"start": 1833, "end": 1926}}, {"id": "rule-f4d8f616-0dfd-4bb0-8c6a-06c8f490fc48", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding uc (\\> 10 años)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años).", "source_span": {"start": 3280, "end": 3429}}, {"id": "rule-2c03a597-2dbc-4cab-b0c5-b99138d3ec37", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Known infection with enteric pathogens, pathogenic ova or parasites, C.", "source_span": {"start": 1407, "end": 1478}}, {"id": "rule-411534de-11c5-45b4-8967-05c232525854", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Known infection with Hepatitis B or C, or HIV.", "source_span": {"start": 2598, "end": 2644}}, {"id": "rule-0ae28682-7517-4f5f-a630-b9aed3e92c07", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures.", "source_span": {"start": 1213, "end": 1330}}, {"id": "rule-d1f5db68-922d-4efa-89b3-d0a7c2565125", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction or unstable angina within the past 6 months", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "A history of myocardial infarction or unstable angina within the past 6 months.", "source_span": {"start": 1751, "end": 1830}}, {"id": "rule-adafbfb1-3b28-40e7-9e96-de23fb523512", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "time_window": null, "certainty": "medium", "evidence_text": "History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 años).", "source_span": {"start": 3280, "end": 3429}}, {"id": "rule-1d24ea0a-bf70-40c5-a168-cb4d36cb8a3e", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active ulcerative colitis with documented clinical", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Active ulcerative colitis with documented clinical symptoms and endoscopic findings.", "source_span": {"start": 44, "end": 128}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00053", "nct_id": "NCT00793403", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 29.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=3", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "medication": 1, "other": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication", "other"], "eligibility_text": "Inclusion Criteria:\n\n* Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.\n* Patients eligible to anti-TNF therapy\n* Patients naïve to anti-TNFa drugs\n* Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method \\[Sharp JT et al. 1985; Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form\n\nExclusion Criteria:\n\n* Patients with tumors\n* Patients already included in clinical trials", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "eighteen years of age or older with", "unit": null, "evidence_text": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines."}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.", "unit": null, "evidence_text": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients naïve to anti-TNFa drugs", "unit": null, "evidence_text": "Patients naïve to anti-TNFa drugs"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form", "unit": null, "evidence_text": "1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.", "unit": null, "evidence_text": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines."}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients naïve to anti-TNFa drugs", "unit": null, "evidence_text": "Patients naïve to anti-TNFa drugs"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form", "unit": null, "evidence_text": "1989\\] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form"}], "rule_v1_extra_rules": [{"id": "rule-b22e9066-7c1a-43f7-860f-f6c5e9ee37ac", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "tumors", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with tumors", "source_span": {"start": 649, "end": 669}}, {"id": "rule-d49d3615-2956-4396-9ebc-ef18c9edfa07", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "local guidelines", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.", "source_span": {"start": 23, "end": 181}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00054", "nct_id": "NCT00584350", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 29.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=2", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "history": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["condition", "history"], "eligibility_text": "Inclusion Criteria:. * minimum 18 years old. * chronic renal insufficiency with a calculated creatinine clearance below 60 cc /min. (estimated with the MDRD formula). * hemodynamically stable. Exclusion Criteria:. * Acute renal failure or in recuperation of acute renal failure. * urgent coronary angiogram. * moderate to severe valvulopathy or presence of a valvular prosthesis. * diagnostic of multiple myeloma. * dialysis before test. * having had a test with contrast product in the 2 weeks preceding. * receiving a nephrotoxic in the last month.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "contrast product in the 2 weeks preceding", "unit": null, "evidence_text": "* having had a test with contrast product in the 2 weeks preceding"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* minimum 18 years old"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "contrast product in the 2 weeks preceding", "unit": null, "evidence_text": "* having had a test with contrast product in the 2 weeks preceding"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* minimum 18 years old"}], "rule_v1_extra_rules": [{"id": "rule-bbeb0da5-9b77-4484-b7e9-a37a66f0fab6", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "had a test with contrast product in", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "having had a test with contrast product in the 2 weeks preceding.", "source_span": {"start": 440, "end": 505}}, {"id": "rule-b550476f-0df9-4cdc-a377-3ada3b92eb20", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00055", "nct_id": "NCT00145158", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 28.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=4", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 1, "sex": 1}, "extra_rules_by_field": {"condition": 2, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex", "history"], "eligibility_text": "Inclusion Criteria. 1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Melanoma must be at one of the following AJCC 2002 stages:. * Regional metastatic disease (any T; N2b, N2c or N3; M0).. * Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale ≥70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range. * Hemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l. * Granulocytes ≥ 1,500/µl. * Lymphocytes ≥ 700/µl. * Platelets ≥ 100,000/µl. * Serum creatinine ≤ 2.0 mg/dl or ≤ 177 μmol/l. * Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 μmol/l. * ASAT and ALAT ≤ 2 x the normal upper limits. * LDH ≤ the normal upper limit.. 9. Viral tests:. * HIV (human immunodeficiency virus): negative antibodies.. * HBV (hepatitis B virus): negative antigens; antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age ≥ 18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "non-specific immunotherapy such as interferon alpha", "unit": null, "evidence_text": "Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins"}, {"type": "INCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "non-specific immunotherapy such as interferon alpha", "unit": null, "evidence_text": "Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "INCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:"}], "rule_v1_extra_rules": [{"id": "rule-2a5367a5-95fd-46c0-8e5c-0e8daf0d8410", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "more than one regimen of systemic chemotherapy", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins.", "source_span": {"start": 1511, "end": 1672}}, {"id": "rule-d86e930b-8ef8-407c-aa96-cfc91e66bddf", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "non specific immunotherapy such as interferon alpha", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins.", "source_span": {"start": 1511, "end": 1672}}, {"id": "rule-40c55025-c63b-4fb7-87a9-8bb0b300bcfb", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Women of childbearing potential: Refusal or inability to use effective means of contraception.", "source_span": {"start": 2743, "end": 2837}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00056", "nct_id": "NCT00901953", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 28.0, "priority_reasons": ["missing_critical_rules=2", "rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "history": 1, "medication": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "medication"], "eligibility_text": "Inclusion Criteria:\n\n* migraine according to IHS criteria\n* migrainous vertigo according to the Neuhauser-criteria\n\nExclusion Criteria:\n\n* no history of other neurological, vestibular, opthalmologic and ENT disorders\n* no medications that could possibly influence test results\n* intact hearing measured by audiometry\n* pregnancy", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other neurological, vestibular, opthalmologic and ent disorders", "unit": null, "evidence_text": "no history of other neurological, vestibular, opthalmologic and ENT disorders"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "no history of other neurological, vestibular, opthalmologic and ENT disorders", "unit": null, "evidence_text": "no history of other neurological, vestibular, opthalmologic and ENT disorders"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "no medications that could possibly influence test results", "unit": null, "evidence_text": "no medications that could possibly influence test results"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine according to IHS criteria", "unit": null, "evidence_text": "migraine according to IHS criteria"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "no history of other neurological, vestibular, opthalmologic and ENT disorders", "unit": null, "evidence_text": "no history of other neurological, vestibular, opthalmologic and ENT disorders"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "no medications that could possibly influence test results", "unit": null, "evidence_text": "no medications that could possibly influence test results"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine according to IHS criteria", "unit": null, "evidence_text": "migraine according to IHS criteria"}], "rule_v1_extra_rules": [{"id": "rule-1035a3b1-e04b-416a-99a3-0ad5d95ead20", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00057", "nct_id": "NCT00550758", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 28.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "history": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["condition", "history"], "eligibility_text": "Inclusion Criteria:. * age 3- to 6-years. * respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\]. * cough duration of more than 4 weeks. * normal chest auscultation and baseline FEV1\\>75% predicted for healthy preschool children, on the day of testing.. Exclusion Criteria:. * presence of other chronic respiratory conditions. * emergency room visit or the presence of respiratory infection within the last month. * oral or inhaled steroids or other anti-inflammatory medication taken in the last two weeks. * bronchodilator taken within 24-hours prior to the test.", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* age 3- to 6-years"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* age 3- to 6-years"}], "rule_v1_extra_rules": [{"id": "rule-fb5603e0-edbb-44d7-aaf6-e1a727348879", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "respiratory diseases", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\].", "source_span": {"start": 44, "end": 147}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00058", "nct_id": "NCT00264966", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 26.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=4", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "medication": 1, "sex": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex", "condition", "medication"], "eligibility_text": "Inclusion Criteria:. * Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline ≥70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 ≤16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:. * Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "pregnant or lactating women"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women actively seeking pregnancy or who are not using adequate contraception"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asm8", "unit": null, "evidence_text": "use of medications that may interact with ASM8"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "baseline saline in methacholine challenge during screening", "unit": null, "evidence_text": "20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "episodic wheeze and shortness of breath", "unit": null, "evidence_text": "history of episodic wheeze and shortness of breath"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 28, "unit": "days", "evidence_text": "use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 28, "unit": "days", "evidence_text": "use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "episodic wheeze and shortness of breath", "unit": null, "evidence_text": "history of episodic wheeze and shortness of breath"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Part 1: Men and women 18 to 65 years of age"}], "rule_v1_extra_rules": [{"id": "rule-73d28a77-f653-434f-b424-214fee2ce77c", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "serious adverse effect (sae) or hypersensitivity to any drug", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "history of serious adverse effect (SAE) or hypersensitivity to any drug;", "source_span": {"start": 1376, "end": 1448}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00059", "nct_id": "NCT00438984", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 26.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=4", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 2, "history": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age", "history"], "eligibility_text": "Inclusion Criteria:. * Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease. * Expression of HLA-A2, B44, or A3 as determined by Fred Hutchinson Cancer Research Center (FHCRC) human leukocyte antigen (HLA) typing lab. * Zubrod performance status of 0-1. * Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, CT scan). * Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension. * FOR LEUKAPHERESIS:. * Pulse \\> 45 or \\< 120. * Weight \\>= 45 kg. * White blood cell count (WBC) \\>= 3,000. * Temperature =\\< 38C (=\\< 100.4 F). * Hematocrit (HCT) \\>= 30%. * Platelets \\>= 100,000. * FOR T CELL INFUSION: Patients must be willing and able to discontinue the use of all anti-hypertensive medications 24 hours prior to and during IL-2 therapy. Exclusion Criteria:. * Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry. * Serum creatinine \\> 1.6 mg/dL or Creatinine clearance \\< 75 ml/min. * Serum glutamic oxaloacetic transaminase (SGOT) \\> 150 IU or \\> 3x upper limit of normal. * Bilirubin \\> 1.6 mg/dL. * Prothrombin time \\> 1.5 x control. * Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \\< 2.0 L or carbon monoxide diffusing capacity (DLco) (corr for Hgb) \\< 75% will be excluded. * Significant cardiovascular abnormalities as defined by any one of the following:. * Congestive heart failure;. * Clinically significant hypotension;. * Symptoms of coronary artery disease;. * Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy;. * Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\]). * Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis. * Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy. * Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy). * Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives. * FOR T CELL INFUSION: Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy. * FOR T CELL INFUSION: Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy. * FOR T CELL INFUSION: Current treatment with steroids. * FOR T CELL INFUSION: Patients must not be receiving any other experimental drugs within 3 weeks of the initiation of the protocol and must have recovered from all side effects of such therapy", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 50, "unit": "years", "evidence_text": "* Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "steroids", "unit": null, "evidence_text": "* FOR T CELL INFUSION: Current treatment with steroids"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the severely depressed immune system found in", "unit": null, "evidence_text": "the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* FOR T CELL INFUSION: Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the diagnosis of metastatic disease", "unit": null, "evidence_text": "* Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "cardiac disease, a family history of cardiac", "unit": null, "evidence_text": "* Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the severely depressed immune system found in", "unit": null, "evidence_text": "the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 50, "unit": "years", "evidence_text": "* Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "cardiac disease, a family history of cardiac", "unit": null, "evidence_text": "* Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}], "rule_v1_extra_rules": [{"id": "rule-38434486-c62e-4059-bce3-a7a873b57033", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histopathological documentation of melanoma concurrent with the", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease.", "source_span": {"start": 23, "end": 119}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00060", "nct_id": "NCT00398645", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 25.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=12"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3}, "extra_rules_by_field": {"age": 2, "condition": 8, "history": 1, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age", "history", "sex"], "eligibility_text": "Inclusion criteria:. * Type of Subject: Outpatient. * Age: 12 years of age or older at Visit 1 (or ³18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only).. * Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days),. * Asthma Diagnosis: Asthma as defined by the National Institutes of Health \\[National Institutes of Health, 2002; GINA, 2005\\].. * Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\].. * Reversibility of Disease: Demonstrated ³12% and 200mL reversibility of FEV1 within 30 minutes following 200 to 400mcg of albuterol/salbutamol inhalation aerosol (or one nebulized albuterol/salbutamol treatment) at Visit 1. If a subject fails to demonstrate an increase in FEV1 of ³12% and 200mL, the subject is not eligible for the study and will not be allowed to re-screen.. * Concurrent Anti-Asthma Therapy: Subjects must be using an inhaled corticosteroid for at least 3 months prior to Visit 1 and be maintained on a stable dose for four weeks prior to Visit 1 at one of the following doses: Anti-Asthma Therapy Maximum Daily Dose (mcg/day) Fluticasone propionate MDI CFC/HFA ≤220mcg1/≥250mcg2 Fluticasone propionate DPI 200mcg Beclomethasone dipropionate 420mcg1/500mcg2 Beclomethasone dipropionate HFA 160mcg1/200mcg2 Budesonide DPI 400mcg Flunisolide 1000mcg Triamcinolone acetonide 1000mcg Mometasone furoate 200mcg Ciclesonide 160mcg1/200mcg2. 1. Ex-actuator dose: dose delivered to the lungs. 2. Ex-valve dose: dose expressed from the valve. * Short-Acting Beta2-Agonist: All subjects must be able to replace short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for use as-needed for the duration of the study. Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1. The use of albuterol/salbutamol through the DISKUS/ACCUHALER device will not be allowed during the study.. * Informed Consent: All subjects must be able and willing to give written informed consent to take part in the study.. * Compliance: Subjects must be able to comply with all the study requirements.. Exclusion criteria:. * History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.. * Anti-Asthma Medications: Asthma medications listed below must not have been used prior to Visit 1 for the required interval listed below, and not taken during the study: Within 24 hours of Visit 1: Oral short-acting beta2-agonists: Within 2 weeks of Visit 1:Combination therapy containing inhaled beta2-agonists and ICS for asthma (e.g., fluticasone propionate/salmeterol combination, budesonide/formoterol combination);Slow-release bronchodilators (e.g., aminophylline, theophylline);Anticholinergics; Long-acting beta2-agonists (e.g., salmeterol); Ketotifen; Nedocromil sodium; Sodium cromoglycate; Oral long-acting beta2-agonists. Within 4 weeks of Visit 1: Anti-leukotrienes including suppressors of leukotriene production and antagonists. Within 12 weeks of Visit 1: Systemic, oral, parenteral, or depot corticosteroids; Anti-IgE (e.g., omalizumab).. * Other Medications: The medications listed below must not have been used prior to Visit 1 for the required interval indicated below, and not taken during the study: Within 4 weeks of Visit 1: Known potent inhibitors of CYP3A4 (e.g., ritonavir, ketoconazole). * Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2.. * Asthma Exacerbation: History of a an asthma exacerbation within 4 weeks of Visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of Visit 1, or any hospitalization due to asthma exacerbation within 6 months of Visit 1.. * Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Visit 1 or within ten half-lives (t1/2) of the prior investigational study (which ever is longer of the two) or concurrently during the study.. * Concurrent Diseases/Abnormalities: Historical or current evidence of clinically significant uncontrolled disease including, but not limited to: cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, bronchopulmonary dysplasia, and chronic obstructive pulmonary disease). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.. * Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has evidence of oropharyngeal candidiasis at Visit 1.. * Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy.. * Milk Protein Allergy: History of severe milk protein allergy.. * Immunosuppressive Medications: A subject must not be using, or require use of, immunosuppressive medications during the study.. Note: Immunotherapy for the treatment of allergies is allowed during the study provided that it was initiated prior to Visit 1 and the subject is maintained on a stable daily dose throughout the study period.. * Attendance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol or scheduled visits to the study center and compliance with study medication or procedures (e.g., completion of daily diary). Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation.. * Tobacco Use: A subject may not have used tobacco products within the past one year (i.e., cigarettes, cigars, or pipe tobacco) and must not have historical use of \\>10 pack years (e.g., 20 cigarettes/day for 10 years).. * Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe milk protein allergy", "unit": null, "evidence_text": "* Milk Protein Allergy: History of severe milk protein allergy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a respiratory tract infection within 4 weeks", "unit": null, "evidence_text": "* Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest or hypoxic seizures", "unit": null, "evidence_text": "* History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "all the requirements", "unit": null, "evidence_text": "* Compliance: Subjects must be able to comply with all the study requirements"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the exception of its use during reversibility", "unit": null, "evidence_text": "Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a respiratory tract infection within 4 weeks", "unit": null, "evidence_text": "* Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest or hypoxic seizures", "unit": null, "evidence_text": "* History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "all the requirements", "unit": null, "evidence_text": "* Compliance: Subjects must be able to comply with all the study requirements"}], "rule_v1_extra_rules": [{"id": "rule-f143cd24-28db-418d-b169-2002b9934b5d", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an asthma exacerbation within 4 weeks of visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of visit 1, or any hospitalization due to asthma exacerbation within 6 months of visit 1", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Asthma Exacerbation: History of a an asthma exacerbation within 4 weeks of Visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of Visit 1, or any hospitalization due to asthma exacerbation within 6 months of Visit 1..", "source_span": {"start": 5755, "end": 6000}}, {"id": "rule-13cd0bda-5a07-4103-a03d-3bed8849ef07", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation..", "source_span": {"start": 8114, "end": 8304}}, {"id": "rule-cf5cb2e7-fdbb-4415-8c61-18cf10564964", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures..", "source_span": {"start": 4242, "end": 4448}}, {"id": "rule-81a0c29b-e607-4089-9ce8-2e74c11a1d45", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "life threatening asthma: history of life threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures..", "source_span": {"start": 4242, "end": 4448}}, {"id": "rule-95cd79cf-b67c-48ed-9634-6fbc2ee23014", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "respiratory tract infection within 4 weeks of visit 1", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1.", "source_span": {"start": 5569, "end": 5659}}, {"id": "rule-1fd962df-4219-4264-9756-6f3bedbf0046", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the need of treatment", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Concurrent Diseases/Abnormalities: Historical or current evidence of clinically significant uncontrolled disease including, but not limited to: cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, bronchopulmonary dysplasia, and chronic obstructive pulmonary disease).", "source_span": {"start": 6256, "end": 6728}}, {"id": "rule-9a5535d2-e357-42d8-b64a-dffacbb9e230", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "time_window": null, "certainty": "medium", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1.", "source_span": {"start": 5569, "end": 5659}}, {"id": "rule-4faa7292-56b2-4192-ab13-948ef1288072", "type": "INCLUSION", "field": "age", "operator": "<=", "value": 17, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]..", "source_span": {"start": 2028, "end": 2373}}, {"id": "rule-2ce8422f-b809-4c58-81c4-d973749cc77f", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Age: 12 years of age or older at Visit 1 (or ³18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only)..", "source_span": {"start": 54, "end": 226}}, {"id": "rule-6ee129d1-4742-4e7b-b35d-6590ce135791", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "all the study requirements", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Compliance: Subjects must be able to comply with all the study requirements..", "source_span": {"start": 4141, "end": 4218}}, {"id": "rule-fe607564-7c88-4b62-899c-293394da752b", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Asthma Diagnosis: Asthma as defined by the National Institutes of Health \\[National Institutes of Health, 2002;", "source_span": {"start": 1899, "end": 2010}}, {"id": "rule-ea87c913-e540-41e2-990a-6403adc79326", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating.", "source_span": {"start": 229, "end": 357}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00061", "nct_id": "NCT00322517", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 25.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["history", "condition"], "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent.. * Must have received prior treatment with an anthracycline and a taxane either concurrently or sequentially in the adjuvant and/or advanced disease treatment settings. Patients may have received as many as 2 other chemotherapy regimens in the advanced disease setting. Patients whose tumors are Her-2-positive must have received prior trastuzumab therapy. Prior hormonal therapy or immunotherapy in the adjuvant and/or advanced/metastatic disease settings is permitted. Prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease.. Exclusion Criteria:. * Prior treatment with \\>/= 3 regimens of chemotherapy in the metastatic disease setting beyond those containing anthracyclines and taxanes. * Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months and should be asymptomatic", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "curative intent", "unit": null, "evidence_text": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}], "rule_v1_extra_rules": [{"id": "rule-5ffd76de-bc63-4a42-8cde-eaf06cb14a75", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histologically or cytologically proven", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent..", "source_span": {"start": 23, "end": 203}}, {"id": "rule-dd639416-0244-4e72-8246-b58904571f7f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "surgery", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease..", "source_span": {"start": 674, "end": 838}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00062", "nct_id": "NCT00001885", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 24.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {"age": 1}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["history", "age"], "eligibility_text": "* INCLUSION CRITERIA:. Individuals 21 years of age or older with any of the following:. RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or. RA-only, or. Biopsy-proven idiopathic PF-only, or. Healthy research volunteers.. EXCLUSION CRITERIA:. Individuals with any of the following:. Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).. Chronic pulmonary disorders other than pulmonary fibrosis.. Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).. Non-rheumatoid arthritis.. Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).. Pregnancy.", "current_labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "Individuals 21 years of age or older with any of the following:"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "Individuals 21 years of age or older with any of the following:"}], "rule_v1_extra_rules": [{"id": "rule-1eef2330-bc33-4e0c-a8d4-002f4e9adcc7", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 21, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Individuals 21 years of age or older with any of the following:.", "source_span": {"start": 23, "end": 87}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00063", "nct_id": "NCT00002781", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 24.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["history", "condition"], "eligibility_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study"}], "rule_v1_extra_rules": [{"id": "rule-a31573a5-0373-4203-b16f-b89df867cc13", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study.", "source_span": {"start": 267, "end": 639}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00064", "nct_id": "NCT00162305", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 24.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["history", "condition"], "eligibility_text": "Inclusion Criteria:. * Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).. * Fasting glucose (FG) \\< - 240 mg/dL, while on metformin or antidiabetic diet alone.. * HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%. Exclusion Criteria:. * Women of childbearing potential", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of childbearing potential"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive)"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive)"}], "rule_v1_extra_rules": [{"id": "rule-09a59294-96f5-4315-b3e5-e26b0873ee80", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "established", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive)..", "source_span": {"start": 23, "end": 133}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00065", "nct_id": "NCT00289627", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 23.0, "priority_reasons": ["missing_critical_rules=1", "contract_errors=1", "contract_warnings=1", "rule_v1_missing=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {}, "contract_error_count": 1, "contract_warning_count": 1, "contract_error_codes": {"FIELD_OPERATOR_INVALID": 1}, "contract_warning_codes": {"DEPRECATED_VALUE": 1}}, "focus_fields": ["history"], "eligibility_text": "Inclusion Criteria:. * Patients with previously treated Stage III (unresectable)or Stage IV melanoma", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Patients with previously treated Stage III (unresectable)or Stage IV melanoma"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review note", "unit": null, "evidence_text": "* Patients with previously treated Stage III (unresectable)or Stage IV melanoma"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00066", "nct_id": "NCT00774241", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 22.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "history": 1}, "extra_rules_by_field": {"age": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history", "age"], "eligibility_text": "Inclusion Criteria:\n\n* male and female patients, \\>=18 years of age;\n* stage IV, HER2 negative metastatic breast cancer;\n* candidate for taxane-based therapy;\n* ECOG performance status 0-2.\n\nExclusion Criteria:\n\n* prior chemotherapy for metastatic breast cancer;\n* concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;\n* suspicion of CNS metastasis;\n* clinically significant cardiovascular disease.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant cardiovascular disease.", "unit": null, "evidence_text": "clinically significant cardiovascular disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;", "unit": null, "evidence_text": "concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stage IV, HER2 negative metastatic breast cancer;", "unit": null, "evidence_text": "stage IV, HER2 negative metastatic breast cancer;"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant cardiovascular disease.", "unit": null, "evidence_text": "clinically significant cardiovascular disease."}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;", "unit": null, "evidence_text": "concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stage IV, HER2 negative metastatic breast cancer;", "unit": null, "evidence_text": "stage IV, HER2 negative metastatic breast cancer;"}], "rule_v1_extra_rules": [{"id": "rule-da2e561e-844e-4cd2-bd00-848ca82447ad", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "male and female patients, \\>=18 years of age;", "source_span": {"start": 23, "end": 68}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00067", "nct_id": "NCT01209091", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 22.0, "priority_reasons": ["missing_critical_rules=1", "contract_warnings=2", "rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "other": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["age", "other", "condition"], "eligibility_text": "Inclusion Criteria:\n\nAge \\> 18\n\nExclusion Criteria:\n\nN/A", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age \\> 18"}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Age \\> 18"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age \\> 18"}, {"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Age \\> 18"}], "rule_v1_extra_rules": [{"id": "rule-716ba9f6-4ee7-450b-8b06-b7bfc5e772c7", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00068", "nct_id": "NCT00001677", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 19.0, "priority_reasons": ["rule_v1_missing=4", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "condition": 2, "sex": 1}, "extra_rules_by_field": {"condition": 3}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age", "sex"], "eligibility_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age equal to or older than 18"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stroke, seizure disorder, or chronic neurologic", "unit": null, "evidence_text": "No history of stroke, seizure disorder, or chronic neurologic disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a purine nucleoside analog at any", "unit": null, "evidence_text": "No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age equal to or older than 18"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a purine nucleoside analog at any", "unit": null, "evidence_text": "No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stroke, seizure disorder, or chronic neurologic", "unit": null, "evidence_text": "No history of stroke, seizure disorder, or chronic neurologic disease"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control"}], "rule_v1_extra_rules": [{"id": "rule-f90ce305-99ae-4fb5-b1b4-58a343a81b91", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a chronic and progressive lung disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%)..", "source_span": {"start": 2524, "end": 2749}}, {"id": "rule-649235ba-6927-4c69-b995-d0b9124ac26a", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a purine nucleoside analog at any time", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time.", "source_span": {"start": 2817, "end": 2943}}, {"id": "rule-05c7a18c-22f4-498f-9b46-4dc2731ff925", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active lung disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%)..", "source_span": {"start": 2524, "end": 2749}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00069", "nct_id": "NCT00510302", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 18.0, "priority_reasons": ["rule_v1_missing=4", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 4}, "extra_rules_by_field": {"age": 1, "condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:. * (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997.. * Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible.. * Melanoma patients, their spouses/partners, and FDRs are eligible if they can speak, read, and write English.. * Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent.. * Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment.. * A melanoma patient's FDR is eligible if he/she is a sibling or child of the melanoma patient.. Exclusion Criteria:. * Melanoma patients, spouses/partners of patients, and FDRs of patients are not eligible if they cannot provide informed consent.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, spouses/partners of patients, and FDRs of patients are not eligible if they cannot provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and FDRs are eligible if they can speak, read, and write English"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "partners and fdrs of melanoma", "unit": null, "evidence_text": "* Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in situ, localized, or regional melanoma after", "unit": null, "evidence_text": "* (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, spouses/partners of patients, and FDRs of patients are not eligible if they cannot provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in situ, localized, or regional melanoma after", "unit": null, "evidence_text": "* (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "* Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "partners and fdrs of melanoma", "unit": null, "evidence_text": "* Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment"}], "rule_v1_extra_rules": [{"id": "rule-706e5208-553d-4805-a888-106b5d44007c", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible..", "source_span": {"start": 198, "end": 320}}, {"id": "rule-3c353b4a-e892-41ce-b51c-c1d6a50eef2e", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in situ", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "(FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997..", "source_span": {"start": 23, "end": 195}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00070", "nct_id": "NCT00483301", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 18.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3}, "extra_rules_by_field": {"condition": 6}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Histologically confirmed diagnosis of melanoma with measurable disease. * Patients with stage IV, previously untreated, refractory to initial therapy or progressing after response to initial therapy. * Patients with unresectable stage III, including unresectable in-transit metastases. * Two prior chemotherapy regimen is allowed. * One prior immunotherapy regimen is allowed. * No other concurrent investigational therapy. * Radiation therapy to non-target lesions or to one of multiple target lesions may be allowed on a case-by-case basis. * Patients must be past the nadir from previous cytotoxic therapy. * Age at least 18 years. * ECOG performance status 0-2. * Hemoglobin \\> 9.0 g/dl, absolute neutrophil count (ANC) \\> 1,500/mm3, platelet count \\> 100,000/mm3. * Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care.. * Creatinine \\< 1.5 x ULN, serum calcium within normal limits. * Patients with stable brain metastasis who have been treated with either whole brain radiation or Gamma Knife and have been off steroids for \\> 4 weeks. * Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.. * Ability to understand and sign a written informed consent document. All patients must have a signed informed consent before registration and initiation of therapy. Exclusion Criteria:. * Cardiac disease: Congestive heart failure \\> class II NYHA.. * Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.. * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.. * Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management.. * No known severe hypersensitivity or suspected allergy to sorafenib, ABI-007 or any of the excipients. * Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude progressing brain metastasis.. * Peripheral neuropathy greater than grade II. * Serious intercurrent medical or psychiatric illness, including serious active infection. * Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.. * Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.. * Pulmonary hemorrhage/bleeding event \\> CTCAE Grade 2 within 4 weeks of first dose of study drug.. * Any other hemorrhage/bleeding event \\> CTCAE Grade 3 within 4 weeks of first dose of study drug.. * Serious non-healing wound, ulcer, or bone fracture.. * Evidence or history of bleeding diathesis or coagulopathy. * Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.. * Use of St. John's Wort or rifampin (rifampicin). * Any condition that impairs patient's ability to swallow whole pills.. * Any malabsorption problem. * No treatment for melanoma within the previous 4 weeks.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Age at least 18 years"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Men and women should use adequate birth control for at least three months after the last administration of protocol drugs"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Men and women should use adequate birth control for at least three months after the last administration of protocol drugs"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bleeding diathesis or coagulopathy", "unit": null, "evidence_text": "* Evidence or history of bleeding diathesis or coagulopathy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Serious intercurrent medical or psychiatric illness, including serious active infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma with measurable disease", "unit": null, "evidence_text": "* Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "unresectable stage iii, including unresectable in-transit metastases", "unit": null, "evidence_text": "* Patients with unresectable stage III, including unresectable in-transit metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "an agent such as warfarin or heparin", "unit": null, "evidence_text": "Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "x uln for", "unit": null, "evidence_text": "* Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "* Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma with measurable disease", "unit": null, "evidence_text": "* Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "unresectable stage iii, including unresectable in-transit metastases", "unit": null, "evidence_text": "* Patients with unresectable stage III, including unresectable in-transit metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "x uln for", "unit": null, "evidence_text": "* Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits"}], "rule_v1_extra_rules": [{"id": "rule-04689dc3-f712-4ba7-8fe7-6083650bea4b", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "anginal", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months..", "source_span": {"start": 2173, "end": 2343}}, {"id": "rule-5210d9ce-976b-4a01-b133-f8c60159b21e", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "neurological", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude progressing brain metastasis..", "source_span": {"start": 2666, "end": 2783}}, {"id": "rule-a78856e5-8e2e-46ad-b54b-411a97514c5d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histologically confirmed", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease.", "source_span": {"start": 23, "end": 94}}, {"id": "rule-8ca452b0-d8e7-4c75-a251-a8978c15a722", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "measurable disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease.", "source_span": {"start": 23, "end": 94}}, {"id": "rule-02dff4ac-92bd-4b52-a3f5-276bb89f8d6d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stage iv", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with stage IV, previously untreated, refractory to initial therapy or progressing after response to initial therapy.", "source_span": {"start": 97, "end": 222}}, {"id": "rule-ffa4da0d-529f-4f81-b1a9-8ba7fc12fb5c", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "unresectable stage iii", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with unresectable stage III, including unresectable in-transit metastases.", "source_span": {"start": 225, "end": 308}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00071", "nct_id": "NCT00687440", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 18.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "sex": 1}, "extra_rules_by_field": {"condition": 4, "history": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex", "history"], "eligibility_text": "Inclusion Criteria:. Patients must fulfill all the following criteria:. * Females aged 18 to 70 years-old.. * Willingness to participate in the study and comply with its procedures.. * Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +).. * No prior chemotherapy for metastatic breast cancer.. * Adjuvant or neo-adjuvant chemotherapy is allowed according to the following rules:. * patients treated with anthracyclines if all the following conditions are met:. * Doxorubicin total dose \\<= 300 mg/m\\^2. * Epirubicin total dose \\<= 480 mg/m\\^2. * Chemotherapy-free interval of \\> 12 months. * no taxane-based adjuvant or neo-adjuvant chemotherapy is allowed;. * patients treated with non-anthracycline/taxane adjuvant or neo-adjuvant chemotherapy regimens are freely eligible (i.e. cyclophosphamide/methotrexate/fluorouracil (CMF) or similar regimens).. * At least one measurable lesion according to RECIST criteria.. * Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment.. * Complete Tumor baseline evaluation including a total body computed tomography (CT) scan within 4 weeks prior to start of treatment.. * Left ventricular ejection fraction (LVEF) \\>= 50% as determined by echocardiogram or Multi Gated Acquisition (MUGA) scan.. * World Health Organization (WHO) performance status 0,1.. * Life expectancy \\> 3 months.. * Laboratory requirements :. * Hematology :. * Neutrophils \\> 1.5 x 10\\^9/L. * Platelets \\> 100 x 10\\^9/L. * Hemoglobin \\> 10 g/dL. * Hepatic function:. * Total bilirubin \\<= 1.25 x the upper-normal limits (UNL);. * ASAT (Aspartate Aminotransferase or SGOT), ALAT (Alanine aminotransferase or SGPT) \\<= 2.5 x the upper-normal limits;. * For patients with liver metastases:. * Total bilirubin \\< 1.5 x the UNL (Upper limit of normal) ;. * ASAT and/or ALAT \\< 3 x the UNL;. * Renal function :. * Serum Creatinine \\< 1.5 x the UNL.. * Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception.. * Patients must be accessible for treatment and follow-up.. Exclusion Criteria:. Patients will not be enrolled if any of the following criteria apply:. * Prior chemotherapy for metastatic disease.. * History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).. * Radiation to disease areas within 3 weeks of study initiation.. * Symptomatic peripheral neuropathy \\> grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria.. * Other serious illness or medical condition.. * LVEF \\< 50% as determined by echocardiogram or MUGA scan.. * Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.. * History of significant neurologic or psychiatric disorders including dementia or seizures.. * Active infection.. * Active peptic ulcer, unstable diabetes mellitus or other contraindications for the use of dexamethasone.. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.. * Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible.. * Taxane-based adjuvant or neo-adjuvant chemotherapy \\< 12 months.. * Other concurrent chemotherapy, immunotherapy, radiotherapy or any other investigational medication, for the treatment of the tumor.. * Pregnant or breast-feeding women.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Females aged 18 to 70 years-old"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 70, "unit": "years", "evidence_text": "* Females aged 18 to 70 years-old"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or breast-feeding women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other experimental drugs", "unit": null, "evidence_text": "* Concurrent treatment with other experimental drugs"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "corticosteroids used for reasons other than for", "unit": null, "evidence_text": "* Concurrent treatment with corticosteroids used for reasons other than for premedication"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant neurologic or psychiatric disorders including dementia", "unit": null, "evidence_text": "* History of significant neurologic or psychiatric disorders including dementia or seizures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any investigational drug within 30 days prior", "unit": null, "evidence_text": "Participation in another clinical trial with any investigational drug within 30 days prior to study screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "however", "unit": null, "evidence_text": "However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "its procedures", "unit": null, "evidence_text": "* Willingness to participate in the study and comply with its procedures"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 10, "unit": "years", "evidence_text": "* History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "however", "unit": null, "evidence_text": "However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant neurologic or psychiatric disorders including dementia", "unit": null, "evidence_text": "* History of significant neurologic or psychiatric disorders including dementia or seizures"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or breast-feeding women"}], "rule_v1_extra_rules": [{"id": "rule-09d34204-3411-4e0f-b035-2e7d82293c82", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia..", "source_span": {"start": 2873, "end": 2998}}, {"id": "rule-acdc1307-38ab-4b06-af93-9e1189cbd7f5", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)..", "source_span": {"start": 2366, "end": 2492}}, {"id": "rule-90a2fe02-7c56-4e4a-bdad-a04cb5022c29", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant neurologic or psychiatric disorders including dementia or seizures", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of significant neurologic or psychiatric disorders including dementia or seizures..", "source_span": {"start": 3001, "end": 3092}}, {"id": "rule-4d7f1651-e8bf-49c3-83b9-b7c7d1194272", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 1, "unit": "years", "time_window": null, "certainty": "medium", "evidence_text": "Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia..", "source_span": {"start": 2873, "end": 2998}}, {"id": "rule-4c11250f-82e3-4d13-97af-ac360d666cc3", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +)..", "source_span": {"start": 185, "end": 390}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00072", "nct_id": "NCT00973557", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 18.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "medication": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "medication"], "eligibility_text": "Inclusion Criteria:\n\n* Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month\n* Adults (18 years of age or older)\n\nExclusion Criteria:\n\n* Patients who are taking medications known to affect serum prolactin levels\n* Patients who are pregnant\n* Patients who have pituitary disease\n* Minors (Under the age of 18)", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients who have pituitary disease", "unit": null, "evidence_text": "Patients who have pituitary disease"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are taking medications known to affect serum prolactin levels", "unit": null, "evidence_text": "Patients who are taking medications known to affect serum prolactin levels"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Adults (18 years of age or older)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "bevacizumab for at least 1 month", "unit": null, "evidence_text": "Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Patients who have pituitary disease", "unit": null, "evidence_text": "Patients who have pituitary disease"}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Patients who are taking medications known to affect serum prolactin levels", "unit": null, "evidence_text": "Patients who are taking medications known to affect serum prolactin levels"}], "rule_v1_extra_rules": [{"id": "rule-002ff778-953d-4fe4-b237-880023ddc6bf", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colorectal cancer", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month", "source_span": {"start": 23, "end": 170}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00073", "nct_id": "NCT00877318", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 18.0, "priority_reasons": ["missing_critical_rules=1", "contract_warnings=2", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"other": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 2, "contract_error_codes": {}, "contract_warning_codes": {"DEPRECATED_VALUE": 1, "OTHER_EXISTS_VALUE_NON_NULL": 1}}, "focus_fields": ["other", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* Patient with a dysfunction of left ventricle with ejection fraction of left ventricle \\< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation.\n\nExclusion Criteria:\n\n* Patient non authorized to follow an effort training\n* Therapeutic education impossible\n* Pregnant woman or breast-feeding\n* No assent\n* Incapacity to use the terminal\n* Minor patient or under supervision", "current_labeled_rules": [{"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Patient with a dysfunction of left ventricle with ejection fraction of left ventricle \\< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation."}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "other", "operator": "EXISTS", "value": "eligibility criterion", "unit": null, "evidence_text": "Patient with a dysfunction of left ventricle with ejection fraction of left ventricle \\< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation."}], "rule_v1_extra_rules": [{"id": "rule-edc67c8c-b42b-4b5a-9ed2-1cbca02b2b7e", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00074", "nct_id": "NCT01110395", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 17.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=2"], "priority_breakdown": {"missing_rules_by_field": {"age": 1, "history": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["age", "history"], "eligibility_text": "Inclusion Criteria:\n\n* Individuals with left ventricular dysfunction\n\nExclusion Criteria:\n\n* Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study", "current_labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "excessive alcohol use, or any condition (e", "unit": null, "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g."}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnet", "unit": null, "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "left ventricular dysfunction", "unit": null, "evidence_text": "Individuals with left ventricular dysfunction"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnet", "unit": null, "evidence_text": "Age \\< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00075", "nct_id": "NCT00128297", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 16.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "sex": 1}, "extra_rules_by_field": {"condition": 4}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "Inclusion Criteria:. * Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer are allowed.. * Normal or borderline renal function (serum creatinine \\< 1.5 x upper normal limit \\[UNL\\]).. * Normal calcium levels in serum, or slightly non-symptomatic high levels (\\< 1.25 x UNL).. * Performance status 0, I or II in World Health Organization (WHO) scale.. Exclusion Criteria:. * Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions.. * Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia.. * Metastases in central nervous system (CNS).. * Hypersensitivity to bisphosphonates or other components of the formula.. * Pregnant or lactating women.. * Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates is only allowed if the", "unit": null, "evidence_text": "* Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a second chemotherapy line or a", "unit": null, "evidence_text": "* Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a second chemotherapy line or a", "unit": null, "evidence_text": "* Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates is only allowed if the", "unit": null, "evidence_text": "* Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating women"}], "rule_v1_extra_rules": [{"id": "rule-d960b303-b031-448c-a913-c24ae005add9", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a second chemotherapy line or a third", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease.", "source_span": {"start": 809, "end": 926}}, {"id": "rule-50d39689-9858-4581-aae0-31552ff7b479", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates in the 30 previous days", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions..", "source_span": {"start": 437, "end": 565}}, {"id": "rule-c1de29cf-5b20-45ba-a9b7-27e139687b26", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates is only allowed", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia..", "source_span": {"start": 568, "end": 652}}, {"id": "rule-b893a00d-39aa-47a0-8302-183edd3a6edf", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00076", "nct_id": "NCT00257283", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 16.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3}, "extra_rules_by_field": {"age": 1, "condition": 3}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:. * Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 months. * Patients with documented cardiovascular disease, at least one of the following. 1. Angina pectoris. 2. Previous Acute myocardial infarction. 3. Previous PTCA/CABG or demonstated atheroclerosis after coronary angio. 4. Previous Transitory Cerebral Ischemia. 5. Previous Apoplexia Cerebri. 6. Symptoms of peripheral vascular disease. * Written informed consent. Exclusion Criteria:. * Active malignant disease, except basal cell carcinoma or spinocellular carcinoma. * Patients undergoing peritoneal dialysis. * Any condition associated with a risk of poor compliance, as judged by investigator. * Pregnant or breastfeeding. * Participation in other clinical studies involving treatment with drugs.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "drugs", "unit": null, "evidence_text": "* Participation in other clinical studies involving treatment with drugs"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a risk of poor compliance, as", "unit": null, "evidence_text": "* Any condition associated with a risk of poor compliance, as judged by investigator"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "chronic hemodialysis for at least 6", "unit": null, "evidence_text": "* Patients having been treated with chronic hemodialysis for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented cardiovascular disease, at least one", "unit": null, "evidence_text": "* Patients with documented cardiovascular disease, at least one of the following"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a risk of poor compliance, as", "unit": null, "evidence_text": "* Any condition associated with a risk of poor compliance, as judged by investigator"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "chronic hemodialysis for at least 6", "unit": null, "evidence_text": "* Patients having been treated with chronic hemodialysis for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented cardiovascular disease, at least one", "unit": null, "evidence_text": "* Patients with documented cardiovascular disease, at least one of the following"}], "rule_v1_extra_rules": [{"id": "rule-446ec4f3-32bf-49a3-83d7-ad153568ed01", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a risk of poor compliance", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Any condition associated with a risk of poor compliance, as judged by investigator.", "source_span": {"start": 656, "end": 739}}, {"id": "rule-973c0f32-3498-4de2-96be-0c67fd31b04e", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Males and females above 18 years of age.", "source_span": {"start": 23, "end": 63}}, {"id": "rule-929c5dbd-dcfb-4997-a786-29bee97acb06", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "been treated with chronic hemodialysis for at", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients having been treated with chronic hemodialysis for at least 6 months.", "source_span": {"start": 66, "end": 143}}, {"id": "rule-9c7e328b-0987-415f-8de5-8c39600ea3ce", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented cardiovascular disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with documented cardiovascular disease, at least one of the following.", "source_span": {"start": 146, "end": 225}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00077", "nct_id": "NCT00004925", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 14.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "sex": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen. * Overexpression of HER2 protein (2+ or 3+). * Evaluable disease. * History of brain metastases allowed if off steroids and asymptomatic, with a 3 month or greater interval since last dose of brain irradiation, and no evidence of progression. * Hormone receptor status:. * Not specified. PATIENT CHARACTERISTICS:. Age:. * 18 and over. Sex:. * Female. Menopausal status:. * Not specified. Performance status:. * ECOG 0-1. Life expectancy:. * Not specified. Hematopoietic:. * Absolute neutrophil count at least 1,500/mm\\^3. * Platelet count at least 100,000/mm\\^3. * Hemoglobin at least 10 g/dL. Hepatic:. * Bilirubin no greater than 1.5 times upper limit of normal (ULN). Renal:. * AST or ALT no greater than 4 times ULN. Cardiovascular:. * Adequate cardiac function. * LVEF at least 50% predicted or lower limit of normal. Other:. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * No other concurrent medical or psychological condition that would preclude study compliance. * No history of hypersensitivity to anthracyclines, eggs, or egg products. PRIOR CONCURRENT THERAPY:. Biologic therapy:. * Prior trastuzumab (Herceptin) allowed. Chemotherapy:. * See Disease Characteristics. * At least 3 weeks since prior antineoplastic therapy. * No more than 1 prior systemic cytotoxic regimen for locally advanced, metastatic, or inflammatory breast cancer. * No prior anthracyclines greater than 240 mg/m2. * No other concurrent antineoplastic agents. * No concurrent treatment with other liposomal products other than doxorubicin HCl liposome. Endocrine therapy:. * See Disease Characteristics. * At least 3 weeks since prior hormonal agents. * No concurrent hormonal therapy. Radiotherapy:. * See Disease Characteristics. Surgery:. * Not specified. Other:. * At least 3 weeks since other prior investigational drugs", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "hypersensitivity to anthracyclines, eggs, or egg", "unit": null, "evidence_text": "* No history of hypersensitivity to anthracyclines, eggs, or egg products"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other liposomal products other than doxorubicin", "unit": null, "evidence_text": "* No concurrent treatment with other liposomal products other than doxorubicin HCl liposome"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "hypersensitivity to anthracyclines, eggs, or egg", "unit": null, "evidence_text": "* No history of hypersensitivity to anthracyclines, eggs, or egg products"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other liposomal products other than doxorubicin", "unit": null, "evidence_text": "* No concurrent treatment with other liposomal products other than doxorubicin HCl liposome"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female"}], "rule_v1_extra_rules": [{"id": "rule-0a3ef835-fcdc-42dc-881e-31844a9f4660", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a 3 month or greater interval since", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of brain metastases allowed if off steroids and asymptomatic, with a 3 month or greater interval since last dose of brain irradiation, and no evidence of progression.", "source_span": {"start": 289, "end": 463}}, {"id": "rule-cd6b7de4-dea3-4224-a0ab-384c974b730e", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other liposomal products other than doxorubicin hcl", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No concurrent treatment with other liposomal products other than doxorubicin HCl liposome.", "source_span": {"start": 1729, "end": 1819}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00078", "nct_id": "NCT00420290", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 14.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 6}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements ≥ 5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "patients with active infections (including chronic or local infection)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pulmonary tb infection with or without documented", "unit": null, "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active tb, are excluded from the", "unit": null, "evidence_text": "Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active tb, are excluded from the", "unit": null, "evidence_text": "Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pulmonary tb infection with or without documented", "unit": null, "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy"}], "rule_v1_extra_rules": [{"id": "rule-cf430f18-cdf7-4dff-b43d-58d66fc19a89", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active tb", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study.", "source_span": {"start": 1590, "end": 1709}}, {"id": "rule-be7f63e5-e907-42b8-8178-c3fdd7f3d67c", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current active tb", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study.", "source_span": {"start": 1590, "end": 1709}}, {"id": "rule-5d133033-4586-4fb1-86eb-c19f7cea1cee", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);.", "source_span": {"start": 748, "end": 990}}, {"id": "rule-d2cb602c-fb1f-4b1f-b31c-090925872f55", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or without documented adequate therapy", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy.", "source_span": {"start": 1476, "end": 1589}}, {"id": "rule-a5fcfa45-18d4-44fc-9e90-c16b19af8647", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pulmonary tb infection with or without documented adequate therapy", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy.", "source_span": {"start": 1476, "end": 1589}}, {"id": "rule-3f26d602-36f5-4d1f-a00d-48a233e155d6", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00079", "nct_id": "NCT00116701", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 14.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition"], "eligibility_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:. * acute myocardial ischemia;. * hospitalization for congestive heart failure;. * myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "study procedures", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}], "rule_v1_extra_rules": [{"id": "rule-f32effa2-b631-485c-8add-2812135f87cb", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 18 years old", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial.", "source_span": {"start": 21, "end": 729}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00080", "nct_id": "NCT00384722", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 14.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history", "condition"], "eligibility_text": "Inclusion Criteria:. * Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prior to enrollment. * Age 18 or above, or of legal age to give informed consent specific to state and national law. * Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigation center and at the intervals defined by this protocol. * Geographically stable residents who are available for follow-up. Exclusion Criteria:. * Have a known hypersensitivity to a 0.5 mg nominal dose of dexamethasone acetate. * Have or had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement. * Have pre-existing cardioversion/defibrillation leads or right ventricular pacing leads other than those specified in the investigational plan (unless the investigator intends to replace them with permitted cardioversion/defibrillation leads). * Currently requiring dialysis. * Have had a myocardial infarct, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment. * Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis). * Documented life expectancy of less than six months or expected to undergo heart transplant within the next six months. * Enrolled or participating in any concurrent study, including drug investigations, without Guidant written approval, that may confound the results of this study. * Have a pre-existing unipolar pacemaker that will not be explanted/abandoned. * Have a mechanical tricuspid heart valve. * Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women who are pregnant or plan to become pregnant"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}], "rule_v1_extra_rules": [{"id": "rule-3e3a22fb-b699-4a0f-aeb6-7a9ba9acb3e9", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00081", "nct_id": "NCT00960245", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 14.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"medication": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication", "condition"], "eligibility_text": "Inclusion Criteria:\n\n* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.\n\nExclusion Criteria:\n\n* Positive test results for HIV or hepatitis B or C.\n* Treatment for drug or alcohol dependence.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Positive test results for HIV or hepatitis B or C."}, {"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Treatment for drug or alcohol dependence.", "unit": null, "evidence_text": "Treatment for drug or alcohol dependence."}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "medication", "operator": "NOT_IN", "value": "Treatment for drug or alcohol dependence.", "unit": null, "evidence_text": "Treatment for drug or alcohol dependence."}], "rule_v1_extra_rules": [{"id": "rule-101360c9-6ec6-4a2b-9a6b-cd089bf85f0b", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00082", "nct_id": "NCT00054145", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 13.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "sex": 1}, "extra_rules_by_field": {"sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed breast cancer. * Recurrent or refractory, locally advanced or metastatic disease. * At least 1 unidimensionally measurable lesion. * At least 20 mm by conventional techniques OR 10 mm by spiral CT scan. * Previously irradiated lesions are not considered measurable unless they have demonstrated progression before study entry. * No measurable disease limited to bone lesions. * No known brain metastases. * Hormone receptor status:. * Not specified. PATIENT CHARACTERISTICS:. Age. * 18 and over. Sex. * Male or female. Menopausal status. * Not specified. Performance status. * ECOG 0-2 OR. * Karnofsky 60-100%. Life expectancy. * More than 3 months. Hematopoietic. * WBC at least 3,000/mm\\^3. * Absolute neutrophil count at least 1,500/mm\\^3. * Platelet count at least 100,000/mm\\^3. * No history of hemolytic disorder. Hepatic. * Bilirubin no greater than 1.25 times upper limit of normal (ULN). * AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present). Renal. * Creatinine normal OR. * Creatinine clearance at least 60 mL/min. Cardiovascular. * No symptomatic congestive heart failure. * No unstable angina pectoris. * No cardiac arrhythmia. * No evidence of cardiac dysfunction. Gastrointestinal. * No history of biliary flow obstruction. * No abnormalities of the gastrointestinal tract that would preclude study drug absorption. * No active peptic ulcer disease. Other. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * No ongoing or active infection. * No poorly controlled diabetes mellitus. * No other uncontrolled illness. * No prior allergic reactions to compounds of similar chemical or biological composition to perifosine. * No psychiatric illness or social situation that would preclude study compliance. PRIOR CONCURRENT THERAPY:. Biologic therapy. * Not specified. Chemotherapy. * No more than 2 prior lines of chemotherapy for advanced disease, excluding adjuvant chemotherapy. * Prior adjuvant chemotherapy allowed. * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered. Endocrine therapy. * At least 4 weeks since prior endocrine therapy. * Multiple lines of endocrine therapy for advanced disease allowed. Radiotherapy. * At least 4 weeks since prior radiotherapy and recovered. * Prior radiotherapy for metastatic disease allowed. Surgery. * No prior major gastric surgery. * Prior surgery, including for metastatic disease, allowed. Other. * No other concurrent anticancer or investigational agents. * No concurrent antiretroviral therapy in HIV-positive patients. * Concurrent bisphosphonates allowed", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "hemolytic disorder", "unit": null, "evidence_text": "* No history of hemolytic disorder"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "biliary flow obstruction", "unit": null, "evidence_text": "* No history of biliary flow obstruction"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "biliary flow obstruction", "unit": null, "evidence_text": "* No history of biliary flow obstruction"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "hemolytic disorder", "unit": null, "evidence_text": "* No history of hemolytic disorder"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}], "rule_v1_extra_rules": [{"id": "rule-d6d5e5ee-242f-4602-8775-5c68af75ef94", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Male or female.", "source_span": {"start": 573, "end": 588}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00083", "nct_id": "NCT00060125", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 13.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2, "sex": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "Inclusion Criteria:. * Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease. * Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:. * Bone lesions. * Leptomeningeal disease. * Ascites. * Pleural/pericardial effusion. * Lymphangitis cutis/pulmonis. * Abdominal masses that are not confirmed and followed by imaging techniques. * Cystic lesions. * Lesions that are situated in a previously irradiated area. * No history of brain metastases. * No allergies to azoles (e.g. ketoconazole) or allergies to compounds structurally similar to R115777. * No more than 1 prior immunotherapy regimen for treatment of advanced melanoma; an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable; prior chemotherapy for any stage of melanoma is not allowed. * No radiotherapy or immunotherapy within four weeks prior to the initiation of therapy on this study. * CTC (ECOG) performance status 0-1. * Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control; women of child-bearing age will undergo pregnancy testing. * ANC \\>= 1500/uL. * Platelets \\>= 100,000/uL. * Bilirubin =\\< 1.5 mg/dL. * Creatinine =\\< 2.0 mg/dL", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women of child-bearing age will undergo pregnancy testing"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women and men of reproductive potential should agree to use an effective means of birth control"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "women and men of reproductive potential should agree to use an effective means of birth control"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "* No history of brain metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in addition", "unit": null, "evidence_text": "in addition, patients must have measurable disease"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "* No history of brain metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in addition", "unit": null, "evidence_text": "in addition, patients must have measurable disease"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "women and men of reproductive potential should agree to use an effective means of birth control"}], "rule_v1_extra_rules": [{"id": "rule-13c1f419-8482-42f8-9f36-d65e1b86aefc", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histological or cytological", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease.", "source_span": {"start": 23, "end": 205}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00084", "nct_id": "NCT01139086", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 13.0, "priority_reasons": ["rule_v1_missing=3", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 3}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:\n\n* Age 40-75 years\n* Chronic heart failure: ejection fraction\\<40% and at stable condition\n* Coronary Disease and dilated cardiomyopathy without heart failure\n* Control group without diagnosis of any heart disease\n\nExclusion Criteria:\n\n* Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study", "unit": null, "evidence_text": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "Age 40-75 years"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 40, "unit": "years", "evidence_text": "Age 40-75 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "control group without", "unit": null, "evidence_text": "Control group without diagnosis of any heart disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Control group without diagnosis of any heart disease", "unit": null, "evidence_text": "Control group without diagnosis of any heart disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Coronary Disease and dilated cardiomyopathy without heart failure", "unit": null, "evidence_text": "Coronary Disease and dilated cardiomyopathy without heart failure"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study", "unit": null, "evidence_text": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Control group without diagnosis of any heart disease", "unit": null, "evidence_text": "Control group without diagnosis of any heart disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Coronary Disease and dilated cardiomyopathy without heart failure", "unit": null, "evidence_text": "Coronary Disease and dilated cardiomyopathy without heart failure"}], "rule_v1_extra_rules": [{"id": "rule-5ec396e6-337e-4fd3-bff5-39d7dc43b44b", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinical", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Clinical diagnosis of neuromusculoskeletal , pulmonary, or other systemic diseases that may affect the testing of the study", "source_span": {"start": 258, "end": 381}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00085", "nct_id": "NCT00356629", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 13.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=1"], "priority_breakdown": {"missing_rules_by_field": {"history": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["history"], "eligibility_text": "Inclusion criteria. * Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5). * aged more or equal to 18. * stable disease. * able to perform PFTs. * informed consent signed. * affiliated to french social insurance. Exclusion Criteria:. * acute exacerbation of the disease during the last 2 weeks. * IV or oral steroids or antibiotics during the last 2 weeks. * hospitalization during the last 2 weeks. * colonization by S aureus methicillin resistant and/or Burkholderia cepacia", "current_labeled_rules": [{"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* hospitalization during the last 2 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* acute exacerbation of the disease during the last 2 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* IV or oral steroids or antibiotics during the last 2 weeks"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "* hospitalization during the last 2 weeks"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00086", "nct_id": "NCT00548574", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 13.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=1"], "priority_breakdown": {"missing_rules_by_field": {"medication": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["medication"], "eligibility_text": "Inclusion Criteria:. * newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology. * females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception. Exclusion Criteria:. * subjects with relapsing UC who were in relapse for \\> 6 weeks prior to baseline. * subjects who relapsed on maintenace therapy with doses of mesalazine =\\> 2g/day. * subjects who had unsuccessfully treated their current relapse with steroids or a mesalazine dose of \\> 2g/day. * subjects with Crohn's disease, proctitis, bleeding disorders, active peptic ulcer disease, previous colonic surgery, or those at an immediate risk of toxic megacolon or a stool culture positive for enteric pathogens. * subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit. * subjects with hypersensitivity to salicylates and subjects with moderate/severe renal impairment", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "compatible histology", "unit": null, "evidence_text": "* newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "* subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "* subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00087", "nct_id": "NCT90000005", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 13.0, "priority_reasons": ["missing_critical_rules=1", "rule_v1_missing=1"], "priority_breakdown": {"missing_rules_by_field": {"procedure": 1}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["procedure"], "eligibility_text": "Inclusion Criteria: Participants with rheumatoid arthritis. Exclusion Criteria: major surgery in the last 6 months.", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "rheumatoid arthritis", "unit": null, "evidence_text": "Inclusion Criteria: Participants with rheumatoid arthritis"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "evidence_text": "Exclusion Criteria: major surgery in the last 6 months"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "evidence_text": "Exclusion Criteria: major surgery in the last 6 months"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00088", "nct_id": "NCT00329732", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 12.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=4"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "sex": 1}, "extra_rules_by_field": {"condition": 3, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "Inclusion Criteria:. * Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine. * Presenting to clinic in migraine status, meaning the migraine has continued for greater than or equal to 3 days but less than 3 months.. * Pain must be reported as at least moderate pain level at time of injections. Exclusion Criteria:. A subject is ineligible to participate in this study if he/she satisfies any of the following criteria:. * Subjects who have received greater occipital nerve blocks in the past. * Subjects who in their own or the investigator's opinion are unable to describe their symptoms. * Subjects who are pregnant or lactating", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a previous diagnosis fulfilling ihs for episodic", "unit": null, "evidence_text": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a previous diagnosis fulfilling ihs for episodic", "unit": null, "evidence_text": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}], "rule_v1_extra_rules": [{"id": "rule-8ce57968-7ced-4d7b-a849-4e6cf457f329", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "s opinion are unable to describe their", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects who in their own or the investigator's opinion are unable to describe their symptoms.", "source_span": {"start": 593, "end": 687}}, {"id": "rule-9c82276d-f410-4297-8b0f-44f1c1e8959d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a previous diagnosis fulfilling ihs criteria for", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine.", "source_span": {"start": 23, "end": 173}}, {"id": "rule-215c8aba-d34a-4f42-8621-243a10cafc8a", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "with a previous", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine.", "source_span": {"start": 23, "end": 173}}, {"id": "rule-1c54022c-f962-43b5-8ebe-99ad3f278cae", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine.", "source_span": {"start": 23, "end": 173}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00089", "nct_id": "NCT00232726", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 11.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 2, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "Inclusion Criteria:. * Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-naïve). * Measurable disease according to Response Criteria in Solid Tumours (RECIST). * Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status. * Age 18 years or more. * Life expectancy \\> 3 months. * Signed informed consent. * Adequate haematological and biological functions:. * Bone marrow function:. 1. Neutrophils ≥ 1.5 x 10\\^9/L. 2. Platelets ≥ 100 x 10\\^9/L. 3. Hemoglobin (Hb) ≥ 10 g/dL. * Hepatic function:. 1. AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN). If liver metastases, ≤ 5 times institutional ULN.. 2. Serum bilirubin and alkaline phosphatase ≤ 1.5 times institutional ULN. * Renal function:. * Creatinine ≤ 1.5 times institutional ULN. Exclusion Criteria:. * Known brain metastases. * Diagnosis of ocular malignant melanoma. * Radiotherapy to more than 30% of bone marrow. * Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study. * Prior immunotherapy and/or chemotherapy for the treatment of melanoma. * Requirement of concomitant treatment with a non-permitted medication:. * Alternative drugs. * High doses of vitamins. * History of allergic reactions to Ara-C or egg. * Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection). * Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance. * Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients. * Known positive status for HIV and/or hepatitis B or C. * Drug and/or alcohol abuse. * Any reason why, in the Investigator's opinion, the patient should not participate", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "ocular malignant melanoma", "unit": null, "evidence_text": "* Diagnosis of ocular malignant melanoma"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reactions to ara-c or egg", "unit": null, "evidence_text": "* History of allergic reactions to Ara-C or egg"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known positive status for HIV and/or hepatitis B or C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "uncontrolled intercurrent illness including ongoing or active infection)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or absence of adequate contraception for", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "ocular malignant melanoma", "unit": null, "evidence_text": "* Diagnosis of ocular malignant melanoma"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or absence of adequate contraception for", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}], "rule_v1_extra_rules": [{"id": "rule-d0977520-8c34-475a-8e99-5bc715d0460a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "fertile", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients.", "source_span": {"start": 1739, "end": 1844}}, {"id": "rule-2812c7ae-b963-4f4b-8306-22b81dd88471", "type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients.", "source_span": {"start": 1739, "end": 1844}}, {"id": "rule-e688c4fd-3bdd-4c64-940c-950f6b6d11c7", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00090", "nct_id": "NCT00369499", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 11.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"age": 1, "condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:. * Migraine history of at least 1 year.. * Migraine patients experiencing at least 2 migraine attacks per month.. * Migraine patients experiencing at least 1 migraine attack with aura per month.. * Failure of or intolerance to at least 2 classes of prophylactic migraine medication evaluated in adequate, approved medication trials. At least one of the classes shall come from beta-blockers, anticonvulsants, calcium channel blockers and tricyclic antidepressants.. * Aged 18 - 50 years and of legal age in the host country.. * The patient or legal guardian has signed a study specific informed consent form agreeing to data collection and follow-up requirements.. * The patient agrees to abstain from starting prophylactic migraine medication or agrees to maintain existing prophylactic migraine medication without changing dose or drug from entering the baseline period throughout the duration of the study until final assessments.. * Documented right to left shunt that is suitable for device closure.. Exclusion Criteria:. * Taking migraine preventative medication for conditions other than migraine.. * History of 15 or more headache days per month.. * 8 or more non-migraine headache days per month.. * Overuse of acute headache medication (use on 10 or more days per month).. * Patient has severe central nervous system disease such as seizure disorder, inflammatory disease of the central nervous system, or a previous stroke.. * Previous surgical or device closure of a PFO or ASD.. * Artificial heart valve.. * Pacemaker or ICD implanted within past 3 months.. * Anatomic variant that could affect successful deployment such as coronary sinus, pulmonary veins, Chiari network.. * Uncontrolled bacteremias or dental or surgical procedure within past 30 days or planned within study period.. * Allergy to contrast media, and/or to any component of the device to be used.. * Contraindicated for any medication used during or after the procedure.. * History of atrial fibrillation or atrial flutter (chronic or paroxysmal).. * Patient is enrolled or intends to participate in another clinical study (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the study or within four weeks prior to his/her enrollment in the study.. * Patient is undergoing dialysis for renal failure.. * Patient has NYHA class 3 or 4 cardiac failure.. * Patient is pregnant, or intends to become pregnant during the trial period.. * Patient requires anticoagulation therapy for a concomitant condition.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Aged 18 - 50 years and of legal age in the host country"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "* Aged 18 - 50 years and of legal age in the host country"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 year", "unit": null, "evidence_text": "* Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine", "unit": null, "evidence_text": "* Migraine patients experiencing at least 2 migraine attacks per month"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "aura per month", "unit": null, "evidence_text": "* Migraine patients experiencing at least 1 migraine attack with aura per month"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 year", "unit": null, "evidence_text": "* Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine", "unit": null, "evidence_text": "* Migraine patients experiencing at least 2 migraine attacks per month"}], "rule_v1_extra_rules": [{"id": "rule-fcc8d34a-7a1d-4d7c-bc51-ef7a8eb4d5e7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "15 or more headache days per month", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of 15 or more headache days per month..", "source_span": {"start": 1128, "end": 1175}}, {"id": "rule-d0c92a6b-f2ed-4e25-8d79-84b04d5120fc", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "atrial fibrillation or atrial flutter (chronic or paroxysmal)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of atrial fibrillation or atrial flutter (chronic or paroxysmal)..", "source_span": {"start": 1976, "end": 2050}}, {"id": "rule-4fb25237-66e2-4e1b-a7f7-bcb27018ed25", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Migraine history of at least 1 year..", "source_span": {"start": 23, "end": 60}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00091", "nct_id": "NCT00055926", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 11.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=7"], "priority_breakdown": {"missing_rules_by_field": {"sex": 1}, "extra_rules_by_field": {"condition": 6, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex", "condition"], "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplification by fluorescence in situ hybridization (FISH). * Progressive metastatic disease. * Must have received at least one prior chemotherapy regimen for metastatic breast cancer. * At least 1 measurable or evaluable lesion. * At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic evaluation. * 18 and over. * Male or female. * ECOG 0-1. * Life expectancy, More than 3 months. * Hematopoietic. * Absolute neutrophil count at least 1,500/mm\\^3\\*. * Platelet count at least 100,000/mm\\^3\\* NOTE: \\*Without hematopoietic growth factors or transfusions. * Hepatic. * Bilirubin no greater than 1.5 mg/dL. * AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present). * Renal. * Creatinine no greater than 1.5 times ULN OR. * Creatinine clearance at least 60 mL/min. * Cardiovascular. * 12-lead ECG with normal tracing. * history of cardiovascular disease (i.e., ischemic heart disease, arrhythmia, or congestive heart failure) unless asymptomatic for the past year with no requirement for antiarrhythmics or a clinically significant medical management change. * Gastrointestinal. * Able to take oral medication\\* Negative pregnancy test. * Fertile patients must use effective contraception. * At least 4 weeks since prior trastuzumab (Herceptin). * At least 4 weeks since other prior biologic therapy or immunotherapy. * At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas). * At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy. * No cumulative doses of more than 300 mg/m\\^2. * At least 2 weeks since prior hormonal therapy for the primary disease. * Concurrent hormone replacement therapy or luteinizing hormone-releasing hormone agonists allowed. * At least 4 weeks since prior radiotherapy. * At least 3 weeks since prior major surgery (2 weeks for minor surgery). * Recovered from prior therapy. * At least 4 weeks since prior investigational treatment. * Coumarin or heparin derivatives allowed for the prevention of deep vein thrombosis or port patency. Exclusion Criteria:. * known or clinically suspected brain metastases or leptomeningeal disease. * symptomatic edema or third-space fluid (e.g., ascites or pleural effusions). * known hepatitis B or C infection. * significant ECG changes that require medical intervention. * QTc interval less than 460 msec. * No history of torsade or other symptomatic QTc abnormality. * LVEF greater than 50% by MUGA. * gastrointestinal abnormality that would require medications (including all antacids). * persistent symptoms of an esophageal or digestive disorder. * pregnant or nursing. * known HIV infection. * active infection. * concurrent uncontrolled systemic disorders or laboratory abnormalities that would preclude study drug safety evaluation. * mental disorder that would preclude study compliance or ability to give informed consent. * No more than 2 prior trastuzumab-based regimens for advanced disease. * concurrent immunotherapy. * more than 1 prior anthracycline- or anthracenedione-containing regimen (except with approval of the sponsor). * prior high-dose chemotherapy with hematopoietic stem cell transplantation. * concurrent anticancer chemotherapy. * No concurrent anticancer hormonal therapy, including tamoxifen. * prior radiotherapy to the only disease site that would be assessed for response. * concurrent radiotherapy. * prior partial or complete gastrectomy. * concurrent antiarrhythmics. * concurrent antacids. * concurrent anticoagulant at therapeutic doses. * other concurrent experimental anticancer medications for breast cancer", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* known HIV infection"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}], "rule_v1_extra_rules": [{"id": "rule-833fe6df-b93d-415c-aa59-99ab739e39d6", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hematopoietic stem cell transplantation", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "prior high-dose chemotherapy with hematopoietic stem cell transplantation.", "source_span": {"start": 3330, "end": 3404}}, {"id": "rule-8d6de033-49d4-414e-8d83-1b8c08585d26", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "persistent", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "persistent symptoms of an esophageal or digestive disorder.", "source_span": {"start": 2775, "end": 2834}}, {"id": "rule-ce3f96c9-5341-4589-bf6d-401fa389a46f", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "torsade or other symptomatic qtc abnormality", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "No history of torsade or other symptomatic QTc abnormality.", "source_span": {"start": 2592, "end": 2651}}, {"id": "rule-e927c1b3-6ebf-4da0-93ef-308a94f223a3", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "doxorubicin or doxorubicin equivalents without any prior", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy.", "source_span": {"start": 1612, "end": 1749}}, {"id": "rule-2dc7befb-bfcc-4bac-b9f8-728ea48795d5", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Fertile patients must use effective contraception.", "source_span": {"start": 1346, "end": 1396}}, {"id": "rule-af706449-334d-4680-a083-60c5c9e5ad13", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "normal tracing", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "12-lead ECG with normal tracing.", "source_span": {"start": 992, "end": 1024}}, {"id": "rule-0c2c7603-6531-4f22-ac08-8e497ce1c00c", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Male or female.", "source_span": {"start": 472, "end": 487}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00092", "nct_id": "NCT00001302", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 10.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception.", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "No history of brain metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "kidney, breast, ovarian cancers, and lymphomas", "unit": null, "evidence_text": "Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "No history of brain metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "kidney, breast, ovarian cancers, and lymphomas", "unit": null, "evidence_text": "Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged"}], "rule_v1_extra_rules": [{"id": "rule-afd79279-f6ec-4adc-9c21-c1a6308fa313", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "cyclosporine", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone..", "source_span": {"start": 760, "end": 1240}}, {"id": "rule-8a192915-83fa-48eb-8c22-2f3789a68ce9", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "kidney", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged..", "source_span": {"start": 95, "end": 185}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00093", "nct_id": "NCT00181272", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 10.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inpatient medical service at Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center. * Evidence of airflow obstruction on spirometry (FEV1/FVC\\<70%). * Age 18 years or older. Exclusion Criteria:. * History of allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin). * Treatment with any macrolide in the 4 weeks prior to study entry. * Elevated AST or ALT (2 or more times the upper limit of normal) on current admission. * Elevated alkaline phosphatase (\\>1.25 times the upper limit of normal) on current admission. * Elevated total serum bilirubin (more than upper limit of normal) on current admission. * Previous participation in this study. * Patients prescribed digoxin (azithromycin may increase digoxin levels). * Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin). * Patients prescribed pimozide (azithromycin may increase risk of arrhythmias). * Patient unable to provide consent (e.g., language difficulty or history of dementia). * Patient to be discharged to a location other than home (e.g., other hospital, long-term care facility)", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Age 18 years or older"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any macrolide in the 4 weeks", "unit": null, "evidence_text": "* Treatment with any macrolide in the 4 weeks prior to study entry"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "azithromycin may increase inr in", "unit": null, "evidence_text": "* Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin)"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any macrolide in the 4 weeks", "unit": null, "evidence_text": "* Treatment with any macrolide in the 4 weeks prior to study entry"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "azithromycin may increase inr in", "unit": null, "evidence_text": "* Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin)"}], "rule_v1_extra_rules": [{"id": "rule-b2efe182-edfa-4b4f-be6e-3edb55e461ee", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin).", "source_span": {"start": 343, "end": 447}}, {"id": "rule-1fe98420-f5f9-47ab-9081-f541eca8d761", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "dementia)", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patient unable to provide consent (e.g., language difficulty or history of dementia).", "source_span": {"start": 1072, "end": 1157}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00094", "nct_id": "NCT00468039", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 10.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "sex": 1}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "Inclusion Criteria:. * Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes. * Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry. * Body mass index 22-40 kg/meter squared. * HbA1c \\> 11% and/or FPG \\>270 mg/dL. Exclusion Criteria:. * Pregnant or lactating female. * History of type 1 diabetes. * Evidence of significant diabetic complications. * Treatment with insulin or any other oral antidiabetic agent. Other protocol-defined inclusion/exclusion criteria may apply.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "type 1 diabetes", "unit": null, "evidence_text": "* History of type 1 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "insulin or any other oral antidiabetic agent", "unit": null, "evidence_text": "* Treatment with insulin or any other oral antidiabetic agent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes for at least 4", "unit": null, "evidence_text": "* Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes", "unit": null, "evidence_text": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating female"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes for at least 4", "unit": null, "evidence_text": "* Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry"}], "rule_v1_extra_rules": [{"id": "rule-0d824d8e-eee4-43c1-9b74-0fc4d175fb78", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes.", "source_span": {"start": 23, "end": 159}}, {"id": "rule-ea631634-007e-4b9b-b208-39a3c1e37afc", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes.", "source_span": {"start": 23, "end": 159}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00095", "nct_id": "NCT00595361", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 10.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1, "sex": 1}, "extra_rules_by_field": {"condition": 1, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "sex"], "eligibility_text": "Inclusion Criteria:. * Both male and female. * 18 to 50 years of age. * Resting FEV1 ≥ 65% of predicted normal. * Exercise-induced bronchoconstriction defined as a decrease in FEV1 of ≥ 20% following a standardized exercise challenge when compared to pre-exercise baseline FEV1 value measured 5 minutes before exercise. * Must be Arg/Arg or Gly/Gly genotype. Exclusion Criteria:. * Long-acting beta agonist use within 12 weeks of the first exercise challenge. * Smoking within past 12 months. * Greater than 10-pack years smoking history. * Unresolved signs and/or symptoms of an upper respiratory tract infection within 4 weeks of first exercise challenge. * Asthma exacerbation within 4 weeks of first exercise challenge requiring change in type, dose or frequency of medications and/or an unscheduled visit to an health care provider, including emergency room or hospital. * Subject has exercised or performed strenuous activity within 72 hours of the first exercise challenge. * Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm within 2 hours of exercise challenge. * In addition to asthma, the subject has an active, acute or chronic pulmonary disorder documented by history, physical examination, or chest x-ray. * Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing. * Subject has used systemic corticosteroids within 1 month of first exercise challenge", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* 18 to 50 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "* 18 to 50 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Both male and female"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the ability to achieve protocol-specified heart rates", "unit": null, "evidence_text": "* Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the ability to achieve protocol-specified heart rates", "unit": null, "evidence_text": "* Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Both male and female"}], "rule_v1_extra_rules": [{"id": "rule-9ebd1024-46b9-45db-a887-5b560dc5f443", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "subject has been exposed to cold air", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm within 2 hours of exercise challenge.", "source_span": {"start": 983, "end": 1104}}, {"id": "rule-8f9c2c9e-f734-4e47-b367-b43338989ab5", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Both male and female.", "source_span": {"start": 23, "end": 44}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00096", "nct_id": "NCT00339703", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 10.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=6"], "priority_breakdown": {"missing_rules_by_field": {"sex": 1}, "extra_rules_by_field": {"condition": 5, "sex": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex", "condition"], "eligibility_text": "Inclusion Criteria:. * Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study.. * Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.. Exclusion Criteria:. * Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.. * Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma flares may also be considered in", "unit": null, "evidence_text": "Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age"}], "rule_v1_extra_rules": [{"id": "rule-aafd9156-a97c-4b3c-9d7a-728d0e2cadfd", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asthma or reactive airway disease", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.", "source_span": {"start": 966, "end": 1366}}, {"id": "rule-15c5b99a-c004-4673-8e4b-c899b271d62a", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or clinical", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.", "source_span": {"start": 966, "end": 1366}}, {"id": "rule-81a2a80e-6485-42b1-8fa9-1161cdd2eadd", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "prior", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.", "source_span": {"start": 966, "end": 1366}}, {"id": "rule-320a82c5-aeb8-4670-8276-ce6477e4867d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "and characterized by at least daily", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted.", "source_span": {"start": 23, "end": 349}}, {"id": "rule-312df310-785d-4826-a202-9d2dfa10c0e5", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "night", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted.", "source_span": {"start": 23, "end": 349}}, {"id": "rule-46e426cc-56d1-4704-9525-9b4d5dec6d4d", "type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "time_window": null, "certainty": "high", "evidence_text": "Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted.", "source_span": {"start": 23, "end": 349}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00097", "nct_id": "NCT00048542", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 9.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"sex": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex", "condition"], "eligibility_text": "Inclusion Criteria:. * Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular. If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification.. * At the time of study screening, the subject must have continuing active disease defined as \\>= 5 swollen joints and \\>= 3 joints with limitation of motion (LOM). These joints are not mutually exclusive.. * Subjects may be either naïve to MTX, inadequate responders to MTX, or intolerant to MTX. Intolerance to MTX will be defined by the subject's physician. The MTX must be maintained at a dose of at least 10 mg/m2 body surface area/week for a minimum of 3 months, prior to screening.. * Duration of disease is not limited, but must have been long enough for a subject to have been given an adequate trial of nonsteroidal anti-inflammatory drugs (NSAIDs).. * Have not received other disease-modifying anti-rheumatic drugs (DMARDs) including penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin; or intravenous immunoglobulin (IV Ig); or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must demonstrate active disease (defined above) prior to a minimum 4 weeks (28 days) washout of all DMARDs.. * Subjects who are refractory to MTX after 3 months of treatment must demonstrate active disease (defined above) prior to enrollment in the open-label part of the trial.. * Have not received an intra-articular glucocorticoid injection within 4 weeks (28 days) prior to enrollment into the study.. * Have good venous access and stable hematocrit \\>= 24%.. * All sexually active male and female study participants must be practicing adequate contraception. Post-pubertal females must have a negative serum pregnancy test no greater than 10 days prior to the first dose of study drug.. * Parent or guardian has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject's parent or legal guardian has had the opportunity to ask questions.. Exclusion Criteria:. * Pregnant or nursing female.. * Functional class IV by ACR criteria.. * Laboratory parameters outside limits established in the protocol.. * Medical history, medical condition, or previous treatment not allowed by the protocol.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or nursing female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* All sexually active male and female study participants must be practicing adequate contraception"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or nursing female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* All sexually active male and female study participants must be practicing adequate contraception"}], "rule_v1_extra_rules": [{"id": "rule-cd1557c0-998a-48d1-97f9-e013ad57feeb", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00098", "nct_id": "NCT00062491", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 9.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "* Confirmed diagnosis of malignant melanoma. * Measurable disease. * Granulocytes ≥1,500/µl, Platelets ≥100,000/µl, Creatinine ≤ULN, Bilirubin ≤1.5 mg/dl, AST ≤2.5 x ULN. * No prior treatment with other camptothecin drug.. * ≥ 21 days since completion of prior chemotherapy, ≥6 weeks since prior Mitomycin-C. * ECOG Performance Status 0-1. * Negative pregnancy test for female patients", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Negative pregnancy test for female patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "malignant melanoma", "unit": null, "evidence_text": "* Confirmed diagnosis of malignant melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "negative pregnancy test for female", "unit": null, "evidence_text": "* Negative pregnancy test for female patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other camptothecin drug", "unit": null, "evidence_text": "* No prior treatment with other camptothecin drug"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "malignant melanoma", "unit": null, "evidence_text": "* Confirmed diagnosis of malignant melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "negative pregnancy test for female", "unit": null, "evidence_text": "* Negative pregnancy test for female patients"}], "rule_v1_extra_rules": [{"id": "rule-4d288f30-003a-4f73-9809-579322d7323a", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "confirmed", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Confirmed diagnosis of malignant melanoma.", "source_span": {"start": 2, "end": 44}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00099", "nct_id": "NCT00129701", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 9.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mental or cognitive issues requiring physical", "unit": null, "evidence_text": "New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "follow up in a hospital clinic", "unit": null, "evidence_text": "Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mental or cognitive issues requiring physical", "unit": null, "evidence_text": "New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "follow up in a hospital clinic", "unit": null, "evidence_text": "Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems"}], "rule_v1_extra_rules": [{"id": "rule-2c744224-7afa-4bf1-ad03-d48b8813464c", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "mental or cognitive issues patients", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing.", "source_span": {"start": 527, "end": 670}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00100", "nct_id": "NCT00292175", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 9.0, "priority_reasons": ["rule_v1_missing=2", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * petients with colitis who meet surveillance criteria. * patients over 18 years of age. Exclusion Criteria:. * pregnant patients. * unable or unwilling to give informed consent. * patients with severe active colitis who would be unsafe to endoscope", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* patients over 18 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pregnant", "unit": null, "evidence_text": "* pregnant patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe active colitis who would be unsafe", "unit": null, "evidence_text": "* patients with severe active colitis who would be unsafe to endoscope"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colitis who meet surveillance", "unit": null, "evidence_text": "* petients with colitis who meet surveillance criteria"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pregnant", "unit": null, "evidence_text": "* pregnant patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colitis who meet surveillance", "unit": null, "evidence_text": "* petients with colitis who meet surveillance criteria"}], "rule_v1_extra_rules": [{"id": "rule-8c6e1e8a-ca73-4329-a922-32c5322d046b", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colitis who meet surveillance criteria", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "petients with colitis who meet surveillance criteria.", "source_span": {"start": 23, "end": 76}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00101", "nct_id": "NCT00235859", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 9.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=5"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 5}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints. * Subjects must have received at least one prior DMARD besides MTX, but may have had efficacy failures on no more than four standard DMARDs other than MTX. * Therapy with MTX for at least 6 months prior to screening and on a stable dose of MTX for at least 4 weeks prior to screening visit. * Age 18 years and older. Exclusion Criteria:. * Prior treatment with any TNF antagonist, including adalimumab. * History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin.. * Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide.. * Chest X-ray with calcified granuloma and/or pleural scarring. * Positive TB skin test, RT23 dose skin test, \\>5 mm at 48 to 72 hours. * Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months of the screening evaluation) or any poorly controlled medical condition. * Intra-articular, intramuscular or iv administration of corticosteroids within 4 weeks prior to screening evaluation. * Female who is pregnant or breast-feeding.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Age 18 years and older"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female who is pregnant or breast-feeding"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any tnf antagonist, including adalimumab", "unit": null, "evidence_text": "* Prior treatment with any TNF antagonist, including adalimumab"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any tnf antagonist, including adalimumab", "unit": null, "evidence_text": "* Prior treatment with any TNF antagonist, including adalimumab"}], "rule_v1_extra_rules": [{"id": "rule-02b60ae2-7ecb-4bb3-86cc-0e44bbf55132", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any investigational biologic agent", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide..", "source_span": {"start": 808, "end": 1359}}, {"id": "rule-ba9ff8c4-c57b-43b4-9368-8a1d1023cf76", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any other investigational agent within 30 days", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide..", "source_span": {"start": 808, "end": 1359}}, {"id": "rule-1e4ef4db-b1b2-4c80-9ceb-bb5880460b11", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any tnf antagonist", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Prior treatment with any TNF antagonist, including adalimumab.", "source_span": {"start": 462, "end": 524}}, {"id": "rule-28ac5870-c1f3-4558-8932-af4d1fc9d2e4", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (tb), lymphoma or leukemia,and any malignancy with the exception of successfully treated non metastatic basal cell carcinoma of the skin", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin..", "source_span": {"start": 527, "end": 805}}, {"id": "rule-e8449ba8-39e4-439a-8f69-3ef878362811", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "meet acr criteria for", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints.", "source_span": {"start": 23, "end": 121}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00102", "nct_id": "NCT00072085", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 8.0, "priority_reasons": ["rule_v1_missing=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 2}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "DISEASE CHARACTERISTICS:. * Diagnosis of metastatic melanoma. * Measurable disease. * Progressive disease during or after prior standard treatment with or without interleukin-2. PATIENT CHARACTERISTICS:. Age. * 16 and over. Performance status. * ECOG 0-2. Life expectancy. * More than 6 months. Hematopoietic. * WBC at least 3,000/mm\\^3. * Platelet count at least 90,000/mm\\^3. * Lymphocyte count greater than 500/mm\\^3. Hepatic. * Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome). * ALT and AST less than 3 times normal. * Hepatitis B surface antigen negative. Renal. * Creatinine no greater than 2.0 mg/dL. Cardiovascular. * No symptomatic cardiac disease. Immunologic. * No active systemic infection. * No autoimmune disease. * No known immunodeficiency disease. * No known hypersensitivity to study agents. * No form of primary or secondary immunodeficiency. * No opportunistic infection. * HIV negative. Other. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. PRIOR CONCURRENT THERAPY:. Biologic therapy. * See Disease Characteristics. * No prior gp100 peptide vaccine. Chemotherapy. * More than 6 weeks since prior nitrosoureas. Endocrine therapy. * No concurrent systemic steroid therapy. Radiotherapy. * Not specified. Surgery. * Prior recent (within the past 3 weeks) minor surgical procedures allowed. Other. * Recovered from prior therapy (toxicity no greater than grade 1). * More than 3 weeks since prior systemic anticancer therapy. * No other concurrent systemic anticancer therapy", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "metastatic melanoma", "unit": null, "evidence_text": "* Diagnosis of metastatic melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without interleukin-2", "unit": null, "evidence_text": "* Progressive disease during or after prior standard treatment with or without interleukin-2"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "dl for", "unit": null, "evidence_text": "* Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome)"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "dl for", "unit": null, "evidence_text": "* Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "metastatic melanoma", "unit": null, "evidence_text": "* Diagnosis of metastatic melanoma"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00103", "nct_id": "NCT00383968", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 8.0, "priority_reasons": ["rule_v1_missing=2"], "priority_breakdown": {"missing_rules_by_field": {"sex": 2}, "extra_rules_by_field": {}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex"], "eligibility_text": "Inclusion criteria:. * Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.. * Hypertension: Systolic blood pressure ≥140, and /or diastolic blood pressure ≥ 90 with or without antihypertensive drugs.. * Microalbuminuria:. * Albumin concentration of 20-200mg/L, with albumin-to-creatinine ratio of 3-30mg/mmol or 30-300mg/g. * Female: 3.0-30.0mg/mmol or 30-300mg/g. * Male: 2.0-20.0mg/mmol or 20. * Elevated Serum creatinine:. * Female: \\>1.2mg/dl. * Male: \\>1.4mg/dl. Exclusion Criteria:. * Known diabetics will be excluded.. * unable to give informed consent", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Male: \\>1.4mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female: \\>1.2mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Male: 2.0-20.0mg/mmol or 20"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female: 3.0-30.0mg/mmol or 30-300mg/g"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without antihypertensive drugs", "unit": null, "evidence_text": "* Hypertension: Systolic blood pressure ≥140, and /or diastolic blood pressure ≥ 90 with or without antihypertensive drugs"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female: \\>1.2mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* Male: \\>1.4mg/dl"}], "rule_v1_extra_rules": [], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00104", "nct_id": "NCT00349427", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 8.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=3"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 2, "history": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "history"], "eligibility_text": "Inclusion:. * Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks. * If Patients are taking another oral antidiabetic agent may stop their oral agent and adjust their insulin dose properly over 8 weeks prior to screening if they are asked by doctor who considers him/her suitable for study in all other respects, and the HbA1c level\\>7.5%.. Exclusion:. * Fasting plasma glucose \\>13 mmol/L at screening. * Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months. * Drug abuse. * Women pregnant or lactating. * Use any rosiglitazone like drug in 3 months. * Use more than one oral antidiabetic agent in 2 months. * Uncontrolled hypertension. * Chronic heart failure. * Anemia", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women pregnant or lactating"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "peripheral edema requiring pharmacological treatment within 12", "unit": null, "evidence_text": "* Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "peripheral edema requiring pharmacological treatment within 12", "unit": null, "evidence_text": "* Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}], "rule_v1_extra_rules": [{"id": "rule-9abe2415-e936-49b4-b1c9-ae155ed2b0bf", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "peripheral edema requiring pharmacological treatment within 12 months", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months.", "source_span": {"start": 481, "end": 579}}, {"id": "rule-ae81ef54-5c05-4135-9859-cd5fbd4a41d4", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "time_window": null, "certainty": "medium", "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months.", "source_span": {"start": 481, "end": 579}}, {"id": "rule-3feb221a-664f-4691-b658-f6daff3df7cc", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00105", "nct_id": "NCT00649922", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 7.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"age": 1, "history": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age", "history"], "eligibility_text": "Inclusion Criteria:. * Male/Females at least 20 years of age.. * Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control.. * Females have a negative pregnancy test at screening.. * Diagnosis of RA and met ACR criteria.. * Must discontinue any TNF at least 2 months prior to baseline.. * In condition of general good health.. Exclusion Criteria:. * History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix.. * History of current acute inflammatory joint disease.. * Use of TAMIFLU or Symmetrel within 3 months of study drug administration.. * Recent (3 month) history of influenza or pneumococcal bacterial infection.. * Known positive human immunodeficiency virus (HIV) status.. * Positive hepatitis B or hepatitis C virus.. * Positive PPD \\>5 mm.. * Chest x-ray with calcified granulomas and/or pleural scarring or significant abnormalities.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 20, "unit": "years", "evidence_text": "* Male/Females at least 20 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "active infection with Listeria or TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "listeria or tb", "unit": null, "evidence_text": "active infection with Listeria or TB"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant sensitivity to any drug", "unit": null, "evidence_text": "* History of significant sensitivity to any drug"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current acute inflammatory joint disease", "unit": null, "evidence_text": "* History of current acute inflammatory joint disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known positive human immunodeficiency virus (HIV) status"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "influenza or pneumococcal bacterial infection", "unit": null, "evidence_text": "* Recent (3 month) history of influenza or pneumococcal bacterial infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ra and met acr", "unit": null, "evidence_text": "* Diagnosis of RA and met ACR criteria"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ra and met acr", "unit": null, "evidence_text": "* Diagnosis of RA and met ACR criteria"}], "rule_v1_extra_rules": [{"id": "rule-2631cbf2-0771-435b-ad70-297a5f6ae416", "type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "time_window": null, "certainty": "medium", "evidence_text": "sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix..", "source_span": {"start": 582, "end": 798}}, {"id": "rule-0105e32f-fa37-4e1f-82e6-f993f3da570b", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control..", "source_span": {"start": 65, "end": 181}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00106", "nct_id": "NCT00068003", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:. INCLUSION CRITERIA:. * Patients must have a form of cancer currently being studied in the NCI-SB.. * Patient is able to understand and willing to sign a written informed consent document.. * Age greater than or equal to 18 years.. * Clinical performance status of ECOG 0 or 1.. * Serology. * Seronegative for HIV antibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities).. * Seronegative for hepatitis B surface antigen and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.. * Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity.. EXCLUSION CRITERIA:. * Active systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system.. * Patients who cannot give proper informed consent to the experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk.. * Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus.. ELIGIBILITY CRITERIA FOR HEALTHY VOLUNTEERS:. INCLUSION CRITERIA for PBMC Donors:. * Age greater than or equal to 18 years.. * Non-reactive for HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, HBV/HCV/HIV-1 NAT, anti-HTLV-I/II, anti-T. cruzi, West Nile Virus NAT,syphilis, and babesia.. * PBMC donors must meet the strict behavioral and medical history requirements as per applicable NCI-SB Apheresis Donor SOP(s).. INCLUSION CRITERIA FOR WHOLE BLOOD DONORS:. * Age greater than or equal to 18 years.. * Whole blood donors must meet the DTM inclusion criteria for allogeneic whole blood donation.. EXCLUSION CRITERIA for PBMC Donors:. * Has had babesiosis.. * Is at risk or has Creutzfeldt-Jakob Disease.. * Is on steroid therapy or any other medication or has received vaccination that might interfere with cell preparation per Principal Investigator s (PI) discretion.. * Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the PI.. * Has had yellow jaundice, liver disease, or hepatitis since the age of 11.. * Has uncontrolled diabetes.. * Has a hematologic malignancy or any bleeding abnormalities.. * Has received any type of organ transplant in the past 12 months.. * Has undergone xenotransplantation at any time.. * Has received a dura mater graft.. * If female, is pregnant or has given birth within the last six weeks.. * Has had an ear or body piercing or tattoos within the past 12 months.. * Has had a blood transfusion within the past 12 months.. * Has spent time outside the United States to a restricted country.. * Has participated in any high-risk activities.. EXCLUSION CRITERIA for Whole Blood Donors:. \\- Whole blood donors who do not meet the DTM criteria for allogeneic whole blood donation.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* If female, is pregnant or has given birth within the last six weeks"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "eligibility for", "unit": null, "evidence_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "acceptable morbidity", "unit": null, "evidence_text": "* Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* If female, is pregnant or has given birth within the last six weeks"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "eligibility for", "unit": null, "evidence_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:"}], "rule_v1_extra_rules": [{"id": "rule-3cf523ef-8fdd-4d83-b2b0-966ef89975ce", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Non-reactive for HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, HBV/HCV/HIV-1 NAT, anti-HTLV-I/II, anti-T.", "source_span": {"start": 1736, "end": 1836}}, {"id": "rule-9e35cd35-99fd-421b-89c5-531a5533e6bb", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "eligibility criteria for patients with a current", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:.", "source_span": {"start": 2, "end": 72}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00107", "nct_id": "NCT00151892", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days. * female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:. * proctitis. * previous resective colonic surgery. * Crohn's disease. * hypersensitivity to salicylates. * moderate/severe renal impairment", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a negative urine pregnancy test at", "unit": null, "evidence_text": "* female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a negative urine pregnancy test at", "unit": null, "evidence_text": "* female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception"}], "rule_v1_extra_rules": [{"id": "rule-0ffdff21-28a4-48ba-b4b8-29208f0c20a4", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a negative urine pregnancy test at screening", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception.", "source_span": {"start": 150, "end": 310}}, {"id": "rule-373c8b3a-ea67-46f1-bf56-11ac2c14880f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "previous", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days.", "source_span": {"start": 23, "end": 147}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00108", "nct_id": "NCT00159380", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. Healthy non-smokers (n=10):. * Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s). * Normal spirometry. * Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):. * Forced expiratory volume in one second (FEV1) of no less than 70% of predicted (exhaled NO greater than or equal to 15 ppb; flow 50 ml/s). * Clinically stable (steroid-naïve or taking no \\> 600 mcg/day of inhaled steroids). * Able to comprehend and grant a written informed consent. Exclusion Criteria:. * Currently smoking. * Any lung disease other than asthma which may interfere with the study. * Treatment within the last 4 weeks with oral steroids. * Respiratory infection within 4 weeks prior to entry into the trial. * Females who are pregnant or lactating. * History of current or past drug or alcohol abuse", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current or past drug or alcohol", "unit": null, "evidence_text": "* History of current or past drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "oral steroids", "unit": null, "evidence_text": "* Treatment within the last 4 weeks with oral steroids"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the study", "unit": null, "evidence_text": "* Any lung disease other than asthma which may interfere with the study"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current or past drug or alcohol", "unit": null, "evidence_text": "* History of current or past drug or alcohol abuse"}], "rule_v1_extra_rules": [{"id": "rule-eb9b7115-68f1-4d9e-8e5b-30992d43c8d7", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current or past drug or alcohol abuse", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of current or past drug or alcohol abuse", "source_span": {"start": 808, "end": 856}}, {"id": "rule-38fa45ca-2bdf-498f-82f7-cbd9372a2f4f", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00109", "nct_id": "NCT00320034", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"sex": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex", "condition"], "eligibility_text": "Inclusion Criteria:. * Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55.. * Stable, mild atopic asthma with forced expiratory volume in one second (FEV1.0) greater than 70% of predicted for age and height, and not requiring any medical treatment other than short acting inhaled beta-agonists as needed.. * No recent or significant history of cigarette smoking (no cigarettes within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking).. * Peak decrease in FEV1 in both early (0-2 hour) and late (3-7 hour) allergen-provoked response of \\> 15% compared with the baseline (pre-allergen challenge) spirometric determination.. * Signed written informed consent to participate in the protocol; ability to return to the outpatient clinic for repeated clinic visits.. * No history of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a six week period preceding entry into the screening phase of the study.. Exclusion Criteria:. * Significant gastrointestinal (including hepatic), hematological, cardiovascular, cerebrovascular or other body system disorder.. * History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks.. * Baseline AST or ALT (indicators of liver damage) greater than twice the upper limit of the normal range for the local laboratory.. * History of allergy or hypersensitivity to short-acting beta-agonists.. * Inability to discontinue asthma medications for the duration of the study or receipt of oral or inhaled corticosteroids or leukotriene receptor antagonist in the three weeks prior to entry into the screening phase of the study.. * Recent (within the past 2 months) or planned (within the study period) lung volume reduction surgery.. * Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic.. * Pregnant or nursing females.. * Any other medical or social condition which, in the opinion of the investigator, could confound the interpretation of the data derived from this study.", "current_labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergy or hypersensitivity to short-acting beta-agonists", "unit": null, "evidence_text": "* History of allergy or hypersensitivity to short-acting beta-agonists"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "this protocol problematic", "unit": null, "evidence_text": "* Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}], "rule_v1_extra_rules": [{"id": "rule-c6c9266e-0b5a-4632-8983-1d0494d0b1a5", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks..", "source_span": {"start": 1272, "end": 1379}}, {"id": "rule-fefa81e1-fcf2-47d8-90d5-edd3b0857d46", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00110", "nct_id": "NCT00502853", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"age": 1, "condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:. * adult patients, 18-75 years of age;. * rheumatoid arthritis for \\>=3 months and \\<=10 years;. * inadequate response to methotrexate (12.5-25mg/week) for \\>=3 months;. * evidence of erosive disease and/or clinical synovitis in a signal joint.. Exclusion Criteria:. * autoimmune rheumatic diseases other than RA;. * surgical operations on bones/joints in 12 weeks prior to baseline visit;. * concomitant treatment with biologic agents;. * previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* adult patients, 18-75 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* adult patients, 18-75 years of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "biologic agents", "unit": null, "evidence_text": "* concomitant treatment with biologic agents"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "more than one biologic agent approved for", "unit": null, "evidence_text": "* previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients, 18-75 years of age"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients, 18-75 years of age"}], "rule_v1_extra_rules": [{"id": "rule-0e467bff-f238-4892-8af2-37a1f083b343", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cell depleting therapies", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.", "source_span": {"start": 460, "end": 563}}, {"id": "rule-f17315ef-905b-4004-91d6-f572238ac61d", "type": "INCLUSION", "field": "age", "operator": "<=", "value": 10, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "rheumatoid arthritis for \\>=3 months and \\<=10 years;.", "source_span": {"start": 62, "end": 116}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00111", "nct_id": "NCT00724841", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically confirmed metastatic melanoma. * Up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed. * Normal organ and marrow function. * Willing to submit to blood sampling for planned PK/PD analyses. * Ability of understand and willingness to sign a written informed consent. Exclusion Criteria:. * No other investigational or commercial agents or therapies. * Prior exposure to GMX1777, GMX1778 or CHS828. * Patients with uncontrolled, intercurrent illness. * Pregnant or breastfeeding women", "current_labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or breastfeeding women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled, intercurrent illness", "unit": null, "evidence_text": "* Patients with uncontrolled, intercurrent illness"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled, intercurrent illness", "unit": null, "evidence_text": "* Patients with uncontrolled, intercurrent illness"}], "rule_v1_extra_rules": [{"id": "rule-b7579f7b-bbe9-4335-8429-5a47e1f80092", "type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Patients with uncontrolled, intercurrent illness.", "source_span": {"start": 472, "end": 521}}, {"id": "rule-dac6c271-1fd2-4c05-8d11-ca20943d61a4", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study specific condition", "unit": null, "time_window": null, "certainty": "low", "evidence_text": "Inclusion Criteria:", "source_span": null}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00112", "nct_id": "NCT00941577", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 6.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=2"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"age": 2}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:\n\n* Men and women with well controlled mild allergic asthma, aged 18 to 65 years\n* Only asthma med is short-acting bronchodilator used not more than twice weekly\n* FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "well controlled mild allergic asthma", "unit": null, "evidence_text": "Men and women with well controlled mild allergic asthma, aged 18 to 65 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Only asthma med is short-acting bronchodilator used not more than twice weekly", "unit": null, "evidence_text": "Only asthma med is short-acting bronchodilator used not more than twice weekly"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "Only asthma med is short-acting bronchodilator used not more than twice weekly", "unit": null, "evidence_text": "Only asthma med is short-acting bronchodilator used not more than twice weekly"}], "rule_v1_extra_rules": [{"id": "rule-498c9d02-88e1-42c5-9520-ca075b80bf82", "type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Men and women with well controlled mild allergic asthma, aged 18 to 65 years", "source_span": {"start": 23, "end": 99}}, {"id": "rule-2da48076-5676-4dfe-9529-9956e2f3c8cc", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Men and women with well controlled mild allergic asthma, aged 18 to 65 years", "source_span": {"start": 23, "end": 99}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00113", "nct_id": "NCT00106535", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * adult patients at least 18 years of age with moderate to severe active RA for at least 6 months;. * inadequate response to a stable dose of MTX;. * patients of reproductive potential must be using reliable methods of contraception.. Exclusion Criteria:. * major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study;. * prior treatment failure with an anti-tumor necrosis factor agent;. * women who are pregnant or breast-feeding.", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* women who are pregnant or breast-feeding"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an anti-tumor necrosis factor agent", "unit": null, "evidence_text": "* prior treatment failure with an anti-tumor necrosis factor agent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe active ra for", "unit": null, "evidence_text": "* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe active ra for", "unit": null, "evidence_text": "* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}], "rule_v1_extra_rules": [{"id": "rule-0e6ef75b-c237-4f2d-9208-1051178cbad8", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe active ra for at", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "adult patients at least 18 years of age with moderate to severe active RA for at least 6 months;.", "source_span": {"start": 23, "end": 120}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00114", "nct_id": "NCT00159458", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Histologically proven dx of recurrent or metastatic breast cancer. * Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer. Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease. Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease.. * Unidimensionally measurable dz (by RECIST). * At least 18 yrs of age. * SWOG PS 0-2. * AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0. * Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln. * Creatinine less than or equal to 2.0. * Fully recovered from acute toxicities secondary to prior tx. * Signed informed consent (including HIPAA authorization). * Peripheral neuropathy grade 0-1. Exclusion Criteria. * Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment.. * Underlying medical, psychiatric, or social conditions that would preclude patient from receiving tx. * Peripheral neuropathy greater than or equal to Gr 2. Exclusion Criteria:. \\-", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* At least 18 yrs of age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "gemcitabine or oxaliplatin", "unit": null, "evidence_text": "* Prior tx with gemcitabine or oxaliplatin"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "gemcitabine or oxaliplatin", "unit": null, "evidence_text": "* Prior tx with gemcitabine or oxaliplatin"}], "rule_v1_extra_rules": [{"id": "rule-21309efe-de6c-4642-b461-eaa02b95091d", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "gemcitabine or oxaliplatin", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Prior tx with gemcitabine or oxaliplatin.", "source_span": {"start": 1043, "end": 1084}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00115", "nct_id": "NCT00184288", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Clinical diagnosis of brain metastases. Exclusion Criteria:. * children. * pregnancy", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "* Clinical diagnosis of brain metastases"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "* Clinical diagnosis of brain metastases"}], "rule_v1_extra_rules": [{"id": "rule-0a2d5d16-af1f-4fef-b53b-f0907715da34", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "clinical", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Clinical diagnosis of brain metastases.", "source_span": {"start": 23, "end": 62}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00116", "nct_id": "NCT00291577", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. * Candidate for treatment with docetaxel. Exclusion Criteria:. * Prior chemotherapy in the advanced disease setting. * Inflammatory breast cancer. * HER2 positive disease", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "docetaxel", "unit": null, "evidence_text": "* Candidate for treatment with docetaxel"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of unresectable, locally recurrent or metastatic", "unit": null, "evidence_text": "* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of unresectable, locally recurrent or metastatic", "unit": null, "evidence_text": "* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}], "rule_v1_extra_rules": [{"id": "rule-2c5d8906-9944-4a1b-a6b9-92d804f0e328", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of unresectable", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.", "source_span": {"start": 23, "end": 108}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00117", "nct_id": "NCT00351988", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"age": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}], "rule_v1_extra_rules": [{"id": "rule-1a364f0d-d916-4bdd-8962-0904d6dce2c4", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "18 years of age or older;.", "source_span": {"start": 283, "end": 309}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00118", "nct_id": "NCT00400491", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"sex": 1}, "extra_rules_by_field": {"age": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["sex", "age"], "eligibility_text": "Inclusion Criteria:. * Type 2 diabetes for at least 1 year. * age 21-75 years. * long-acting insulin at bedtime. * metformin during the day. * for women of child bearing age use of reliable method of birth control. Exclusion Criteria:. * serum creatinine above 130 umol/l for men and above 110 for women. * systolic blood pressure \\> 175 or diastolic \\> 104 mmHg. * heart disease. * serum calcium \\> 2.54 mmol/l. * history of renal stones", "current_labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 21, "unit": "years", "evidence_text": "* age 21-75 years"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* age 21-75 years"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "* serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* for women of child bearing age use of reliable method of birth control"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "renal stones", "unit": null, "evidence_text": "* history of renal stones"}], "rule_v1_missing_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* serum creatinine above 130 umol/l for men and above 110 for women"}], "rule_v1_extra_rules": [{"id": "rule-acbaad23-3e45-4578-9eeb-74191e671a44", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "Type 2 diabetes for at least 1 year.", "source_span": {"start": 23, "end": 59}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00119", "nct_id": "NCT00422513", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"age": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition", "age"], "eligibility_text": "Inclusion Criteria:. * adult patients, \\>=18 years of age;. * CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months;. * CKD-related anemia treated with epoetin alfa iv 3x/week for \\>= 3 months;. * average hemoglobin (Hb) 10-12 g/dL over last 3 months.. Exclusion Criteria:. * failed renal transplant within 12 months prior to screening;. * poorly controlled hypertension;. * previous treatment with Mircera.", "current_labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mircera", "unit": null, "evidence_text": "* previous treatment with Mircera"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients, \\>=18 years of age"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients, \\>=18 years of age"}], "rule_v1_extra_rules": [{"id": "rule-9aa43498-ea59-4a3f-b611-7a09c8dbbe2b", "type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "time_window": null, "certainty": "high", "evidence_text": "adult patients, \\>=18 years of age;.", "source_span": {"start": 23, "end": 59}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
{"task_id": "parsing-relabel-r1-00120", "nct_id": "NCT00440817", "status": "PENDING", "task_type": "parsing_relabel", "guideline_version": "m5-v1", "priority_score": 5.0, "priority_reasons": ["rule_v1_missing=1", "rule_v1_extra=1"], "priority_breakdown": {"missing_rules_by_field": {"condition": 1}, "extra_rules_by_field": {"condition": 1}, "contract_error_count": 0, "contract_warning_count": 0, "contract_error_codes": {}, "contract_warning_codes": {}}, "focus_fields": ["condition"], "eligibility_text": "Inclusion Criteria:. * Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis. For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries. Exclusion Criteria:. * Patients who do not have Crohns disease or rheumatoid arthritis and who did not participate in one of the identified registries will be excluded from the study", "current_labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "for the lymphoma analysis", "unit": null, "evidence_text": "For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries"}], "rule_v1_missing_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "for the lymphoma analysis", "unit": null, "evidence_text": "For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries"}], "rule_v1_extra_rules": [{"id": "rule-1c218b31-f9d2-4568-9264-bc1dc6705085", "type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a lymphoma during their participation in one", "unit": null, "time_window": null, "certainty": "medium", "evidence_text": "For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries.", "source_span": {"start": 154, "end": 282}}], "instructions": "Re-label this trial using eligibility_text only. Enforce parsing contract v2 and avoid placeholder values.", "target_annotator": "annotator_a"}
